PD-L1-binding peptides and peptide conjugates and methods of use thereof
Patent Information
- Application Number
- JP2023532342
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-28
- Filing Date
- 2021-11-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for additional PD-L1 binding agents that can target PD-L1 to overcome the limitations of existing anti-PD-L1 antibodies in cancer therapy, such as size restrictions and off-target effects, while providing effective immune cell engagement.
Development of cystine-dense peptides (CDPs) that bind to PD-L1, stabilized by disulfide bridges, which can be used in peptide conjugates with active agents to target cancer cells and modulate immune responses.
The CDPs effectively inhibit PD-L1, enhance immune cell recruitment, and induce cancer cell death, offering a potent therapeutic approach with improved selectivity and tissue penetration compared to traditional antibodies.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 63 / 119,195, filed November 30, 2020, entitled "Compositions and Methods for Selective Depletion of Target Molecules," and U.S. Provisional Application No. 63 / 273,103, filed October 28, 2021, entitled "PD-L1-Binding Peptides and Peptide Conjugates and Methods of Use Thereof," each of which is incorporated herein by reference in its entirety for all purposes.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The said ASCII copy, created on November 23, 2021, is named 108406-709288_SL.txt and is 627,485 bytes in size. [Background technology]
[0003] Programmed death-ligand 1 (PD-L1), a transmembrane protein that binds to programmed cell death protein 1 (PD-1), is thought to play a role in immune suppression and T cell inactivation. PD-L1-expressing cancer cells evade the host immune response by binding to the PD-1 receptor on host T cells, inactivating the T cells and preventing the host immune system from destroying the cancer cells. Anti-PD-L1 antibodies can block the binding of PD-L1 to PD-1. However, additional PD-L1-binding agents that can be used to target PD-L1 are needed. Summary of the Invention
[0004] In various aspects, the present disclosure provides a method for manufacturing a semiconductor device, comprising: (a) X 1 X 2 X 3 X 4 X 5 X 6 CX 7 X 8 X 9 C SEQ ID NO: 361) (wherein X1 is D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 2 is G, E, Q, or F; X 3 is D or K; X 4 is G, V, or P; X 5 is G, H, R, V, F, W, or P; X 6 is A, D, or K; X 7 is E, H, Q, L, or F; X 8 is D, E, R, S, T, M, L, or F; X 9 is G, A, D, E, H, K, R, M, L, or P), or (b) X 1 FX 2 VFX 2 CLX 3 X 3 C (SEQ ID NO: 363) 1 is K or P; X 2 are independently D or K; X 3 and (iii) are independently any non-cysteine amino acid.
[0005] In some embodiments, the PD-L1-binding peptide comprises at least six cysteine residues. In some embodiments, the at least six cysteine residues are located at amino acid positions n, n+4, n+14, n+28, n+38, and n+42, where n corresponds to the position of the first cysteine residue of the at least six cysteine residues. In some embodiments, amino acid position n corresponds to amino acid position 4, such that the at least six cysteine amino acid residues are located at amino acid positions 4, 8, 18, 32, 42, and 46.
[0006] In some embodiments, the PD-L1-binding peptide further comprises at least three disulfide bonds connecting the at least six cysteine residues. In some embodiments, the at least three disulfide bonds connect the first cysteine residue of the at least six cysteine residues to the sixth cysteine residue of the at least six cysteine residues, the second cysteine residue of the at least six cysteine residues to the fifth cysteine residue of the at least six cysteine residues, and the third cysteine residue of the at least six cysteine residues to the fourth cysteine residue of the at least six cysteine residues. In some embodiments, the first cysteine residue is at amino acid position n, the second cysteine residue is at amino acid position n+4, the third cysteine residue is at amino acid position n+14, the fourth cysteine residue is at amino acid position n+28, the fifth cysteine residue is at amino acid position n+38, and the sixth cysteine residue is at amino acid position n+42. In some embodiments, the first cysteine residue is at amino acid position 4, the second cysteine residue is at amino acid position 8, the third cysteine residue is at amino acid position 18, the fourth cysteine residue is at amino acid position 32, the fifth cysteine residue is at amino acid position 42, and the sixth cysteine residue is at amino acid position 46.
[0007] In some embodiments, the PD-L1-binding peptide further comprises a first α-helix comprising residues n through n+20, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the PD-L1-binding peptide further comprises a second α-helix comprising residues n+34 through n+44, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the second α-helix comprises residues n+29 through n+44.
[0008] In some embodiments, the N-terminal amino acid residue of the first PD-L1-binding motif is located at amino acid residue position n+32, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the N-terminal amino acid residue of the first PD-L1-binding motif is located at amino acid residue position n+32, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the first PD-L1-binding motif comprises the sequence KFDVFKCLDHC (SEQ ID NO: 365).
[0009] In some embodiments, the PD-L1-binding peptide is selected from the group consisting of: (a) CX 1 X 2 X 3 CX 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 C (SEQ ID NO: 360) 1 is K, R, or V; X 2 is E, Q, S, M, L, or V; X 3 is D, E, H, K, R, N, Q, S, or Y; X 4 is D, M, or V; X 5 is A, K, R, Q, S, or T; X 6 is A, D, E, H, Q, S, T, M, I, L, V, or W; X 7 is A, E, R, Q, S, T, W, or P; X 8 is A, E, K, R, N, Q, T, M, I, L, V, or W; X 9 is G, A, E, K, N, T, or Y; X 10 is G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 11 is D, K, R, N, L, or V; X 12 is G, A, D, T, L, W, or P), or (b) CKVX 1 CVX 1 X 1 X1 X 1 X 2 X 3 KX 1 C (SEQ ID NO: 362) 1 are independently any non-cysteine amino acid; X 2 is M, I, L, or V; X 3 is Y, A, H, K, R, N, Q, S, or T). In some embodiments, the N-terminal amino acid residue of the second PD-L1 binding motif is located at amino acid residue position n, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the second PD-L1 binding motif comprises the sequence CKVHCVKEWMAGKAC (SEQ ID NO: 364).
[0010] In some embodiments, the PD-L1-binding peptide comprises the sequence of SEQ ID NO: 358 or SEQ ID NO: 359. In some embodiments, the PD-L1-binding peptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to SEQ ID NO: 1. In some embodiments, the PD-L1-binding peptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to SEQ ID NO: 2. In some embodiments, the PD-L1-binding peptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to SEQ ID NO: 3. In some embodiments, the PD-L1-binding peptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to SEQ ID NO: 4.
[0011] In various aspects, the disclosure provides PD-L1-binding peptides that comprise at least six cysteine residues located at amino acid positions n, n+4, n+14, n+28, n+38, and n+42, where n corresponds to the position of the first cysteine residue of the at least six cysteine residues, and that have at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to SEQ ID NO:57 or SEQ ID NO:59.
[0012] In various aspects, the disclosure provides PD-L1-binding peptides that comprise at least eight cysteine residues located at amino acid position n, n11, n+17, n+21, n+31, n+38, n+40, or n+44, where n corresponds to the position of the first cysteine residue of the at least six cysteine residues, and have at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to SEQ ID NO:58.
[0013] In various aspects, the disclosure provides PD-L1-binding peptides comprising a sequence with at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% sequence identity to any one of SEQ ID NO:1-118, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, or SEQ ID NO:554-567.
[0014] In some embodiments, the PD-L1-binding peptide comprises the sequence of any one of SEQ ID NO:1 through SEQ ID NO:118, SEQ ID NO:435 through SEQ ID NO:436, SEQ ID NO:437, or SEQ ID NO:554 through SEQ ID NO:567.
[0015] In some embodiments, the PD-L1-binding peptide has an equilibrium dissociation constant (K D ) can bind to PD-L1. In some embodiments, the PD-L1-binding peptide can bind to PD-L1 with an equilibrium dissociation constant (KD In some embodiments, the PD-L1-binding peptides can bind to PD-L1 with equilibrium dissociation constants (K ) that differ by no more than 1.5-fold, no more than 2-fold, no more than 5-fold, or no more than 10-fold. D ) and can bind to human PD-L1 and cynomolgus monkey PD-L1.
[0016] In some embodiments, the PD-L1-binding peptide comprises at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, or at least 49 amino acid residues.
[0017] 30. The PD-L1-binding peptide of any one of claims 1-29, wherein the PD-L1-binding peptide comprises 43-51 amino acid residues. In some embodiments, the PD-L1-binding peptide comprises 50 or fewer amino acid residues. In some embodiments, the PD-L1-binding peptide comprises 43-49 amino acid residues.
[0018] In some embodiments, the PD-L1-binding peptide further comprises a half-life modifying agent. In some embodiments, the half-life modifying agent is selected from the group consisting of a polymer, polyethylene glycol (PEG), hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine, and serine, a water soluble polymer comprising glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, albumin, and a molecule that binds to albumin. In some embodiments, the half-life modifying agent is an albumin-binding peptide. In some embodiments, the half-life modifying agent is an Fc domain. In some embodiments, the half-life modifying agent is polyethylene glycol. In some aspects, the half-life modifying agent is a fatty acid.
[0019] In various aspects, the disclosure provides peptide conjugates comprising a PD-L1-binding peptide conjugated to an active agent, wherein the PD-L1-binding peptide comprises at least six cysteine residues located at amino acid positions n, n+4, n+14, n+28, n+38, and n+42, and comprises at least three disulfide bonds connecting the first cysteine residue of the at least six cysteine residues to the sixth cysteine residue, connecting the second cysteine residue of the at least six cysteine residues to the fifth cysteine residue of the at least six cysteine residues, and connecting the third cysteine of the at least six cysteine residues to the fourth cysteine residue of the at least six cysteine residues, where n corresponds to the amino acid position of the first cysteine residue of the at least six cysteine residues.
[0020] In some embodiments, amino acid position n corresponds to amino acid position 4, such that at least six cysteine amino acid residues are located at amino acid positions 4, 8, 18, 32, 42, and 46. In some embodiments, the PD-L1-binding peptide further comprises a first α-helix comprising residues n through n+20, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the PD-L1-binding peptide further comprises a second α-helix comprising residues n+34 through n+44, where n corresponds to the amino acid position of the first cysteine residue. In some embodiments, the second α-helix comprises residues n+29 through n+44.
[0021] In some embodiments, the PD-L1-binding peptide comprises: (a) X 1 X 2 X 3 X 4 X 5 X 6 CX 7 X 8 X 9 C (SEQ ID NO: 361) 1 is D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 2 is G, E, Q, or F; X 3 is D or K; X 4is G, V, or P; X 5 is G, H, R, V, F, W, or P; X 6 is A, D, or K; X 7 is E, H, Q, L, or F; X 8 is D, E, R, S, T, M, L, or F; X 9 is G, A, D, E, H, K, R, M, L, or P), or (b) X 1 FX 2 VFX 2 CLX 3 X 3 C (SEQ ID NO: 363) 1 is K or P; X 2 are independently D or K; X 3 are independently any non-cysteine amino acid). In some embodiments, the N-terminal amino acid residue of the first PD-L1 binding motif is located at amino acid residue position n+32. In some embodiments, the C-terminal amino acid residue of the first PD-L1 binding motif is located at amino acid residue position n+42. In some embodiments, the first PD-L1 binding motif comprises the sequence KFDVFKCLDHC (SEQ ID NO: 365).
[0022] In some embodiments, the PD-L1-binding peptide is (a) CX 1 X 2 X 3 CX 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 C (SEQ ID NO: 360) 1 is K, R, or V; X 2 is E, Q, S, M, L, or V; X 3 is D, E, H, K, R, N, Q, S, or Y; X 4 is D, M, or V; X 5 is A, K, R, Q, S, or T; X 6is A, D, E, H, Q, S, T, M, I, L, V, or W; X 7 is A, E, R, Q, S, T, W, or P; X 8 is A, E, K, R, N, Q, T, M, I, L, V, or W; X 9 is G, A, E, K, N, T, or Y; X 10 is G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 11 is D, K, R, N, L, or V; X 12 is G, A, D, T, L, W, or P), or (b) CKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 C (SEQ ID NO: 362) 1 are independently any non-cysteine amino acid; X 2 is M, I, L, or V; X 3 is Y, A, H, K, R, N, Q, S, or T). In some embodiments, the N-terminal amino acid residue of the second PD-L1-binding motif is located at amino acid residue position n. In some embodiments, the C-terminal amino acid residue of the first PD-L1-binding motif is located at amino acid residue position n14. In some embodiments, the second PD-L1-binding motif comprises the sequence CKVHCVKEWMAGKAC (SEQ ID NO: 364). In some embodiments, amino acid position n corresponds to amino acid position 4 of the PD-L1-binding peptide, such that at least six cysteine amino acid residues are located at amino acid positions 4, 8, 18, 32, 42, and 46 of the PD-L1-binding peptide.
[0023] In some embodiments, the PD-L1-binding peptide has an equilibrium dissociation constant (K D) can bind to PD-L1. In some embodiments, the PD-L1-binding peptide comprises at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, or at least 49 amino acid residues. In some embodiments, the PD-L1-binding peptide comprises between 43 and 51 amino acid residues. In some embodiments, the PD-L1-binding peptide comprises between 43 and 49 amino acid residues.
[0024] In various aspects, the disclosure provides peptide conjugates comprising any of the PD-L1-binding peptides described herein conjugated to an active agent.
[0025] In some embodiments, the active agent comprises an immune cell targeting agent. In some embodiments, the immune cell targeting agent is an immune cell targeting peptide. In some embodiments, the immune cell targeting agent includes a single-chain variable fragment (scFv), a cysteine-dense peptide, an avimer, a Kunitz domain, an affibody, an adnectin, a nanophytin, a finomer, a beta-hairpin, a stapled peptide, a bicyclic peptide, an antibody, an antibody fragment, a protein, a peptide, a peptide fragment, a binding domain, a small molecule, or a nanobody capable of binding to an immune cell. In some embodiments, the immune cell targeting agent is capable of binding to T cells, B cells, macrophages, natural killer cells, fibroblasts, regulatory T cells, regulatory immune cells, neural stem cells, or mesenchymal stem cells. In some embodiments, the immune cell targeting agent is capable of binding to T cells. In some embodiments, the immune cell targeting agent is capable of binding to regulatory T cells. In some embodiments, the immune cell targeting agent can bind to CD3, 4-1BB, CD28, CD137, CD89, CD16, CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1. In some embodiments, the immune cell targeting agent can bind to CD3. In some embodiments, the immune cell targeting agent can bind to CD25. In some embodiments, the immune cell targeting agent can bind to 4-1BB. In some embodiments, the immune cell targeting agent can bind to CD28. In some embodiments, the immune cell targeting agent comprises a sequence having at least 90% sequence identity to SEQ ID NO: 122 or any one of SEQ ID NOs: 442 through 491.
[0026] In some embodiments, the immune cell targeting agent is fused to a first heterodimerization domain and the PD-L1-binding peptide is fused to a second heterodimerization domain. In some embodiments, the first heterodimerization domain complexes with the second heterodimerization domain to form a heterodimer. In some embodiments, the first heterodimerization domain, the second dimerization domain, or both, comprise an Fc domain. In some embodiments, the first heterodimerization domain, the second dimerization domain, or both, comprise the sequence of any one of SEQ ID NOs: 124 to 153. In some embodiments, the first heterodimerization domain comprises the sequence of any one of SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 142, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, or SEQ ID NO: 152, and the second heterodimerization domain comprises the sequence of any one of SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, or SEQ ID NO: 153. In some embodiments, the first heterodimerization domain comprises strand 1 of a heterodimerization pair provided in Table 3. In some embodiments, the second heterodimerization domain comprises strand 2 of a heterodimerization pair provided in Table 3. In some embodiments, the second heterodimerization domain comprises the sequence of any one of SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:150, or SEQ ID NO:152, and the first heterodimerization domain comprises the sequence of any one of SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:133, SEQ ID NO:135, SEQ ID NO:137, SEQ ID NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145, SEQ ID NO:147, SEQ ID NO:149, SEQ ID NO:151, or SEQ ID NO:153.In some embodiments, the first heterodimerization domain comprises chain 2 of a heterodimerization pair provided in Table 3. In some embodiments, the second heterodimerization domain comprises chain 1 of a heterodimerization pair provided in Table 3. In some embodiments, the peptide complex comprises a sequence having at least 90% sequence identity to SEQ ID NO: 119 or SEQ ID NO: 120. In some embodiments, the peptide complex comprises a sequence having at least 90% sequence identity to SEQ ID NO: 123.
[0027] In some embodiments, the immune cell targeting agent and PD-L1-binding peptide are fused to a homodimerization domain. In some embodiments, the immune cell targeting agent and PD-L1-binding peptide form a single polypeptide chain. In some embodiments, the peptide conjugate comprises a sequence having at least 90% sequence identity to SEQ ID NO: 121 or any one of SEQ ID NOs: 438-441.
[0028] In some embodiments, the immune cell targeting agent is linked to the PD-L1-binding peptide via a linker. In some embodiments, the linker comprises a peptide linker. In some embodiments, the linker comprises a small molecule linker. In some embodiments, the linker comprises an Fc domain. In some embodiments, the peptide conjugate further comprises an albumin binding domain, polyethylene glycol, or both.
[0029] In some embodiments, the active agent comprises a transmembrane domain, a cytoplasmic domain, or a combination thereof. In some embodiments, the active agent comprises a chimeric antigen receptor. In some embodiments, the peptide conjugate further comprises a T cell.
[0030] In some aspects, the active agent comprises a therapeutic agent, a detectable agent, or a combination thereof. In some aspects, the detectable agent includes a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a radionuclide, or a radionuclide chelator. In some aspects, the therapeutic agent includes an anti-cancer agent, a chemotherapeutic agent, a radiotherapeutic agent, an anti-inflammatory agent, a pro-inflammatory cytokine, an oligonucleotide, an immunotherapy agent, or a combination thereof. In some aspects, the active agent comprises a radioisotope. In some embodiments, the radioisotope includes an alpha emitter, a beta emitter, a positron emitter, a gamma emitter, a metal, actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, yttrium, actinium 225, lead 212, 11 C or 14 C. 13 N, 18 F, 67 Ga, 68 Ga, 64 Cu, 67 Cu, 89 Zr, 177 Lu, indium-111, technetium-99m, yttrium-90, iodine-131, iodine-123, or astatine-211.
[0031] In some embodiments, the oligonucleotide includes DNA, RNA, antisense oligonucleotide, aptamer, miRNA, siRNA, alternative splicing modulator, mRNA-binding sequence, miRNA-binding sequence, siRNA-binding sequence, RNase H1-binding oligonucleotide, RISC-binding oligonucleotide, polyadenylation modulator, or combinations thereof. In some embodiments, the oligonucleotide comprises any one of SEQ ID NOs: 366-396, 492-545, or 552. In some embodiments, the oligonucleotide binds to a target sequence comprising any one of SEQ ID NOs: 397-430 or 546-549. In some embodiments, the peptide complex remains intact after incubation in human serum. In some embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% remain intact after incubation in human serum. In some embodiments, the PD-L1-binding peptide, when complexed with the oligonucleotide, has an equilibrium dissociation constant (K D In some embodiments, the PD-L1 binding peptide has a lower affinity for PD-L1 at pH 5.5, 6.0, or 6.5 than at pH 7.4.
[0032] In some embodiments, anti-inflammatory agents include anti-inflammatory cytokines, steroids, glucocorticoids, corticosteroids, cytokine inhibitors, ROR gamma inhibitors, JAK inhibitors, tyrosine kinase inhibitors, or nonsteroidal anti-inflammatory drugs. In some embodiments, anti-cancer agents include anti-tumor agents, cytotoxic agents, tyrosine kinase inhibitors, mTOR inhibitors, retinoids, microtubule polymerization inhibitors, pyrrolobenzodiazepine dimers, or anti-cancer antibodies. In some embodiments, pro-inflammatory cytokines include TNFα, IL-2, IL-6, IL-12, IL-15, IL-21, or IFNγ. In some embodiments, anti-inflammatory agents include anti-inflammatory cytokines, steroids, glucocorticoids, corticosteroids, cytokine inhibitors, ROR gamma inhibitors, JAK inhibitors, tyrosine kinase inhibitors, or nonsteroidal anti-inflammatory drugs. In some embodiments, the anti-cancer agent includes an anti-tumor agent, a cytotoxic agent, a tyrosine kinase inhibitor, an mTOR inhibitor, a retinoid, a microtubule polymerization inhibitor, a pyrrolobenzodiazepine dimer, or an anti-cancer antibody. In some embodiments, the pro-inflammatory cytokine includes TNFα, IL-2, IL-6, IL-12, IL-15, IL-21, or IFNγ. In some embodiments, the therapeutic agent includes an oncolytic viral vector.
[0033] In some embodiments, the peptide conjugate further comprises a half-life modifying agent. In some embodiments, the half-life modifying agent is selected from the group consisting of a polymer, polyethylene glycol (PEG), hydroxyethyl starch, polyvinyl alcohol, a water-soluble polymer, a zwitterionic water-soluble polymer, a water-soluble poly(amino acid), a water-soluble polymer of proline, alanine, and serine, a water-soluble polymer comprising glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, and an albumin-binding molecule. In some embodiments, the albumin-binding molecule is a serum albumin-binding peptide.
[0034] In some embodiments, the peptide conjugate further comprises a cell-penetrating peptide. In some embodiments, the cell-penetrating peptide comprises the sequence of any one of SEQ ID NOs: 249 to 341.
[0035] In various aspects, the disclosure provides pharmaceutical compositions comprising any PD-L1-binding peptide described herein, or any peptide conjugate described herein, and a pharmaceutically acceptable carrier.
[0036] In various aspects, the disclosure provides methods of inhibiting PD-L1 in a subject, the method comprising administering to the subject a composition comprising a PD-L1-binding peptide comprising at least six cysteine residues and at least three disulfide bonds connecting the at least six cysteine residues; allowing the PD-L1-binding peptide to bind to PD-L1 on PD-L1-positive cells; and inhibiting PD-L1.
[0037] In some embodiments, the at least six cysteine residues are located at amino acid positions n, n+4, n+14, n+28, n+38, and n+42, where n corresponds to the amino acid position of the first cysteine residue of the at least six cysteine residues. In some embodiments, amino acid position n corresponds to amino acid position 4, such that the at least six cysteine amino acid residues are located at amino acid positions 4, 8, 18, 32, 42, and 46.
[0038] In various aspects, the disclosure provides methods of inhibiting PD-L1 in a subject, the method comprising administering to the subject a composition comprising any of the PD-L1-binding peptides described herein, allowing the PD-L1-binding peptide to bind to PD-L1 on PD-L1-positive cells, and inhibiting PD-L1.
[0039] In some embodiments, inhibiting PD-L1 comprises inhibiting PD-1 from binding to PD-L1. In some embodiments, the method further comprises alleviating immunosuppression, alleviating T cell depletion, restoring immune function, or a combination thereof. In some embodiments, the method further comprises treating a condition in the subject. In some embodiments, the condition is cancer and the PD-L1 positive cells are cancer cells. In some embodiments, treating cancer comprises enhancing an immune response to the cancer cells.
[0040] In various aspects, the disclosure provides methods of delivering an active agent to PD-L1 positive cells in a subject, the method comprising administering to the subject a peptide conjugate comprising a PD-L1-binding peptide comprising at least six cysteine residues and at least three disulfide bonds connecting the at least six cysteine residues, complexed to an active agent; allowing the PD-L1-binding peptide to bind to the PD-L1 positive cells; and delivering the active agent to the PD-L1 positive cells.
[0041] In some embodiments, the at least six cysteine residues are located at amino acid positions n, n+4, n+14, n+28, n+38, and n+42, where n corresponds to the amino acid position of the first cysteine residue of the at least six cysteine residues. In some embodiments, amino acid position n corresponds to amino acid position 4, such that the at least six cysteine amino acid residues are located at amino acid positions 4, 8, 18, 32, 42, and 46.
[0042] In various aspects, the disclosure provides methods of delivering an active agent to PD-L1 positive cells in a subject, the method comprising administering to the subject a peptide conjugate comprising any PD-L1-binding peptide described herein, or the peptide conjugate of any one of claims 39-107, conjugated to an active agent; allowing the PD-L1-binding peptide to bind to the PD-L1 positive cells; and delivering the active agent to the PD-L1 positive cells.
[0043] In some embodiments, the active agent comprises an anti-cancer agent, a chemotherapeutic agent, a radiotherapeutic agent, or a pro-inflammatory cytokine. In some embodiments, the active agent comprises an oligonucleotide. In some embodiments, the peptide complex remains intact after incubation in human serum. In some embodiments, the PD-L1-binding peptide, when complexed with the oligonucleotide, has an equilibrium dissociation constant (K D ) binds to PD-L1.
[0044] In some embodiments, the method further comprises binding the oligonucleotide to a target sequence upon delivery to the PD-L1-positive cell. In some embodiments, the method further comprises modulating alternative splicing of the target sequence, locating a polyadenylation site in the target sequence, inhibiting translation of the target sequence, inhibiting binding of the target sequence to a secondary target sequence, recruiting RISC to the target sequence, recruiting RNase H1 to the target sequence, inducing cleavage of the target sequence, or modulating the target sequence upon binding of the oligonucleotide to the target sequence. In some embodiments, the active agent comprises an anti-inflammatory cytokine, a steroid, a glucocorticoid, a corticosteroid, or a non-steroidal anti-inflammatory drug. In some embodiments, the active agent comprises an immune cell targeting agent.
[0045] In some embodiments, the method further comprises binding an immune cell targeting agent to the immune cells and recruiting the immune cells to PD-L1-positive cells. In some embodiments, recruiting the immune cells to the PD-L1-positive cells comprises forming an immune synapse. In some embodiments, the immune synapse has a width of 3 nm to 25 nm, 5 nm to 20 nm, or 10 nm to 15 nm. In some embodiments, the immune synapse has a width of 3 nm or less, 5 nm or less, 8 nm or less, 10 nm or less, 13 nm or less, 15 nm or less, 15 nm or less, 18 nm or less, 20 nm or less, 23 nm or less, 25 nm or less, 30 nm or less, 35 nm or less, 40 nm or less, 45 nm or less, or 50 nm or less.
[0046] In some embodiments, the immune cells include T cells, B cells, macrophages, natural killer cells, fibroblasts, regulatory T cells, regulatory immune cells, neural stem cells, or mesenchymal stem cells. In some embodiments, the immune cell targeting agent binds to CD3, 4-1BB, CD28, CD137, CD89, CD16, CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1. In some embodiments, the immune cell targeting agent binds to CD3. In some embodiments, the immune cell targeting agent binds to CD25. In some embodiments, the immune cell targeting agent binds to 4-1BB. In some embodiments, the immune cell targeting agent binds to CD28.
[0047] In some embodiments, the method further comprises killing the PD-L1 positive cells upon delivery of the immune cells to the PD-L1 positive cells. In some embodiments, the method further comprises inhibiting the PD-L1 positive cells upon delivery of the immune cells to the PD-L1 positive cells. In some embodiments, the immune cell targeting agent includes a single chain variable fragment (scFv), a cysteine-dense peptide, an avimer, a Kunitz domain, an affibody, an adnectin, a nanophytin, a finomer, a beta hairpin, a stapled peptide, a bicyclic peptide, an antibody, an antibody fragment, a protein, a peptide, a peptide fragment, a binding domain, a small molecule, or a nanobody.
[0048] In some embodiments, the immune cell targeting agent is fused to a first heterodimerization domain and the PD-L1-binding peptide is fused to a second heterodimerization domain. In some embodiments, the first heterodimerization domain complexes with the second heterodimerization domain to form a heterodimer. In some embodiments, the first heterodimerization domain, the second dimerization domain, or both, comprise an Fc domain.
[0049] In some embodiments, the immune cell targeting agent is linked to the PD-L1-binding peptide via a linker. In some embodiments, the immune cell targeting agent is linked to the PD-L1-binding peptide via an Fc domain. In some embodiments, the immune cell targeting agent and the PD-L1-binding peptide form a single polypeptide chain.
[0050] In some embodiments, the peptide conjugate comprises a chimeric antigen receptor. In some embodiments, the active agent comprises a transmembrane domain, a cytoplasmic domain, or a combination thereof. In some embodiments, the peptide conjugate further comprises a T cell. In some embodiments, the method further comprises delivering the T cell to a PD-L1-positive cell. In some embodiments, the method further comprises killing the PD-L1-positive cell.
[0051] In some embodiments, the method further comprises treating the condition in the subject. In some embodiments, the condition is cancer. In some embodiments, the PD-L1-positive cells are cancer cells. In some embodiments, the cancer includes melanoma, skin cancer, non-small cell lung cancer, small cell lung cancer, kidney cancer, esophageal cancer, oral cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer, colorectal cancer, colon cancer, rectal cancer, head and neck cancer, lymphoma, bladder cancer, liver cancer, gastric cancer, breast cancer, triple-negative breast cancer, pancreatic cancer, prostate cancer, Merkel cell carcinoma, mesothelioma, brain tumor, or PD-L1-expressing cancer. In some embodiments, the brain tumor includes glioblastoma, astrocytoma, meningioma, primary brain tumor, metastatic brain tumor, PDL1-expressing cancer, or metastatic brain tumor.
[0052] In some embodiments, the condition is hyperglycemia, type 1 diabetes, or type 2 diabetes. In some embodiments, the PD-L1 positive cells comprise pancreatic beta cells. In some embodiments, the immune cells are regulatory T cells, and recruitment of regulatory T cells to pancreatic beta cells protects the pancreatic beta cells and prevents, alleviates the effects of, reduces the symptoms of, or delays the onset of hyperglycemia, type 1 diabetes, or type 2 diabetes in the subject, thereby treating hyperglycemia, type 1 diabetes, or type 2 diabetes.
[0053] In some embodiments, the condition is an autoimmune or inflammatory disorder. In some embodiments, the PD-L1-positive cells comprise pancreatic beta cells. In some embodiments, the immune cells comprise regulatory T cells or mesenchymal stem cells. In some embodiments, the immune cell targeting agent binds to CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, or STRO-1. In some embodiments, when recruited to PD-L1-positive cells, the immune cells inhibit an autoimmune or inflammatory response, thereby treating the autoimmune or inflammatory disorder. In some embodiments, the autoimmune or inflammatory disorder includes rheumatoid arthritis, atherosclerosis, ischemia-reperfusion injury, colitis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, type 1 diabetes, type 2 diabetes, or neuroinflammation.
[0054] In some embodiments, the PD-L1-binding peptide has an equilibrium dissociation constant (K D ) binds to PD-L1.
[0055] Incorporation by Reference All publications, patents, and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0056] The novel features described herein are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative implementations, in which the principles of the invention are utilized, and the accompanying drawings of which: [Brief explanation of the drawings]
[0057] [Figure 1A]Mammalian display and library screening methods for selecting cystine-dense peptide (CDP) scaffolds for PD-L1-binding peptides are shown. A general mammalian surface display screening method using lentiviral vectors to screen for target binding properties or assess peptide quality is shown schematically (right, "Vector SDPR"). Mammalian cells, such as HEK293F cells, express and display GFP-tagged cystine-dense peptides (CDPs) from a CDP library. In the first assay (left, "Vector SDGF"), CDPs are screened for binding to a fluorescently labeled target protein (e.g., a biotinylated protein labeled with fluorescent streptavidin). Cells are sorted based on co-staining fluorescence, and CDPs that bind to the target protein are selected. In the second assay, the quality of tagged CDPs from the CDP library is assessed. Intact tagged CDPs (e.g., CDPs with a 6xHis tag (SEQ ID NO: 248)) are labeled with a co-stain (e.g., a fluorescently labeled anti-6xHis antibody). Cells are sorted based on costaining fluorescence and intact expressed and displayed CDPs are selected. [Figure 1B] Figure 1 shows a mammalian display and library screening method for selecting cystine-dense peptide (CDP) scaffolds for PD-L1-binding peptides. Histogram distribution of surface folding scores for CDPs from a taxonomically diverse CDP library is shown. The highest-scoring CDPs (N=953), corresponding to cystine scaffolds predicted to have high surface expression, protease resistance, or both, were selected for further analysis. [Figure 1C]Figure 1 shows a mammalian display and library screening method for selecting cystine-dense peptide (CDP) scaffolds for PD-L1-binding peptides. A schematic of the system used to identify new CDP library members is shown. Approximately 100,000 curated CDP sequences were searched for CDPs with sequence or cysteine pattern homology to the top-scoring CDPs identified in Figure 1B. The resulting second-generation optimized library ("Gen2 library") contained 8,893 CDPs. [Figure 1D] Mammalian display and library screening methods for selecting cystine-dense peptide (CDP) scaffolds for PD-L1-binding peptides are shown. Flow-based comparison of CDP stability between a first-generation diversified CDP library and a second-generation optimized CDP library containing peptides homologous to the predicted high-stability CDP scaffolds identified in Figure 1C is shown. SDPR-cloned cells with 6xHis-tagged (SEQ ID NO: 248) CDP from either the diversified library (left) or the optimized library (right) were treated with 5 μg / mL trypsin (thin solid line), 20 μg / mL trypsin (thick solid line), or PBS (dashed line, "no trypsin") for 5 minutes. Cells were then treated with DTT for 5 minutes and stained with fluorescent anti-6xHis antibody. CDP histogram distributions were normalized to the mode. The optimized library demonstrated improved surface expression and protease resistance compared to the diversified library. [Figure 2A]Figure 1 shows a selection of various PD-L1-binding peptides consistent with three-dimensional structures, computational modeling, and phylogeny, providing high confidence in the selection of PD-L1-binding peptides with PD-L1 binding activity. Figure 2 shows a schematic representation of the structural modeling pipeline used to predict the three-dimensional structure and disulfide pairing of members of the optimized CDP library. I-TASSER version 5.1 modeling software was used to generate structural models from the CDP sequences. The most likely disulfide pairings were determined by minimizing the average pairwise distance between bonded cysteine sulfur atoms in the structural model. The Rosetta ForceDislufides program uses an all-atom refinement and repacking algorithm to relax the disulfide bond structure and minimize steric clashes. [Figure 2B] Figure 2 shows a selection of various PD-L1-binding peptides consistent with three-dimensional structures, computational modeling, and phylogeny, providing high confidence in the selection of PD-L1-binding peptides with PD-L1 binding activity. Representative alignments of crystal structures and computational models are shown for 20 CDPs from the optimized CDP library obtained as described in Figure 2A. The crystal structures of these CDPs were not included in the structural database used for computational modeling. Crystal structures available from the RCSB Protein Data Bank are referenced by PDB ID number. The root mean square deviation (RMSD) of the alignment between the crystal structure and the modeled structure is displayed below the PDB ID number or sequence number. For crystal structures containing multiple polypeptide chains in the asymmetric unit, the RMSD represents the average alignment between the modeled structure and each polypeptide in the asymmetric unit. [Figure 2C]Figure 2B shows a selection of various PD-L1-binding peptides consistent with three-dimensional structures, computational modeling, and phylogeny, providing high confidence in the selection of PD-L1-binding peptides with PD-L1 binding activity. Figure 2B shows a graphical comparison of the root mean square deviation (RMSD) of the 20 CDP alignments shown in Figure 2A. Computational models are fitted to the asymmetric unit (AU) of the crystal structure (left circle) with an average RMSD of 0.924 Å. Different asymmetric units of the crystal align with each other (right circle) with an average RMSD of 0.333 Å, providing a quantitative assessment of the accuracy of the models used in Figures 2A and 2B. [Figure 3] A structural model of the center-of-mass clusters (mesh cages indicated by arrows) of CDP library peptides docked to programmed death-ligand 1 (PD-L1) is shown. PD-1 bound to PD-L1 is shown as a ribbon structure based on its crystal structure (PDB ID NO: 4ZQK; Zak et al., Structure 23, 2341-2348 (2015)). These center-of-mass clusters are examples of where PD-L1-binding peptides may bind to PD-L1. Center-of-mass clusters located near the PD-1 binding site are indicated by open arrows. These PD-L1-binding peptides can all modulate the activity of PD-1 at its receptor, PD-L1, through steric or direct effects, and PD-L1-binding peptides that bind at or near the PD-1 binding site can directly inhibit PD-1 binding at the PD-1 binding site. [Figure 4A]Figure 1 shows a selection of various PD-L1-binding peptides consistent with three-dimensional structures, computational modeling, and phylogeny, providing high confidence in the selection of PD-L1-binding cystine-dense peptides with PD-L1 binding activity. The PD-L1-binding cystine-dense peptides tested were shown. A plot of the Rosetta energy of the docked scores for various docked PD-L1-binding cystine-dense peptides plotted against the solvent-accessible surface area (SASA) of the CDP scaffold is shown. Each dot, representing a peptide docked into the PD-L1 structure, is color-coded based on the major structural element (e.g., coil, α-helix, β-sheet) within the scaffold. Gray dots correspond to coil-rich CDPs, dark dots and filled triangles correspond to helix-rich CDPs, and light dots and open triangles correspond to sheet-rich CDPs. Triangles represent CDPs identified as binding hits by staining with fluorescently labeled PD-L1 and flow sorting, enriching for peptides that bind well to PD-L1. Four triangles are shown, two of which nearly overlap. Light gray shading corresponds to PD-L1-binding peptide clusters with a dock cluster score below about 26 at the PD-1 binding interface, representing scaffolds from the optimized library used to generate the docked enriched Met / Tyr scan (DEMYS) library. Dark gray shading corresponds to peptide clusters with a median dock cluster score of about 50%, representing scaffolds that were not predicted to bind well to PD-L1, and indeed did not bind well, as confirmed by staining with fluorescently labeled PD-L1 and flow sorting. These results demonstrate the increased likelihood that PD-L1-binding peptides selected and enriched for binding bind to PD-L1, and the utility of the PD-L1-binding peptides described herein. [Figure 4B]Figure 1 shows a selection of various PD-L1-binding peptides consistent with three-dimensional structure, computational modeling, and phylogeny, providing high confidence in the selection of PD-L1-binding cystine-dense peptides with PD-L1 binding activity. The PD-L1-binding cystine-dense peptides tested are shown. A phylogenetic tree showing the taxonomic diversity of high-scoring PD-L1-binding CDPs predicted to dock with PD-L1 near the PD-1 binding interface, with a center-of-mass cluster of PD-L1-binding peptides located near the PD-L1 binding site, and high utility for binding to PD-L1 and inhibiting PD-L1 interactions is shown. [Figure 5A] Enrichment of PD-L1-binding peptides expressed in a mammalian display system and binding of the PD-L1-binding peptides to PD-L1 are shown. A workflow for seeding novel protein-protein interactions using docking enrichment methionine (M)-tyrosine (Y) scanning (DEMYS) is shown (top). This shows an example of how DEMYS enrichment further diversifies an optimized library, changing residues in the reference sequence (in this case, methionine (M) and tyrosine (Y)) from hydrophilic to hydrophobic residues. A sample scaffold with DEMYS applied is also shown (bottom). The sample scaffold is color-coded by hydrophobicity, with the lightest shading indicating carbon atoms not in contact with polar atoms, intermediate shading indicating acidic atoms, and darker shading indicating basic atoms, with the remaining atoms shown in white. The reference sequence scaffold, which is not predicted to bind well to PD-L1, is shown in its parental format (SEQ ID NO: 356) along with three examples of Met or Tyr mutations, corresponding to D18M (SEQ ID NO: 5), R26Y (SEQ ID NO: 6), and R36M (SEQ ID NO: 7), to illustrate how the library can be diversified. [Figure 5B] Figure 1 shows the enrichment of PD-L1-binding peptides expressed in a mammalian display system and the binding of PD-L1-binding peptides to PD-L1. Figure 2 shows the results of a fluorescence-based mammalian display screen of an optimized CDP library. Results are plotted as PD-L1 binding versus CDP expression. Cells displaying CDP bound to PD-L1 are indicated by boxes. [Figure 5C] Figure 1 shows the enrichment of PD-L1-binding peptides expressed in a mammalian display system and the binding of PD-L1-binding peptides to PD-L1. Figure 2 shows the results of an optimized library that was further diversified using a docking-enriched methionine-tyrosine scanning (DEMYS) CDP library fluorescence-based mammalian display screen. Results are plotted as PD-L1 binding versus CDP expression. Cells displaying CDP bound to PD-L1 are indicated by boxes. [Figure 5D] Figure 5B shows the enrichment of PD-L1-binding peptides expressed in a mammalian display system and the binding of PD-L1-binding peptides to PD-L1. Figure 5C shows a structural model of the CDP scaffold parent of SEQ ID NO: 4, identified in the optimized CDP library mammalian display screen shown in Figure 5B. [Figure 5E] Figure 5B shows the enrichment of PD-L1-binding peptides expressed in a mammalian display system and the binding of PD-L1-binding peptides to PD-L1. Figure 5B shows a flow plot plotted as CDP expression versus costained fluorescence for a transiently transfected SDGF cloned CDP corresponding to SEQ ID NO: 4, identified in the PD-L1 mammalian display screen shown in Figure 5B. The dark gray line corresponds to staining in the presence of PD-L1. The light gray line corresponds to staining in the absence of PD-L1. [Figure 5F]Figure 5B shows the enrichment of PD-L1-binding peptides expressed in a mammalian display system and the binding of the PD-L1-binding peptides to PD-L1. Figure 5C shows flow plots plotted as CDP expression versus costained fluorescence for four transiently transfected SDGF cloned CDPs corresponding to SEQ ID NO:4 (top left), SEQ ID NO:57 (top right), SEQ ID NO:58 (bottom left), and SEQ ID NO:59 (bottom right) identified in the PD-L1 DEMYS library screen shown in Figure 5C. The dark gray line corresponds to staining in the presence of PD-L1. The light gray line corresponds to staining in the absence of PD-L1. These data indicate that SEQ ID NO:4, SEQ ID NO:57, SEQ ID NO:58, and SEQ ID NO:59 bind to PD-L1, and that the PD-L1 DEMYS library generated more molecules that bind to PD-L1 than the optimized library. [Figure 6A] Figure 5B shows the structural and competitive binding aspects of PD-L1-binding peptides binding to PD-L1. The data demonstrate that SEQ ID NO: 4 competes with PD-1 to bind to human and cynomolgus PD-L1. Figure 5C shows a structural model (mesh) of the binding interface between the top 200 PD-L1-binding peptides identified in the optimized CDP library screening shown in Figure 5B, docked to PD-L1. The surface representations are color-coded for cynomolgus (left) and mouse (right) homology. PD-1 bound to PD-L1 is shown as a ribbon structure. [Figure 6B]Figure 1 shows the structural and competitive binding aspects of PD-L1-binding peptides binding to PD-L1. The data demonstrate that SEQ ID NO: 4 competes with PD-1 for binding to human and cynomolgus monkey PD-L1. This graph shows the results of a competition assay to assess the ability of the PD-L1-binding CDP corresponding to SEQ ID NO: 4 to disrupt the interaction of PD-1 with PD-L1. HEK293F cells expressing SEQ ID NO: 4 on their surface via SDGF were stained with fluorescently labeled PD-L1. Staining was compared in the presence of 50 nM, 150 nM, 500 nM, 1.5 μM, 5 μM, or 15 μM of PD-1 competitor Fc fusion protein (striped bars) or 50 nM, 150 nM, 500 nM, 1.5 μM, 5 μM, or 15 μM of control Fc fusion protein (dotted bars). [Figure 6C] Figure 1 shows the structural and competitive binding aspects of PD-L1-binding peptides binding to PD-L1. The data demonstrate that SEQ ID NO: 4 competes with PD-1 and binds to human and cynomolgus monkey PD-L1. Flow staining assays of cells surface-expressing SEQ ID NO: 4 binding to either human (darkest gray line), cynomolgus monkey (lightest gray line, "Cyno"), or mouse (medium gray line) PD-L1 are shown. [Figure 7A] Figure 1 shows the identification and enrichment of high affinity binders of PD-L1 binding peptides using site saturation mutagenesis and flow sorting for binding to PD-L1. Figure 2 shows the first round of flow sorting of site saturation mutagenesis (SSM) variants of SEQ ID NO: 4. Cells displaying the CDP variant of SEQ ID NO: 4 were surface stained with fluorescent PD-L1 and flow sorted based on binding to PD-L1. [Figure 7B] Figure 8 shows the identification and enrichment of high affinity binders of PD-L1 binding peptides using site saturation mutagenesis and flow sorting for binding to PD-L1. Figure 9 shows the second round of flow sorting of site saturation mutagenesis (SSM) variants of SEQ ID NO: 4. Cell surfaces displaying CDP variants of SEQ ID NO: 4 were stained with fluorescent PD-L1 and flow sorted based on binding to PD-L1. The top 7% of PD-L1 binders were further analyzed in Figure 8. [Figure 7C]Figure 1 shows the identification and enrichment of high affinity binders of PD-L1 binding peptides using site saturation mutagenesis and flow sorting for binding to PD-L1. Flow sorting of site saturation mutagenesis (SSM) variants of SEQ ID NO: 4 that co-stained only in the absence of PD-L1. [Figure 8]Figure 21 shows an exemplary affinity maturation heat map of SEQ ID NO: 4 variants to identify high-performing residues and point mutations within PD-L1-binding peptides. Heat maps were used to identify PD-L1-binding peptides, including SEQ ID NO: 3, that have high affinity for PD-L1. Shading corresponds to the relative enrichment of each amino acid point mutation (vertical axis) relative to SEQ ID NO: 4 (horizontal axis). Lighter shaded boxes indicate greater (positive) enrichment, while darker shaded boxes indicate depletion. That is, lighter shaded boxes indicate sequences with increased relative abundance after two rounds of selection for PD-L1 binding, indicating improved binding compared to that of SEQ ID NO: 4, and darker shaded boxes indicate sequences with decreased relative abundance after two rounds of selection for PD-L1 binding, indicating disruption of binding compared to that of SEQ ID NO: 4. A binary color map of this data showing residues with positive enrichment is provided in Figure 21, and quantification of the enrichment data is shown in Table 12. The heatmap represents the log2-transformed enrichment of each variant after two rounds of sorting and re-propagation, normalized to both the abundance of the initial variant and the performance of SEQ ID NO:4 itself. Positive enrichment scores represent increased relative abundance and therefore improved binding. The sequences of the parent scaffold (SEQ ID NO:353), primary hit (SEQ ID NO:4), and affinity-matured variant (SEQ ID NO:3) are shown below the heatmap. Mutations are color-coded based on their beneficial or near-passenger status. Asterisks indicate novel N-linked glycosylation sites. "Beneficial in SEQ ID NO:3" indicates a point mutation that was included in combination with SEQ ID NO:3 to increase the affinity of SEQ ID NO:3 for PD-L1 compared to SEQ ID NO:4. "Omitted in SEQ ID NO:3" indicates a point mutation that appeared beneficial alone but became disruptive to binding when combined with other beneficial point mutations. This point mutation was omitted in SEQ ID NO:3. "Disruptive reversion" indicates a point mutation that decreased binding when reverted to the parent amino acid, indicating that those point mutations in SEQ ID NO:4 were beneficial to PD-L1 binding. "Neutral reversion" indicates a reversion to the parent amino acid present in SEQ ID NO:353 that does not affect binding to PD-L1, indicating that these mutations were acquired during library generation but did not aid in the binding of SEQ ID NO:4 to PD-L1.Such neutral reversions are also called passenger mutations. [Figure 9] Figure 8 shows a comparison of PD-L1 binding for six PD-L1-binding cystine-dense peptides containing amino acid substitutions enriched in the affinity maturation assay shown in Figure 8. The cystine-dense peptides contained either all six of the amino acid substitutions E11W, A13M, Y15G, I22N, Y36K, and W40F (SEQ ID NO: 8, "All 6") relative to SEQ ID NO: 4, or five of the six substitutions (SEQ ID NOs: 9 through 14, corresponding to the revertants W11E, M13A, G15Y, N22I, K36Y, and F40W, respectively). Staining was performed in one step (solid bars) or two steps (striped bars). The revertants W11E (SEQ ID NO: 9), G15Y (SEQ ID NO: 11), and K36Y (SEQ ID NO: 13) showed increased affinity for PD-L1 relative to SEQ ID NO: 8, and the corresponding revertants were beneficial for PD-L1 binding relative to the binding of SEQ ID NO: 8 ("All 6"). [Figure 10A] Figure 1 shows the production, purity, purification, stability, and PD-L1 binding affinity of PD-L1-binding cystine-dense peptides. Reverse-phase high-performance liquid chromatography (RP-HPLC) chromatograms (top) and SDS-PAGE gels (bottom) of three recombinant PD-L1-binding cystine-dense peptides (SEQ ID NO:4, SEQ ID NO:3, and SEQ ID NO:1) are shown. RP-HPLC and SDS-PAGE assays were performed under non-reducing (NR) conditions or in the presence of 10 mM DTT. The arrows in the RP-HPLC chromatograms indicate a minor species that likely represents glycosylated SEQ ID NO:3. The data demonstrate the successful production, purity, purification, and disulfide bond formation of SEQ ID NO:4, SEQ ID NO:3, and SEQ ID NO:1. The RP-HPLC data also show that the mature SEQ ID NO:3 and SEQ ID NO:1 unfold less upon exposure to DTT than the original hit SEQ ID NO:4. [Figure 10B]Figure 1 shows the production, purity, purification, stability, and PD-L1 binding affinity of PD-L1-binding cystine-dense peptides. Liquid chromatography-mass spectrometry (LC-MS) data for three recombinant PD-L1-binding cystine-dense peptides (SEQ ID NO: 4, SEQ ID NO: 3, and SEQ ID NO: 1) are shown. The data verify the identity of the aforementioned PD-L1-binding peptides based on the predicted molecular weight of CDP, and verify the formation of cystine disulfide bonds indicative of CDP structure, as DTT-treated (reducing conditions) peptides showed an increase in mass of approximately 6 Da. [Figure 10C] Figure 1 shows the production, purity, purification, stability, and PD-L1 binding affinity of PD-L1-binding cystine-dense peptides. Figure 2 shows surface plasmon resonance (SPR) plots of three recombinant PD-L1-binding cystine-dense peptides (SEQ ID NO: 4, SEQ ID NO: 3, and SEQ ID NO: 1). SEQ ID NO: 4 bound to PD-L1 with an equilibrium dissociation constant (KD) of 39.6 ± 0.3 nM, SEQ ID NO: 3 bound to PD-L1 with a KD = 160 ± 1 pM (kD = 1.25 ± 0.01 × 10 M-1s, kD = 2.00 ± 0.01 × 10-2 s-1), and SEQ ID NO: 1 bound to PD-L1 with a KD = 202 ± 2 pM (kD = 9.73 ± 0.06 × 10 M-1s, kD = 1.96 ± 0.01 × 10-2 s-1). This data demonstrates that SEQ ID NO: 4, SEQ ID NO: 3, and SEQ ID NO: 1 bind to PD-L1 with high affinity. These data also show that the mature variant binders SEQ ID NO: 1 and SEQ ID NO: 3 bind PD-L1 with higher affinity than SEQ ID NO: 4 from which they are derived. [Figure 10D] Figure 1 shows the production, purity, purification, stability, and PD-L1 binding affinity of PD-L1-binding cystine-dense peptides. Figure 2 shows SPR plots of SEQ ID NO: 1 competing with PD-1 for binding to PD-L1. Binding of PD-1 (SEQ ID NO: 349) to PD-L1 was compared in the absence of SEQ ID NO: 1 or in the presence of 0.6 μM or 3 μM SEQ ID NO: 1. This data indicates that SEQ ID NO: 1 can compete with PD-1 for binding to PD-L1. [Figure 11]Schematic representation of two exemplary bispecific immune cell engager (BiICE) complexes capable of binding to T cells by bispecifically binding to PD-L1 and CD3. CDP-based BiICE ("CS-BiICE") is formed from a first fusion protein (SEQ ID NO: 342) containing a PD-L1-binding CDP (SEQ ID NO: 2) with an N-terminal signal peptide (SEQ ID NO: 247; "SP") and a FLAG tag (DYKDEGGS; SEQ ID NO: 246) fused to an Fc "hole" sequence via a linker, and a second fusion protein (SEQ ID NO: 347) containing an anti-CD3 single-chain variable fragment (scFv) fused to an Fc "knob" sequence with an N-terminal signal peptide and a C-terminal 6xHis tag (SEQ ID NO: 248). The "hole" sequence heterodimerizes with the "knob" sequence. scFv-based BiICE ("SS-BiICE") is formed from a first fusion protein (SEQ ID NO: 346) comprising an anti-PD-L1 scFc with a FLAG tag fused to an N-terminal signal peptide and an Fc "hole" sequence, and a second fusion protein (SEQ ID NO: 347) comprising an anti-CD3 single-chain variable fragment (scFv) fused to an Fc "knob" sequence with an N-terminal signal peptide and a C-terminal 6xHis tag (SEQ ID NO: 248). The sequence organization of the components of CS-BiICE and SS-BiICE is shown in the top panel. The structural organization of heterodimerized CS-BiICE and SS-BiICE is shown in the bottom panel. [Figure 12]Figure 1 shows the results of a fluorescence-based binding assay to assess the cross-reactivity of various PD-L1 binding moieties with different PD-L1 orthologs. Cells expressing surface-bound PD-L1 binding moieties, including the PD-L1-binding cystine-dense peptide (SEQ ID NO: 3), a single-chain variable fragment (scFv) derived from an anti-PD-L1 antibody (SEQ ID NO: 345), or an scFv derived from the anti-PD-L1 drug atezolizumab (SEQ ID NO: 348), were stained with human, cynomolgus monkey ("Cyno"), or mouse his-tagged PD-L1 orthologs and co-stained with anti-His-iFluor647 antibody. Anti-His-iFluor647 antibody alone ("Co-stained only") was used as a comparison. Co-stained fluorescence of the cells is shown on the horizontal axis. The data show that SEQ ID NO:3 binds to human and cynomolgus monkey PD-L1 but not to mouse PD-L1, SEQ ID NO:345 binds to human PD-L1 but not to cynomolgus monkey or mouse PD-L1, and SEQ ID NO:348 binds to human, cynomolgus monkey, and mouse PD-L1 to varying degrees. [Figure 13A] Figure 1 shows the production, purity, purification, and binding to PD-L1 of BiICE complexes containing either a PD-L1-binding cystine-dense peptide or a PD-L1-binding scFv. Figure 2 shows an SDS-PAGE gel of purified CS-BiICE molecules (SEQ ID NO: 342 heterodimerized with SEQ ID NO: 347). Distinct bands corresponding to the heterodimer (H) and anti-CD3-scFv-Fc monomer (M) were observed under non-reducing (NR) conditions. Under reducing conditions (DTT), distinct bands corresponding to the CDP-Fc and scFv-Fc species were observed. This data demonstrates the successful production, purity, purification, heterodimerization, and disulfide bonding of CDP-based BiICE. [Figure 13B]Figure 1 shows the production, purity, purification, and binding of BiICE complexes containing either a PD-L1-binding cystine-dense peptide or a PD-L1-binding scFv to PD-L1. Figure 2 shows SPR measurements of CS-BiICE binding to PD-L1. CS-BiICE bound to PD-L1 with a KD of 11.2 nM (k=5.42×105 M-1s, kd=6.07±0.01×10-3s-1). This data demonstrates that CDP-based BiICE binds to PD-L1 with high affinity. [Figure 13C] Figure 1 shows the production, purity, purification, and binding to PD-L1 of BiICE complexes containing either PD-L1-binding cystine-dense peptide or PD-L1-binding scFv. Figure 2 shows an SDS-PAGE gel of purified SS-BiICE molecules (SEQ ID NO: 346 heterodimerized with SEQ ID NO: 347). Distinct bands corresponding to the heterodimer (H) and anti-CD3-scFv-Fc monomer (M) were observed under non-reducing (NR) conditions. A single band corresponding to the scFv-Fc species was observed under reducing (DTT) conditions. This data demonstrates the successful production, purity, dimerization, and purification of scFv-based BiICE. [Figure 13D] Figure 13 shows the production, purity, purification, and binding to PD-L1 of BiICE complexes containing either PD-L1-binding cystine-dense peptide or PD-L1-binding scFv. Figure 13 shows SPR measurements of SS-BiICE binding to PD-L1. SS-BiICE bound to PD-L1 with a KD of 65 nM. This data indicates that scFv BiICE binds to PD-L1 with lower affinity than the CDP-based BiICE shown in Figure 13B. [Figure 14A]Figure 1 shows validation of PD-L1-binding BiICE complexes by binding to T cells and inducing tumor cell death. Flow staining of human primary T cells from patient-derived peripheral blood mononuclear cells (PMBCs) using CS-BiICE and SS-BiICE molecules is shown. Cells are costained with a fluorescent anti-6xHis antibody. Costaining alone was included as a control. Both CS-BiICE and SS-BiICE showed increased staining over costaining alone, indicating T cell binding. This data demonstrates that PD-L1 / CD3-binding CS-BiICE and SS-BiICE molecules can bind to T cells via CD3. [Figure 14B] Validation of PD-L1-binding BiICE complexes by binding to T cells and inducing tumor cell death is shown. Results of a human T cell killing assay in PC3 cancer cell lines are shown for increasing concentrations of CS-BiICE or SS-BiICE. CS-BiICE induced T cell killing with a half-maximal effective concentration (EC50) of 28 pM in PD-L1-expressing ("WT") PC3 cells. SS-BiICE induced T cell killing with an EC50 of 97 pM in PD-L1-expressing ("WT") PC3 cells. T cell killing assays were also performed in PD-L1 knockout (KO) PC3 cells. Both CS-BiICE and SS-BiICE resulted in lower T cell killing in PD-L1 KO cells than in WT cells. These data demonstrate that CS-BiICE and SS-BiICE molecules were able to recruit T cells to cancer cells in a PD-L1-dependent manner and induce cancer cell death in PC3 cells. The data also show that CS-BiICE was more potent in inducing cancer cell death than SS-BiICE. [Figure 14C]Validation of PD-L1-binding BiICE complexes by binding to T cells and inducing tumor cell death is shown. Results of a human T cell killing assay in the MDA-MB-231 cancer cell line are shown for increasing concentrations of CS-BiICE or SS-BiICE. CS-BiICE induced T cell killing with an EC50 of 142 pM. SS-BiICE induced T cell killing with an EC50 of 333 pM. The data indicate that CS-BiICE and SS-BiICE molecules were able to recruit T cells to cancer cells and induce cancer cell death in MDA-MB-231 cells. The data also indicate that CS-BiICE was more potent than SS-BiICE in inducing cancer cell death. [Figure 14D] Validation of PD-L1-binding BiICE complexes by binding to T cells and inducing tumor cell death is shown. Results of a human T cell killing assay in the PBT-05 cancer cell line are shown for increasing concentrations of CS-BiICE or SS-BiICE. CS-BiICE induced T cell killing with an EC50 of 2.4 pM. SS-BiICE induced T cell killing with an EC50 of 7.7 pM. The data indicate that CS-BiICE and SS-BiICE molecules were able to recruit T cells to cancer cells and induce cancer cell death in PBT-05 cells. The data also indicate that CS-BiICE was more potent than SS-BiICE in inducing cancer cell death. [Figure 14E]Validation of a PD-L1-binding BiICE complex by binding to T cells and inducing tumor cell death is shown. A representative BiICE is shown schematically, promoting contact between T cells and cancer cells, enabling the T cells to kill the cancer cells. The immune synapse is narrow enough to allow signal exchange between targeted cells bound by the PD-L1-binding peptide and targeted immune cells bound by an immune cell-binding moiety, such as an anti-CD3 antibody, resulting in an immune response against the cancer cells. In this example, SEQ ID NO: 2 is used. It is understood that any PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118) can be used with an immune cell-binding moiety (e.g., SEQ ID NO: 122 or any one of SEQ ID NOs: 422-491) to create a BiICE and induce an immune response against the target cancer. [Figure 15A] Further purification of SS-BiICE and CS-BiICE complexes and induction of tumor cell death via T cell recruitment are shown. SDS-PAGE gels of IMAC-purified and ultra-purified (IMAC and FLAG) BiICE preparations are shown. The purified SS-BiICE preparation is shown on the left, and the purified CS-BiICE preparation is shown on the right. This data demonstrates that additional FLAG purification removed the anti-CD3-scFv-Fc monomer, an impurity present in the SS-BiICE and CS-BiICE preparations after IMAC purification. [Figure 15B] Further purification of SS-BiICE and CS-BiICE complexes and induction of tumor cell death via T cell recruitment are shown. Results of a human T cell killing assay in the PC3 cancer cell line using various concentrations of standard-purified (IMAC) or ultra-purified (IMAG+FLAG) CS-BiICE or SS-BiICE are shown. The ultra-purified BiICE preparation underwent FLAG purification in addition to IMAC purification. T cell killing activity was retained even after the additional FLAG purification step. These data demonstrate that the T cell recruitment and tumor cell killing properties of SS-BiICE and CS-BiICE complexes are retained even after removal of impurities by additional purification steps, and that tumor cell killing is due to the function of the heterodimeric BiICE molecule, not impurities. [Figure 16A] We demonstrate the ability of PD-L1-binding CDP-based BiICE complexes to shrink tumors in vivo and increase cancer survival rates. The experimental timeline for the in vivo tumor shrinkage assay is shown. Nude mice were implanted with PC3 or MDA-MB-231 tumors. The day when tumors reached a size of 100–200 mm2 was defined as day 0. Mice received four treatments of either SS-BiICE or CS-BiICE on days 1, 4, 8, and 11, and two treatments of activated human T cells on days 2 and 7. Tumor size and mortality were tracked up to day 95 and compared with control groups receiving vehicle alone or T cells alone. [Figure 16B] Figure 16A shows the ability of PD-L1-binding CDP-based BiICE complexes to shrink tumors in vivo and increase cancer survival. Figure 16A shows the survival probability of the first cohort of mice implanted with PC3 tumors and treated as described in Figure 16A. The data demonstrate that CS-BiICE complexes significantly increased the in vivo survival probability of mice implanted with PC3 tumors compared with SS-BiICE complexes, T cells, or vehicle alone. ns: not statistically significant. *: P<0.05. **: P<0.01. ***: P<0.001. No label: P<0.0001. P values for Kaplan-Meier curves were determined by the log-rank (Mantel-Cox) test. [Figure 16C] We demonstrate the ability of PD-L1-binding CDP-based BiICE conjugates to shrink tumors in vivo and increase cancer survival. PC3 tumors were implanted and tumor size was shown for mice treated with vehicle alone (no T cells, no BiICE; top left), T cells alone (no BiICE; top right), T cells and SS-BiICE (bottom left), or T cells and CS-BiICE (bottom right). The data show that while both SS-BiICE and CS-BiICE conjugates demonstrated the ability to shrink tumors in vivo, tumors recurred in mice treated with SS-BiICE but not in mice treated with CS-BiICE. [Figure 16D]The ability of PD-L1-binding CDP-based BiICE conjugates to shrink tumors in vivo and increase cancer survival rates is demonstrated. Figure 16A shows the survival probability of a second cohort of mice implanted with PC3 tumors and treated as described above, with the exception of two groups treated with the clinical anti-PD-L1 antibody durvalumab at either 1 nmol or 0.1 nmol. An additional group treated with 0.1 nmol CS-BiICE was also included, along with a repeat of 1 nmol CS-BiICE. The data show that CS-BiICE conjugates, at doses of 1 nmol or 0.1 nmol, increased the in vivo survival probability of mice bearing implanted PC3 tumors compared with durvalumab or vehicle alone. P < 0.0001 for 1 nmol and 0.1 nmol CS-BiICE versus vehicle and both durvalumab groups. ns: not statistically significant. P values for Kaplan-Meier curves were determined by the log-rank (Mantel-Cox) test. [Figure 16E] The ability of PD-L1-binding CDP-based BiICE conjugates to shrink tumors in vivo and increase cancer survival rates is demonstrated. PC3 tumors were implanted and tumor size was shown for mice treated with vehicle alone (no T cells, no BiICE; top left), T cells and 1 nmol of durvalumab (top center, "Durva(1)"), T cells and 0.1 nmol of durvalumab (top right, "Durva(0.1)"), T cells and 1 nmol of CS-BiICE (bottom left, "CS-BiICE(1)"), or T cells and 0.1 nmol of CS-BiICE (bottom center, "CS-BiICE(0.1)"). The data demonstrate that tumors shrank and did not recur in mice treated with 1 nmol or 0.1 nmol of CS-BiICE. [Figure 16F]Figure 16 shows the ability of PD-L1-binding CDP-based BiICE complexes to shrink tumors in vivo and increase cancer survival. Figure 16A shows the survival probability of mice implanted with MDA-MB-231 tumors and treated as described in Figure 16A. The data demonstrate that CS-BiICE complexes increased the in vivo survival probability of mice bearing implanted MDA-MB-231 tumors compared with T cells alone or vehicle alone. P < 0.0001 for CS-BiICE vs. vehicle alone or T cells alone. ns: not statistically significant. P values for Kaplan-Meier curves were determined by the log-rank (Mantel-Cox) test. [Figure 16G] Figure 16 shows the ability of PD-L1-binding CDP-based BiICE conjugates to shrink tumors in vivo and increase cancer survival. Figure 16A shows the number of days until tumor volume tripled in mice implanted with MDA-MB-231 tumors and treated as described in Figure 16A. The data demonstrate that treatment with CS-BiICE conjugates delayed MDA-MB-231 tumor growth in vivo compared with treatment with SS-BiICE conjugates or T cells alone, or vehicle alone. ns: not statistically significant. *: P<0.05. **: P<0.01. ***: P<0.001. No label: P<0.0001. P values for Kaplan-Meier curves were determined by the log-rank (Mantel-Cox) test. [Figure 16H] Figure 1 shows the ability of PD-L1-binding CDP-based BiICE complexes to shrink tumors and increase cancer survival in vivo. Mice were implanted with MDA-MB-231 tumors and treated with vehicle alone (no T cells, no BiICE; top left), T cells alone (no BiICE; top right), T cells and SS-BiICE (bottom left), or T cells and CS-BiICE (bottom right). The data demonstrate that treatment with CS-BiICE complexes slowed MDA-MB-231 tumor growth in vivo compared with treatment with SS-BiICE complexes or T cells alone, or vehicle alone. [Figure 17]Body weights of mice implanted with PC3 tumors and treated as described in Figure 16A are shown throughout the experiment. The data demonstrate that mice treated with CS-BiICE maintained a healthy weight throughout the study. ns: not statistically significant. P values for Kaplan-Meier curves were determined by the log-rank (Mantel-Cox) test. [Figure 18] This figure shows a complete SDS-PAGE gel of the recombinant proteins described herein. Either PBS or 10 mM DTT was included in the sample buffer before boiling and loading. All Fc-containing proteins, including the knob-and-hole bispecific molecules SS-BiICE and CS-BiICE, contained an IgG1 hinge region between the binder of interest (PD-1, control target, CDP, or scFv) and the Fc domain. This contained two cysteines that formed a pair of interdomain disulfide bonds between the paired hinge regions. This further stabilized the dimer between the Fc domains in an SDS-stable manner. The anti-CD3 scFv Fc knob protein expressed by itself (bottom right) was not a disulfide-stabilized dimer because the knob mutation did not allow stable dimerization and resulting disulfide formation. "*" and "#" indicate the SDS-PAGE mobility of non-BiICE contaminants in SS-BiICE and CS-BiICE, which correspond to the monomeric anti-CD3 scFv Fc knob. [Figure 19] Figure 1 shows an example of a histidine substitution scan to introduce pH-dependent binding affinity into a target-binding peptide. A histidine substitution scan of PD-L1-binding CDP (SEQ ID NO: 1) is shown. The peptide sequence is provided above and to the side, with each black box representing the first and second potential His substitution sites. Falling along the diagonal line from top left to bottom right represents a single His substitution. [Figure 20A] 1 shows the co-crystal structure of a high-affinity PD-L1-binding CDP (SEQ ID NO: 1, cartoon) bound or docked to PD-L1 (surface). [Figure 20B]Figure 20 shows the relative binding enrichment, expressed as the absolute value of the mean SSM enrichment, for PD-L1-binding CDP variants containing amino acid substitutions at resolved (R) or unresolved (UR) residues, as seen in the co-crystal structure in Figure 20 A. Substitutions at resolved residues had a greater positive or negative effect on binding than substitutions at unresolved residues (**: P = 0.0055), indicating that resolved residues played a greater role in the interaction with PD-L1 than unresolved residues. [Figure 20C] The overlay of PD-1 (mesh) and SEQ ID NO: 1 (cartoon) at the binding interface with PD-L1 is shown (surface). The PD-1 binding site overlaps with SEQ ID NO: 1, indicating that SEQ ID NO: 1 is predicted to compete with PD-1 for binding to PD-L1. [Figure 20D] Figure 20A shows close-up views of the PD-L1 co-crystal structure of SEQ ID NO: 1 from two different angles. Residues of SEQ ID NO: 1 that interact with PD-L1 are shown as sticks, including K5, V9, W12, M13, K16, V39, F40, L43, and D44. Residues of PD-L1 that interact with SEQ ID NO: 1 are also labeled, including Y56, Q66, R113, M115, A121, and Y123. [Figure 20E] Isolated side chains of selected residues of SEQ ID NO:1 (gray) are shown at the PD-L1 binding interface (black, minimally clashing rotamers) to the parent CDP (SEQ ID NO:353). The labeled residues of SEQ ID NO:1, including M13, V39, F40, and L43, correspond to substitutions relative to SEQ ID NO:353 that improved binding to PD-L1. [Figure 20F] Figure 6B shows a close-up of the binding interface between SEQ ID NO:1 (cartoon) and PD-L1 (surface). The PD-L1 surface is color-coded according to human (Hs) and mouse (Mm) homology. White corresponds to identical residues, dark shading corresponds to similar residues, and light shading corresponds to different residues. These differences in the binding interface between human PD-L1 and mouse PD-L1 are consistent with the lack of cross-reactivity with mouse PD-L1 seen with SEQ ID NO:187. Furthermore, the data shown in Figures 6B, 6C, and 8 are consistent with the crystal structure. [Figure 20G] The co-crystal structure of SEQ ID NO:1 and PD-L1 is shown, where SEQ ID NO:1 is shown as a wire diagram with the side chain of interest indicated by the thick bar (top). For comparison, the binding of PD-1 to PD-L1 is shown below. The superposition of the PD-1 binding interface with SEQ ID NO:1 on PD-L1 is consistent with the observed competition data shown in Figure 6B, Figure 6B, Figure 6C, and Figure 8. [Figure 21] Figure 8 shows a binary recoloring of the enrichment score map shown in Figure 8. Amino acid substitutions determined to have a neutral or beneficial effect compared to SEQ ID NO: 4 are colored gray. The original residues in the SEQ ID NO: 4 sequence are shown in black. Amino acids in gray or black are considered to promote binding to PD-L1. [Figure 22]The mechanism of action of the oligonucleotides is shown below. Oligonucleotides that form complexes with PD-L1-bound CDPs and target specific sequences for their regulation enter cells through PD-L1 binding and the natural endocytosis of PD-L1, resulting in the oligonucleotides being compartmentalized in endosomes. The oligonucleotides are released from the endocytic compartment into the cytoplasm, where they can move freely between the nucleus and the cytoplasm. Once in the nucleus, the oligonucleotides (1) regulate alternative splicing of the target sequence, (2) determine the location of the polyadenylation (polyA) site in the target sequence, and (3) recruit RNase H1 to induce cleavage of the target sequence. Cytoplasmic oligonucleotides can be designed to bind directly to (4) microRNA (miRNA) or messenger (mRNA) sequences, while siRNAs target specific sequences and regulate their activity. (5) siRNAs can also be used to bind to and regulate target sequences in the cytosol and bind to the RNA-induced silencing complex (RISC), a multiprotein complex incorporating a single strand of small interfering RNA (siRNA) or microRNA (miRNA), which uses the siRNA or miRNA as a template to recognize the target sequence's complementary mRNA. Once the RISC complex finds the complementary strand, it cleaves the target sequence. Alternatively, aptamers targeting specific sequences for regulation can be used to bind to and regulate target molecules. (6) Aptamers directly bind to and inhibit targets within or outside of cells. [Figure 23]Figure 1 shows example structures of various peptide-oligonucleotide conjugates (e.g., CDP-oligonucleotide conjugates in which the peptide moiety comprises a CDP) containing alternative and unconventional bases, represented as single-stranded, double-stranded, and hairpin structures. Examples of oligonucleotides include aptamers, gapmers, anti-miRs, siRNAs, splice blocker ASOs, and U1 adaptors. The CDP portion of the CDP-oligonucleotide conjugate can be used to target oligonucleotide sequences to specific tissues, targets, or cells, or to trigger endocytosis of the oligonucleotide sequence by cells. The legend is as follows: gray circle with black border = 2'-H (DNA); open circle with black border = 2'-OH (RNA); circle with horizontal stripe and black border = 2'-O-ME; circle with vertical stripe = 2'-O-MOE; black circle with gray border = 2'-F; spotted circle with gray border = LNA; hatched circle with gray border = morpholino (intrinsic phosphorodiamidate linkage not shown); gray corner = PO linkage; black corner = PS linkage. [Figure 24A] Incorporation of the indicated groups into RNA or DNA is shown. Structures of oligonucleotides containing a 5'-terminal thiol (thiohexyl, C6) modification (left) and a 3'-terminal thiol (C3) modification (right) are shown. [Figure 24B] Incorporation of the indicated groups into RNA or DNA is shown. MMT-hexylamino linker phosphoramidite is shown. [Figure 24C] Incorporation of the indicated groups into RNA or DNA is shown. TFA-pentylamino linker phosphoramidite is shown. [Figure 24D] Incorporation of the indicated groups into RNA or DNA is shown. RNA residues incorporating amine or thiol residues are shown. [Figure 24E] Incorporation of the indicated groups into RNA or DNA is shown. Oligonucleotides with aminohexyl modifications at the 5' end (left) and 3' end (right) are shown. [Figure 25]1 shows the formation of a cleavable disulfide bond between a peptide (e.g., the PD-L1-binding peptide of SEQ ID NO: 1) and a cyclic dinucleotide. [Figure 26] Figure 1 shows flow sorting data showing enrichment of peptides with pH-dependent binding to PD-L1. The data demonstrate that pH-dependent binding peptides can be generated by flow sorting. A histidine-doped library based on the PD-L1-binding peptide (SEQ ID NO: 187), prepared as described in Figure 19, was screened for peptides that exhibited stronger PD-L1 binding at neutral pH (7.4) and weaker binding at acidic pH (5.5). The input library was initially screened for high PD-L1 binding at pH 7.4. The second and third rounds of screening ("Sort 1" and "Sort 2," respectively) were performed at pH 5.5 to mimic endosomal pH and enriched for poor PD-L1 binding at this pH. The final round of screening ("Sort 3") was performed at pH 7.4. After screening, differential binding was observed at pH 7.4 and pH 5.5 ("Sort 4"). The pentagonal areas in each graph indicate the populations selected during sorting. The darker topographic density map shows PD-L1 staining under pH 7.4 conditions, and the lighter topographic density map shows PD-L1 staining under pH 5.5 conditions. [Figure 27]Figure 26 shows binding data at pH 7.4 (left bar) and pH 5.5 (right bar) for the pH-dependent PD-L1-binding peptide variants identified. Variants of SEQ ID NO: 1 with E2H, M13H, and K16H substitutions were screened individually and in combination for pH-dependent binding to PD-L1. Peptide variants containing substitutions in E2H (SEQ ID NO: 234), M13H (SEQ ID NO: 235), K16H (SEQ ID NO: 236), E2H and M13H (SEQ ID NO: 237), E2H and K16H (SEQ ID NO: 233), M13H and K16H (SEQ ID NO: 238), or E2H, M13H, and K16H (SEQ ID NO: 239) showed varying degrees of pH-dependent binding to PD-L1. "UTF" indicates untransfected cells (negative control). The parent peptide (SEQ ID NO: 187) showed some pH-dependent binding to PD-L1. Some variants of SEQ ID NO: 187 showed more pH-dependence in PD-L1 binding than the parent, while some variants of SEQ ID NO: 187 showed less pH-dependence in PD-L1 binding than the parent. Peptide SEQ ID NO: 234 was shown to have a large difference in binding at pH 7.4 versus pH 5.5, demonstrating higher binding at pH 7.4 than at pH 5.5. Peptide SEQ ID NO: 233 (black arrow) was shown to have a particularly large difference in binding at pH 7.4 versus pH 5.5, also demonstrating higher binding at pH 7.4 than at pH 5.5. This data demonstrates the generation of peptides that bind to PD-L1 at higher levels at pH 7.4 and lower levels at pH 5.5. DETAILED DESCRIPTION OF THE INVENTION
[0058] Programmed death-ligand 1 (PD-L1) has proven to be a valuable therapeutic target for small molecule therapeutics and anti-PD-L1 antibodies, which function as immune checkpoint inhibitors and can be used as anticancer therapies. However, both small molecule therapeutics, which are typically less than 1000 Da in size, and antibody therapeutics, which often exceed 140 kDa in size, have significant limitations in their efficacy and usefulness. Small molecule therapeutics often lack selectivity for their intended targets, resulting in severe off-target effects and a limited therapeutic window (i.e., the range of drug doses that can be therapeutically effective without toxicity). Furthermore, the small target-binding interface can be susceptible to mutational selection, and a single amino acid change in the target at the binding interface can dramatically alter the binding of a small molecule to its target. On the other end of the spectrum, the large size of antibodies can prevent them from accessing targets in the central nervous system or penetrating throughout solid tumors. Furthermore, substantial engineering, such as humanization, may be required to make antibodies suitable for pharmaceutical applications. Furthermore, PD-L1 targeting offers opportunities for cancer targeting via bispecific immune cell engagers. Bispecific immune cell engagers (BiICEs) can have moieties that bind to both cancer cells (e.g., via PD-L1) and immune cells, thus directing immune cells into direct proximity with cancer cells to kill them. However, the specific shape of the immune synapse (e.g., the distance between the cancer cell and the immune cell) may be important for potent cell killing. Antibodies and antibody fragments, such as scFvs or nanobodies, with molecular weights of approximately 15–27 kDa, may not be able to create an immune synapse close enough to drive optimal cell killing.
[0059] Described herein are small, drug-like proteins, typically less than about 10 kDa in size, and often less than 6 kDa in size, that have been engineered to bind to therapeutic targets, including PD-L1, and exert a therapeutic effect. These small proteins, or "miniproteins," can provide a therapeutic effect themselves, for example, by binding to and inhibiting a target protein, or by delivering an additional active agent (e.g., a detectable drug, a small molecule or protein drug, an immune cell-binding moiety, or an additional active agent) to a target area. For example, due to the overexpression of PD-L1 by some cancer cells, the PD-L1-binding peptides described herein can be used to target a therapeutic moiety to cancer cells and tissues, promote cell killing of cancer cells, or both. The present disclosure provides PD-L1-binding peptides (also referred to herein as miniproteins) that bind to PD-L1. These proteins can be cystine-dense peptides (CDPs) or cystine-dense miniproteins, which are stabilized by disulfide bridges formed between cysteine amino acid residues. Cystine-dense peptides may have the additional advantages of being thermostable, protease-resistant, less immunogenic, small in size, and tissue-penetrating. Also described herein are methods of using PD-L1-binding peptides (also referred to as PD-L1-binding CDPs) as therapeutic or diagnostic agents.
[0060] The present disclosure utilizes a 3D protein structure-based peptide design approach to select peptides or proteins that can bind to PD-L1 and are designed to bind at a specific interface of a protein (e.g., a PD-L1 protein) based on the 3D structure of the protein. For example, a peptide can be designed to bind at the PD-1-binding interface of PD-L1.
[0061] As used herein, the abbreviations for natural L-enantiomer amino acids are standard and are as follows: alanine (A, Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gln); glycine (G, Gly); histidine (H, His); isoleucine (I, Ile); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); valine (V, Val). Typically, Xaa can represent any amino acid. In some embodiments, X can be asparagine (N), glutamine (Q), histidine (H), lysine (K), or arginine (R). Some embodiments of the present disclosure contemplate d-amino acid residues of any standard or non-standard amino acid or analog thereof. When an amino acid sequence is represented by a series of three-letter or one-letter amino acid abbreviations, the left-hand direction is the amino-terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.
[0062] The terms "peptide," "polypeptide," "miniprotein," "protein," "hittin," "cystine-dense peptide," "knot peptide," or "CDP" may be used interchangeably herein to refer to a polymer of amino acid residues. In various embodiments, a "peptide," "polypeptide," and "protein" may be a chain of amino acids whose alpha carbons are linked via peptide bonds. Thus, the terminal amino acid at one end of the chain (e.g., the amino-terminus or N-terminus) may have a free amino group, and the terminal amino acid at the other end of the chain (e.g., the carboxy-terminus or C-terminus) may have a free carboxyl group. As used herein, the term "amino terminus" (e.g., N-terminus for short) may refer to the free α-amino group on the amino terminal amino acid of a peptide, or the α-amino group (e.g., an imino group when involved in a peptide bond) of an amino acid at any other position within the peptide. Similarly, the term "carboxy terminus" may refer to the free carboxyl group on the carboxy terminal of a peptide, or the carboxyl group of an amino acid at any other position within the peptide. Peptides also include essentially any polyamino acid, including, but not limited to, peptidomimetics such as amino acids linked by ether or thioether to amide bonds.
[0063] As used herein, the term "peptide construct" or "peptide complex" may refer to a molecule comprising one or more peptides of the present disclosure that may be conjugated, linked, or fused to one or more peptide or cargo molecules. In some cases, the cargo molecule is an active agent. The term "active agent" may refer to any molecule, for example, any molecule capable of eliciting a biological and / or physical effect (e.g., emission of radiation) that may enable localization, detection, or visualization of the respective peptide construct. In various embodiments, the term "active agent" refers to a therapeutic agent and / or diagnostic agent. A peptide construct of the present disclosure may comprise a PD-L1-binding peptide linked to one or more active agents via one or more linker moieties (e.g., cleavable or stable linkers) described herein. As used herein, the term "peptide complex" may also refer to one or more peptides of the present disclosure that are fused, linked, conjugated, or connected to form a complex. In some cases, the one or more peptides may include a PD-L1-binding peptide, an additional peptide active agent, a peptide that binds to an immune cell (e.g., a T cell), a half-life-modifying peptide, a peptide that modifies pharmacodynamic and / or pharmacokinetic properties, or a combination thereof.
[0064] The terms "nucleotide," "oligonucleotide," "polynucleotide," "polynucleic acid," or "nucleic acid" can refer to any molecule containing nucleic acid, such as a short single- or double-stranded DNA or RNA molecule. Nucleotides can include deoxyribonucleotides, ribonucleotides, modified deoxyribonucleotides or ribonucleotides, derivatives of deoxyribonucleotides or ribonucleotides, synthetic nucleotides, other nucleotides containing various nucleic acid bases or various sugars, or combinations thereof. As used herein, "nucleotide," "oligonucleotide," "polynucleotide," "polynucleic acid," or "nucleic acid" includes any single-stranded (ssDNA, ssRNA) or double-stranded (dsDNA, dsRNA) or combination of single and double strands (e.g., with mismatched sequences, hairpins, or other structures), antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotide (ASO), microRNA (miRNA), oligonucleotide complementary to natural antisense transcript (NAT) sequences, siRNA, snRNA, aptamer, gapmer, antimiR, splice blocker ASO, or U1 adaptor. In the peptide-oligonucleotide complexes described herein, the "nucleotide," "oligonucleotide," "polynucleotide," "polynucleic acid," or "nucleic acid" can be intended to regulate gene or protein expression or to regulate inter- or intramolecular interactions, and each can be considered a targeted binding agent capable of binding to a target molecule. The target may be a protein, nucleic acid, or other non-nucleic acid molecule. When the target is a nucleic acid, the sequence of the target molecule can be derived from RNA (eg, mRNA or pre-mRNA) or the open reading frame (ORF) of a gene or protein-coding sequence.The sequence of the target molecule can be found within or derived from the coding or non-coding region of a gene, or the sequence of the target molecule can be found in or derived from a mature mRNA (e.g., an mRNA that has been spliced, polyadenylated, capped, and transported to the cytosol for translation) or an immature pre-mRNA. The targeted binding agent can be a complement to such a target molecule sequence (e.g., an open reading frame, a non-coding sequence, or an RNA).
[0065] As used herein, the terms "complement" or "reverse complement" can refer to a nucleotide sequence that is fully or partially reverse complementary to a target or reference sequence. The term "complementary" can be used interchangeably with "reverse complementary" or "antisense" to describe a nucleotide sequence that forms base-pairing interactions (e.g., A / T, A / U, or C / G interactions) with a target or reference nucleotide sequence.
[0066] As used herein, the term "antisense oligonucleotide" includes small, non-coding, diffusible molecules containing approximately 15-35 nucleotides that form the reverse complement of a nucleic acid target sequence (e.g., a transcript or mRNA molecule). In some embodiments, an antisense molecule may be perfectly reverse complementary to the target sequence. In some embodiments, an antisense molecule may contain one or more base mismatches relative to the target sequence. As used herein, "antisense" can refer to nucleotides of various chemical nature, natural (RNA and / or DNA) or synthetic (e.g., 2' pentose sugar modifications, 2'F, 2'OMe, LNA, PNA, and / or morpholino), with natural or synthetic linkages (e.g., phosphodiester, phosphorothioate, phosphorodiamidate, or thiophosphorodiamidate), as the context requires, and can include oligonucleotides, ribonucleotides, ribonucleosides, deoxyribonucleotides, and deoxyribonucleosides, which may be single-stranded or double-stranded in whole or in part, or in any combination, and modified forms of any of the above, and in any combination, to form polynucleic acids. Similarly, thiophosphorodiamidate linkages may be used. Such polynucleic acids may further include modified bases (e.g., synthetic purines or pyrimidines whose chemical nature differs from that of adenine, cytosine, guanine, thymine, or uracil) or other atypical elements or chemical properties. In various embodiments, the antisense RNA comprises 19-23 nucleotides (nt), or 15-35 nt, complementary to the target RNA. The antisense RNA is about 5-30 nt, 10-25 nt, 15-25 nt, 19-23 nt, or at least 10 nt, at least 15 nt, at least 20 nt, at least 25 nt, or at least 30 nt, at least 50 nt, or at least 100 nucleotides in length. Non-limiting examples of antisense oligonucleotides (ASOs) include aptamers, gapmers, anti-miRs, siRNAs, miRNAs, snRNAs, splice blocker ASOs, and U1 adaptors.
[0067] As used herein, the terms "interfering RNA" or "inhibitory RNA" are used interchangeably and include RNA molecules that participate in sequence-specific suppression of gene expression by forming double-stranded RNA. As used herein, "interfering RNA" or "inhibitory RNA" can contain ribonucleotides, ribonucleosides, deoxyribonucleotides, deoxyribonucleosides, and can be wholly or partially single-stranded or double-stranded, or any combination thereof, forming a polynucleic acid in any of the above or any combination thereof in modified form. Such polynucleic acids can further contain modified bases or other atypical elements or chemical properties. Common forms of "interfering RNA" or "inhibitory RNA" include small inhibitory RNAs (siRNA or RNAi), dsRNA, ssRNA, hairpin RNA, and other known structures. In various embodiments, the inhibitory RNA is about 5-30 nt in length, 10-25 nt in length, 15-25 nt in length, 19-23 nt in length, or at least 10 nt in length, at least 15 nt in length, at least 20 nt in length, at least 25 nt in length, or at least 30 nt in length, at least 50 nt in length, or at least 100 nucleotides in length.
[0068] As used herein, the term "nuclear RNA" includes any RNA molecule present in the nucleus of a cell. As used herein, "nuclear RNA" can include small nuclear RNAs (snRNAs), spliceosomal RNAs, and other known structures.
[0069] As used herein, the term "U1 adaptor" includes a bifunctional oligonucleotide having a targeting domain complementary to a site near the polyadenylation (polyA) site of a target gene and a U1 domain that binds to the U1 small nuclear RNA component of the U1 small nuclear ribonucleoprotein (U1 snRNP). The U1 adaptor can be used as a synthetic oligonucleotide to recruit endogenous U1 snRNP to a target sequence or target site. As used herein, the U1 adaptor can include any nucleotide sequence complementary to the ssRNA component of the U1 small nuclear ribonucleoprotein (U1 snRNP). In various embodiments, the U1 adaptor is about 5-30 nt in length, 10-25 nt in length, 15-25 nt in length, 19-23 nt in length, or at least 10 nt in length, at least 15 nt in length, at least 20 nt in length, at least 25 nt in length, or at least 30 nt in length, at least 50 nt in length, at least 100 nucleotides in length, and is complementary to any sequence along the U1 domain or U1 small nuclear ribonucleoprotein (U1 snRNP) splicing factor.
[0070] As used herein, the terms "comprise" and "have" can be used interchangeably. For example, the terms "a peptide comprising the amino acid sequence of SEQ ID NO: 1" and "a peptide having the amino acid sequence of SEQ ID NO: 1" can be used interchangeably.
[0071] As used herein, unless otherwise specified, the term "PD-L1" or "programmed death-ligand 1" is a class of proteins used herein and can refer to PD-L1 from any species (e.g., human or mouse PD-L1, or any human or non-human animal PD-L1). In some cases, the term "PD-L1" or "programmed death-ligand 1" as used herein refers to human PD-L1 and may include PD-L1 or any combination or fragment thereof (e.g., the extracellular domain). In some cases, PD-L1 may also be referred to as "CD274," "B7-H," "B7H1," "PDCD1L1," "PDCD1LG1," or "PDL1."
[0072] The term "engineered," when applied to a polynucleotide, indicates that the polynucleotide has been removed from its natural genetic environment, and therefore is free of other unrelated or undesired coding sequences, and is in a form suitable for use in a genetically engineered protein production system. Such engineered molecules are those that have been separated from their natural environment and include cDNA and genomic clones (i.e., prokaryotic or eukaryotic cells containing vectors that include segments of DNA derived from different organisms). Engineered DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally or non-natively occurring 5' and 3' untranslated regions, such as enhancers, promoters, and terminators.
[0073] An "engineered" polypeptide or protein is one that exists in a state other than its native environment, such as away from blood and animal tissue. In a preferred form, the engineered polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. The polypeptide is preferably provided in a highly purified form, e.g., greater than 90% pure, greater than 95% pure, more preferably greater than 98% pure, or greater than 99% pure. As used in this context, the term "engineered" does not exclude the existence of the same polypeptide in alternative physical forms, such as dimers, heterodimers, and multimers, heteromultimers, or alternatively glycosylated, carboxylated, modified, or derivatized forms.
[0074] An "engineered" peptide or protein is a polypeptide that differs distinctly in structure, sequence, or composition from a naturally occurring polypeptide. Engineered peptides include non-naturally occurring peptides, artificial peptides, isolated peptides, synthetic peptides, designed peptides, modified peptides, or recombinantly expressed peptides. Engineered PD-L1-binding peptides, variants, or fragments thereof are provided herein. These engineered PD-L1-binding peptides can be further linked to an active agent or half-life extending moiety, or can be further linked to an active agent or detectable agent, or any combination of the foregoing.
[0075] Polypeptides of the present disclosure include polypeptides that have been modified in some way to, for example, (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to reduction, (3) alter binding affinity to form protein complexes, (4) alter binding affinity, (5) alter binding affinity at specific pH values, and (6) impart or alter other physicochemical or functional properties. For example, single or multiple amino acid substitutions (e.g., conservative amino acid substitutions) are made in the naturally occurring sequence (e.g., in a portion of the polypeptide other than the domain(s) that form intermolecular contacts). A "conservative amino acid substitution" may refer to the substitution of an amino acid in a polypeptide with a functionally similar amino acid. The following six groups include amino acids that may be conservative substitutions for each other: i) alanine (A), serine (S), and threonine (T); ii) aspartic acid (D) and glutamic acid (E); iii) asparagine (N) and glutamine (Q); iv) arginine (R) and lysine (K); v) isoleucine (I), leucine (L), methionine (M), and valine (V); vi) phenylalanine (F), tyrosine (Y), and tryptophan (W). In some embodiments, conservative amino acid substitutions may include unnatural amino acids. For example, substitution of an amino acid for a non-naturally occurring derivative of the same amino acid may be a conservative substitution. For example, substitution of an amino acid for a non-naturally occurring derivative of the same amino acid may be a conservative substitution.
[0076] As used herein, the terms "polypeptide fragment" and "truncated polypeptide" can refer to a polypeptide having an amino-terminal and / or carboxy-terminal deletion compared to the corresponding full-length peptide or protein. In various embodiments, the fragment is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1000 amino acids in length. In various embodiments, fragments can also be, for example, up to 1000, up to 900, up to 800, up to 700, up to 600, up to 500, up to 450, up to 400, up to 350, up to 300, up to 250, up to 200, up to 150, up to 100, up to 50, up to 45, up to 40, up to 35, up to 30, up to 25, up to 20, up to 15, up to 10, or up to 5 amino acids in length. A fragment can further comprise one or more additional amino acids at either or both of its termini, for example, a sequence of amino acids derived from a different naturally occurring protein (e.g., an Fc or leucine zipper domain), or an artificial amino acid sequence (e.g., an artificial linker sequence).
[0077] As used herein, the terms "peptide" or "polypeptide," in connection with "variant," "mutant," or "enriched variant," or "permutation-enriched variant," can refer to a peptide or polypeptide that can include an amino acid sequence in which one or more amino acid residues have been inserted into, deleted from, and / or substituted from another polypeptide sequence. In various embodiments, the number of inserted, deleted, or substituted amino acid residues is at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 225, at least 250, at least 275, at least 300, at least 350, at least 400, at least 450, or at least 500 amino acids in length. Variants of the present disclosure include peptide conjugates or fusion molecules (e.g., peptide constructs or peptide complexes).
[0078] A "derivative" of a peptide or polypeptide may be a peptide or polypeptide that may be chemically modified, e.g., conjugated to another chemical moiety, such as polyethylene glycol, albumin (e.g., human serum albumin), phosphorylation, and glycosylation. The term "% sequence identity" may be used interchangeably herein with "% identity" and may refer to the level of amino acid sequence identity between two or more peptide sequences or the level of nucleotide sequence identity between two or more nucleotide sequences when aligned using a sequence alignment program. For example, as used herein, 80% identity means the same as 80% sequence identity determined by a defined algorithm, meaning that a given sequence is at least 80% identical to another sequence of another length. In various embodiments, the percent identity is selected from, e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99%, or up to 100% sequence identity to a given sequence. In various embodiments, the percent identity is within the range of, e.g., about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
[0079] The terms "sequence homology %" or "sequence homology percent" or "sequence identity percent" may be used interchangeably herein with the terms "homology %," "sequence identity %" or "identity %" and may refer to the level of amino acid sequence homology between two or more peptide sequences or the level of nucleotide sequence homology between two or more nucleotide sequences when aligned using a sequence alignment program. For example, as used herein, 80% homology means the same as 80% sequence homology determined by a defined algorithm; thus, homologs of a given sequence have greater than 80% sequence homology over the length of the given sequence. In various embodiments, the % homology is selected from, for example, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, or up to 100% sequence homology to a given sequence. In various embodiments, the percent homology is within the range of, for example, about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
[0080] A protein or polypeptide may be "substantially pure," "substantially homogeneous," or "substantially purified" if at least about 60%-75% of a sample represents a single polypeptide species. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein may typically comprise about 50%, 60%, 70%, 80%, or 90% w / w of a protein sample, more commonly about 95%, e.g., greater than 98% or 99% pure. Protein purity or homogeneity can be demonstrated by a number of means well known in the art, such as subjecting a protein sample to polyacrylamide gel electrophoresis followed by staining the gel with stains well known in the art to visualize a single polypeptide band. For certain purposes, high resolution can be achieved by using high-performance liquid chromatography (e.g., HPLC) or other high-resolution analytical techniques (e.g., LC-mass spectrometry).
[0081] As used herein, the term "pharmaceutical composition" may generally refer to a composition suitable for pharmaceutical use in a subject, such as an animal (e.g., a human or a mouse). A pharmaceutical composition may include a pharmacologically effective amount of an active agent and a pharmaceutically acceptable carrier. The term "pharmacologically effective amount" may refer to an amount of an agent effective to produce an intended biological or pharmacological result.
[0082] As used herein, the term "pharmaceutically acceptable carrier" can refer to any of the standard pharmaceutical carriers, vehicles, buffers, and excipients, such as phosphate-buffered saline or buffered saline, 5% dextrose in water, and emulsions such as oil / water or water / oil emulsions, as well as various types of wetting agents and / or adjuvants. Suitable pharmaceutical carriers and formulations are described in Remington's Pharmaceutical Sciences, 21st Ed. 2005, Mack Publishing Co., Easton. A "pharmaceutically acceptable salt" can be a salt that can be formulated into a compound for pharmaceutical use, including, for example, metal salts (sodium, potassium, magnesium, calcium, etc.), and salts of ammonia or organic amines.
[0083] As used herein, the terms "treat," "treating," and "treatment" can refer to a method of alleviating or alleviating a biological disorder and / or at least one of its associated symptoms. As used herein, "alleviating" a disease, disorder, or condition means, for example, reducing the severity of the disease, disorder, or condition and / or the frequency of occurrence of its symptoms. Furthermore, references to "treatment" herein can include references to curative, palliative, and prophylactic or diagnostic treatment.
[0084] Generally, the cells of the present disclosure can be eukaryotic or prokaryotic. The cells can be epithelial cells, cancer cells, or cells of the immune system. The cells can be microbial, bacterial, yeast, fungal, or algal cells. The cells can be animal or plant cells. Animal cells can include cells derived from marine invertebrates, fish, insects, amphibians, reptiles, or mammals. Mammalian cells can be obtained from primates, apes, equines, bovines, porcines, canines, felines, or rodents. Mammals can be primates, apes, dogs, cats, rabbits, ferrets, etc. Rodents can be mice, rats, hamsters, gerbils, chinchillas, or guinea pigs. Avian cells can be derived from canaries, parakeets, or parrots. Reptile cells can be derived from turtles, lizards, or snakes. Fish cells can be derived from tropical fish. For example, fish cells can be derived from zebrafish (e.g., Danino rerio), helminth cells can be derived from nematodes (e.g., C. elegans), amphibian cells can be derived from frogs, and arthropod cells can be derived from tarantulas or hermit crabs.
[0085] Mammalian cells can also include cells obtained from a primate (e.g., a human or non-human primate). Mammalian cells can include blood cells, stem cells, epithelial cells, connective tissue cells, hormone-secreting cells, nerve cells, skeletal muscle cells, or immune system cells.
[0086] As used herein, the term "vector" generally refers to a DNA molecule capable of replication in a host cell and / or to which another DNA segment can be operatively linked so as to bring about replication of the attached segment. A plasmid is an exemplary vector.
[0087] As used herein, the term "subject" generally refers to a human or another animal. A subject can be of any age, for example, a subject can be an infant, toddler, child, pre-adolescent, adolescent, adult, or geriatric individual.
[0088] Ranges may be expressed herein from "approximately" one particular value and / or to "approximately" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations by use of the antecedent "about," it is understood that the particular value forms another embodiment. It is further understood that each endpoint of a range corresponds to, and is independent of, the other endpoint. As used herein, the term "about" refers to a range of plus or minus 15% from the specified numerical value, within the scope of particular use. For example, about 10 may include a range of 8.5 to 11.5.
[0089] peptide The PD-L1-binding peptides described herein may comprise PD-L1-binding cystine-dense peptides (CDPs). The PD-L1-binding peptides may be engineered to bind to PD-L1 (e.g., human PD-L1). In some cases, the PD-L1-binding peptides may be engineered to bind to a specific interface of PD-L1 (e.g., the PD-1-binding interface). The PD-L1-binding peptides and PD-L1-binding peptide conjugates of the present disclosure may comprise one or more peptides. For example, a PD-L1-binding peptide conjugate may comprise a PD-L1-binding peptide and an additional peptide therapeutic agent. The PD-L1-binding peptides of the present disclosure may be engineered to retain binding to PD-L1 when conjugated to an additional active agent. In some cases, the PD-L1-binding peptides may be engineered to contain one or more amino acid residues that can be modified (e.g., with a linker).
[0090] In some examples, the peptides disclosed herein contain only one lysine residue or no lysine residues. In some examples, one or more or all lysine residues in the peptide are substituted with arginine residues. In some examples, one or more or all methionine residues in the peptide are substituted with leucine or isoleucine. One or more or all tryptophan residues in the peptide may be substituted with phenylalanine or tyrosine. In some examples, one or more or all asparagine residues in the peptide are substituted with glutamine. In some embodiments, one or more or all aspartic acid residues may be substituted with glutamic acid residues. In some examples, one or more or all lysine residues in the peptide may be substituted with alanine or arginine. In some embodiments, the N-terminus of the peptide is blocked or protected, such as with an acetyl group or a tert-butyloxycarbonyl group. Alternatively, or in combination, the C-terminus of the peptide may be blocked or protected, such as with an amide group or by ester formation (e.g., butyl or benzyl ester). In some embodiments, peptides are modified by methylation on free amines, for example, complete methylation is achieved through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0091] In some embodiments, the N-terminal dipeptide may be absent, as shown in SEQ ID NO:1-59, SEQ ID NO:435, or SEQ ID NO:554-560, or the dipeptide GS may be added as the first two N-terminal amino acids, or may be substituted by any other one or two amino acids, as shown in SEQ ID NO:60-118, SEQ ID NO:436, or SEQ ID NO:561-567. In some embodiments, the dipeptide GS is used as a linker or attached to a linker to form a peptide conjugate or fusion molecule, such as a peptide construct or peptide complex. In some embodiments, the linker is a Gx S y(SEQ ID NO: 155) peptide, where x and y are independently any integer, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, or 20, and the G and S residues are arranged in any order. In some embodiments, the peptide linker comprises (GS)x (SEQ ID NO: 156), where x can be any integer, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. In some embodiments, the peptide linker comprises GGSSG (SEQ ID NO: 157), GGGGG (SEQ ID NO: 158), GSGSGSGS (SEQ ID NO: 159), GSGG (SEQ ID NO: 160), GGGGS (SEQ ID NO: 161), GGGS (SEQ ID NO: 154), GGS (SEQ ID NO: 162), GGGSGGGSGGGS (SEQ ID NO: 163), or variants or fragments thereof, or any number of repeats thereof, and combinations thereof. Additionally, KKYKPYVPVTTN (SEQ ID NO: 166) derived from DkTx and EPKSSKTHT (SEQ ID NO: 167) derived from human IgG3, or any number of repeats thereof and combinations thereof, may be used as peptide linkers. In some embodiments, the peptide linker comprises GGGSGGSGGGS (SEQ ID NO: 164), or a variant or fragment thereof, or any number of repeats and combinations thereof. In some embodiments, the peptide linker comprises any of SEQ ID NOs: 154-241 or 433. Additional linkers that can be linked, fused, or conjugated to the PD-L1-binding peptides of the present disclosure are provided in Table 9. It is understood that any of the foregoing linkers or variants or fragments thereof can be used with any number of repeats or any combination thereof. It is also understood that other peptide linkers or variants or fragments thereof known in the art can be used with any number of repeats or any combination thereof. The length of the linker can be adjusted to simultaneously maximize binding of the PD-L1-binding peptide complex to PD-L1 and an additional target (e.g., a target on an immune cell), including taking steric accessibility into consideration.In some embodiments, the linker between the PD-L1-binding peptide and the immune cell-binding peptide is at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65 residues in stepwise increases up to a length of 100 residues.
[0092] In some embodiments of the present disclosure, the peptides or peptide complexes described herein comprise an amino acid sequence set forth in any one of SEQ ID NOs: 1 through 118, 435, 436, or 554 through 567. The peptides disclosed herein may comprise at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least The peptide fragment may be a contiguous fragment of any one of SEQ ID NOs:1-118, 435, 436, or 554-567 that is at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, or at least 65 residues in length, where the peptide fragment is selected from any portion of the peptide. In some embodiments, the peptide sequence is flanked by additional amino acids. The one or more additional amino acids may, for example, confer a particular in vivo charge, isoelectric point, chemical conjugation site, stability, or physiological property to the peptide.
[0093] In some examples, CDPs described herein that are capable of targeting and binding to PD-L1 comprise a length of 80 or less amino acids, or a length of 70 or less, 65 or less, 60 or less, 55 or less, 50 or less, 49 or less, 45 or less, 40 or less, 35 or less, 30 or less, 25 or less, 20 or less, 15 or less, or 10 or less amino acids. In some examples, PD-L1 binding moieties described herein (e.g., scFvs) that are capable of targeting and binding to PD-L1 comprise a length of about 100 to about 400, about 200 to about 300, or about 240 to about 250 amino acids in length.
[0094] In other embodiments, the peptides may be conjugated, linked, or fused to a carrier or molecule that has a targeting or homing function to a cell of interest or target cell (e.g., an immune cell). In other embodiments, the peptides may be conjugated, linked, or fused to a molecule, such as an Fc region or polyethylene glycol, that extends the half-life of the peptide, or alters its pharmacodynamic and / or pharmacokinetic properties, or any combination thereof.
[0095] In some examples, the peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 positively charged residues, such as Arg or Lys, or any combination thereof. In some examples, one or more lysine residues in the peptide are substituted with arginine residues. In some embodiments, the peptide comprises one or more Arg patches. In some embodiments, one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more Arg or Lys residues in the peptide are solvent exposed. In some examples, the peptide comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 histidine residues.
[0096] The peptides of the present disclosure may further comprise neutral amino acid residues. In some embodiments, the peptides have 35 or fewer neutral amino acid residues. In other embodiments, the peptides have 81 or fewer neutral amino acid residues, 70 or fewer neutral amino acid residues, 60 or fewer neutral amino acid residues, 50 or fewer neutral amino acid residues, 40 or fewer neutral amino acid residues, 36 or fewer neutral amino acid residues, 33 or fewer neutral amino acid residues, 30 or fewer neutral amino acid residues, 25 or fewer neutral amino acid residues, or 10 or fewer neutral amino acid residues.
[0097] The peptides of the present disclosure may further comprise negative amino acid residues. In some embodiments, the peptides have 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less negative amino acid residues. The negative amino acid residues may be selected from any negatively charged amino acid residue, but in some embodiments, the negative amino acid residues are either E or D, or a combination of both E and D.
[0098] In some embodiments of the present disclosure, the three-dimensional or tertiary structure of the peptide is composed primarily of beta-sheet and / or alpha-helical structures. In some embodiments, the designed or engineered PD-L1-binding peptides or peptide complexes of the present disclosure are small, compact peptides or polypeptides stabilized by intrachain disulfide bonds (e.g., mediated by cysteines) that form cystine bonds. In some embodiments, the engineered PD-L1-binding peptides have a structure comprising a helical bundle with at least one disulfide bridge between each of the helix-turn-helix motifs, thereby stabilizing the peptide. In some embodiments, the engineered PD-L1-binding peptides or peptide complexes comprise a structure with an alpha helix, one or more beta-sheets, one or more alpha helices, or one or more intrachain disulfide bonds. In some embodiments, the engineered PD-L1-binding peptides or peptide complexes do not comprise a hydrophobic core.
[0099] Cystine-Dense Peptides In some embodiments, the TfR-binding peptides or target-binding peptides of the present disclosure comprise one or more Cys, or one or more disulfide bonds. In some embodiments, the PD-L1-binding peptide or peptide complex is derived from a cystine-dense peptide (CDP), knot peptide, or hittin. In some embodiments, the CDP comprises at least three intramolecular cystine bonds. As used herein, the term "peptide" is considered interchangeable with the terms "knot peptide," "cystine-dense peptide," "CDP," "knottin," and "hittin" (see, e.g., Correnti et al. Screening, large-scale production, and structure-based classification for cystine-dense peptides. Nat Struct Mol Biol. 2018 Mar;25(3):270-278).
[0100] The PD-L1-binding peptides, or derivatives, fragments, or variants thereof, of the present disclosure may have affinity and selectivity for PD-L1 or a derivative or analog thereof. In some cases, the PD-L1-binding peptides of the present disclosure may be engineered using site-saturation mutagenesis (SSM) to exhibit improved PD-L1 binding properties or to alter the nature of the binding interface with PD-L1. In some cases, the peptides of the present disclosure are knot peptides, hittin-derived peptides, or cystine-dense peptides (CDPs) related to knottin-derived peptides. The PD-L1-binding peptide may be a cystine-dense peptide (CDP). PD-L1-binding CDPs may have a "pontoon" structure, characterized by a pair of alpha helices separated by an unstructured loop and stabilized by disulfide bonds, similar to the underside of a pontoon boat. Examples of disulfide bonds in a three-disulfide pontoon scaffold are 1-6, 2-5, and 3-4. PD-L1-binding CDPs may also have a hittin-like structure. Knottins may be a subclass of CDPs, in which six cysteine residues form disulfide bonds according to the connectivity [1-4], 2-5, 3-6, indicating that the first cysteine residue forms a disulfide bond with the fourth residue, the second cysteine residue forms a disulfide bond with the fifth residue, and the third cysteine residue forms a disulfide bond with the sixth residue. The parentheses in this nomenclature indicate that the cysteine residues form a notching disulfide bond. (See, e.g., Correnti et al. Screening, large-scale production, and structure-based classification for cystine-dense peptides. Nat Struct Mol Biol. 2018 Mar;25(3):270-278.) Knottins may be a subclass of CDPs, in which six cysteine residues form disulfide bonds according to the connectivity [1-4], 2-5, [3-6]. Knottins are a class of peptides that typically range in length from about 20 to about 80 amino acids and often fold into compact structures characterized by numerous intramolecular disulfide bridges and assemble into complex tertiary structures that may contain beta-strands and other secondary structures.The presence of disulfide bonds confers remarkable environmental stability to CDPs, including knottins, pontoons, and hittins, allowing them to withstand extreme temperatures and pH and resist proteolytic enzymes and reducing molecules in the bloodstream. In some cases, the peptides described herein may be derived from knot peptides. The amino acid sequences of the peptides disclosed herein may contain multiple cysteine residues. In some cases, at least one cysteine residue of multiple cysteine residues present in the amino acid sequence of the peptide participates in disulfide bond formation. In some cases, all cysteine residues of multiple cysteine residues present in the amino acid sequence of the peptide participate in disulfide bond formation. As described herein, the term "knot peptide" may be used interchangeably with the terms "cystine-dense peptide," "CDP," or "peptide."
[0101] Provided herein are methods for identifying, maturing, characterizing, and utilizing CDPs that allow for the selection, optimization, and characterization of PD-L1-binding CDPs that bind to PD-L1 and can be used alone or in peptide conjugates, including for use as bioactive molecules at therapeutically relevant concentrations in subjects (e.g., humans or non-human animals). This disclosure demonstrates the utility of CDPs as a diverse family of scaffolds that can be screened for potential applications in modern drug discovery strategies. CDPs are an alternative to existing biologics, primarily antibodies, and can avoid some of the disadvantages of immunoglobulin scaffolds, including poor tissue penetration, immunogenicity, larger size, and long serum half-lives, which can be problematic in the event of toxicity. The peptides of the present disclosure, ranging from 20 to 80 amino acids, are medium-sized and medically relevant therapeutic agents that possess many of the favorable binding specificity and affinity characteristics of antibodies, but with improved stability, reduced immunogenicity, and easier manufacturing methods. The intramolecular disulfide structure of CDPs confers a particularly high stability index, thereby reducing fragmentation and immunogenicity, and their small size allows for improved tissue or cell penetration and easier tuning of serum half-life. Disclosed herein are peptides that represent candidate peptides capable of binding to and inhibiting PD-L1 or functioning as vehicles for delivery of active agents to PD-L1-positive cells.
[0102] In some embodiments, a PD-L1-binding peptide may be an engineered peptide. An engineered peptide may be a non-naturally occurring, artificial, isolated, synthetic, designed, or recombinantly expressed peptide. In some embodiments, the PD-L1-binding peptides of the present disclosure comprise one or more properties of a CDP, a knot peptide, or a hitchin, such as stability, resistance to proteolysis, resistance to reducing conditions, and / or the ability to cross the blood-brain barrier.
[0103] CDPs may be advantageous for intratumoral, intracellular, or CNS delivery due to their small size, enhanced tissue or cellular penetration, lack of Fc function, and rapid clearance from serum compared to other molecules, such as antibodies, and their resistance to proteases compared to small peptides (both stability and reduced immunogenicity). In some embodiments, the PD-L1-binding peptides or engineered PD-L1-binding conjugates (e.g., comprising one or more PD-L1-binding peptides and one or more additional active agents) of the present disclosure may have superior properties to PD-L1-binding antibodies or target-binding antibodies (e.g., bispecific antibodies or chimeric antigen receptors). For example, the peptides and conjugates described herein may provide better, deeper, and / or faster tissue or cellular penetration into cells and target tissues (e.g., penetration into brain parenchyma, penetration into solid tumors), as well as faster clearance from non-target tissues and serum. The PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure may have a lower molecular weight than PD-L1-binding antibodies. The low molecular weight may confer advantageous properties to the PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure compared to PD-L1-binding antibodies. For example, the PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure may penetrate cells or tissues more easily than anti-PD-L1 antibodies or have lower molar dose toxicity than anti-PD-L1 antibodies. Furthermore, the PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure may form an immune synapse between immune cells and cancer cells with a better geometry for inducing cancer cell killing. The PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure may be beneficial because they lack the Fc function of antibodies. The PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure may be advantageous because they allow for higher formulation concentrations on a molar basis. The PD-L1-binding peptides or PD-L1-binding peptide conjugates of the present disclosure may have a higher affinity or faster on-rate for PD-L1 than antibodies or antibody fragments.The PD-L1-binding peptides or PD-L1-binding peptide conjugates of the disclosure may also be targeted to cancer cells in the CNS or brain via a blood-brain barrier (BBB)-permeable moiety, such as a BBB-permeable CDP, allowing better access to CNS tumors that are otherwise inaccessible to antibodies.
[0104] CDPs (e.g., knot peptides or hitchins) are a class of peptides typically ranging from about 11 to about 81 amino acids in length that often fold into compact structures. Knot peptides are characterized by numerous intramolecular disulfide bridges and assemble into complex tertiary structures that may include beta-strands, alpha-helices, and other secondary structures. The presence of disulfide bonds confers remarkable environmental stability to knot peptides, allowing them to withstand extreme temperatures and pH and resist proteolytic enzymes in the bloodstream. The presence of disulfide knots can also provide resistance to reduction by reducing agents. The rigidity of knot peptides also allows them to bind to targets without incurring the "entropy penalty" that occurs when flexible peptides bind to targets. For example, binding can be adversely affected by the entropy loss that occurs when a peptide binds to a target and forms a complex. Thus, the "entropy penalty" is a detrimental effect on binding, and the greater the entropy loss that occurs during binding, the greater the "entropy penalty." Furthermore, flexible unbound molecules lose more entropy when forming complexes than rigidly structured molecules because they lose flexibility when bound into complexes. However, the rigidity of unbound molecules also generally limits the number of complexes a molecule can form, thereby increasing specificity. Peptides can bind to targets with affinity similar to that of antibodies, or with nanomolar or picomolar affinities. Close examination of the sequence structure and sequence identity or homology of knot peptides reveals that knot peptides have arisen through convergent evolution in all kinds of animals and plants. In animals, knot peptides are often found in venoms, such as those of spiders and scorpions, and are involved in regulating ion channels. Plant knot proteins can inhibit animal proteolytic enzymes or have antibacterial activity, suggesting that knot peptides may function in molecular defense systems found in plants.
[0105] Peptides (e.g., PD-L1-binding peptides) of the present disclosure may contain cysteine amino acid residues. In some embodiments, peptides have at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 cysteine amino acid residues. In some embodiments, peptides have at least 6 cysteine amino acid residues. In some embodiments, peptides have at least 8 cysteine amino acid residues. In other embodiments, peptides have at least 10 cysteine amino acid residues, at least 12 cysteine amino acid residues, at least 14 cysteine amino acid residues, or at least 16 cysteine amino acid residues. In some embodiments, peptides of the present disclosure have an even number of cysteine residues. In some embodiments, all of the cysteines in a peptide of the present disclosure are joined in cystine disulfide bonds.
[0106] The knot peptide may contain a disulfide bridge. The knot peptide may be a peptide in which 5% or more of the residues are cysteines that form intramolecular disulfide bonds. The disulfide-linked peptide may be a drug scaffold. In some embodiments, the disulfide bridge forms a knot. The disulfide bridge may be formed between cysteine residues, for example, between cysteines 1 and 4, 2 and 5, or 3 and 6. In some embodiments, one disulfide bridge passes through a loop formed by two other disulfide bridges, for example, to form a knot. In other embodiments, the disulfide bridge may be formed between any two cysteine residues.
[0107] Some peptides of the present disclosure may contain at least one amino acid residue that is in the L-configuration. Peptides may contain at least one amino acid residue that is in the D-configuration. In some embodiments, peptides are 15-75 amino acid residues in length. In other embodiments, peptides are 11-55 amino acid residues in length. In still other embodiments, peptides are 11-65 amino acid residues in length. In further embodiments, peptides are at least 20 amino acid residues in length.
[0108] Some CDPs can be derived or isolated from classes of proteins known to be present in or associated with toxins or venoms. In some cases, peptides can be derived from toxins or venoms associated with scorpions or spiders. Peptides can be derived from the venoms and toxins of various genera and species of spiders and scorpions. Examples For example, peptides include Leiurus quinquestriatus hebraeus, Buthus occitanus tunetanus, Hottentotta judaicus, Mesobuthus eupeus, Buthus occitanus israelis, Hadrurus gertschi, Androctonus australis, Centruroides noxius, Heterometrus laoticus, Opistophthalmus carinatus, Haplopelma schmidti, Isometrus maculatus, Haplopelma huwenum, Haplopelma hainanum, Haplopelma schmidti, Agelenopsis aperta, Hadronyche versuta, Selenocosmia huwena, Heteropoda venatoria, Grammostola rosea, Ornithoctonus huwena, Hadronyche versuta, Atrax robustus, Angelenopsis The CDP may be derived from the venom or toxin of Psalmopoeus aperta, Psalmopoeus cambridgei, Hadronyche infensa, Paracoelotes luctosus, and Chilobrachys jingzhaoor, or another suitable genus or species of scorpion or spider. Optionally, the peptide may be derived from Buthus martensii Karsh (scorpion) venom. Optionally, the CDP may be derived from subunit 6 of cytochrome BC1 oxidoreductase or an antibacterial defensin.
[0109] In some embodiments, peptides (e.g., PD-L1-binding peptides) of the present disclosure may comprise a sequence having a cysteine residue at one or more of corresponding positions 4, 8, 18, 32, 42, and 46, e.g., with reference to SEQ ID NO: 1. For example, in certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 4. For example, in certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 8. For example, in certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 18. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 32. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 42. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 46. In some embodiments, the peptide comprises a cysteine at corresponding position n, n+4±2, n+14±2, n+28±2, n+38±2, or n+42±2, or any combination thereof, where n corresponds to the amino acid position of the first cysteine residue (e.g., position 4 in SEQ ID NO: 1). In some embodiments, the peptide comprises a cysteine at corresponding position n, n+4, n+14, n+28, n+38, or n+42, or any combination thereof, where n corresponds to the amino acid position of the first cysteine residue (e.g., position 4 in SEQ ID NO: 1). For example, peptides of the present disclosure may include sequences having cysteines positioned such that the second cysteine residue is located 4 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the third cysteine residue is located 14 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the fourth cysteine residue is located 28 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the fifth cysteine residue is located 38 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, and the sixth cysteine residue is located 42 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, or any combination thereof.In some embodiments, peptides of the present disclosure may include sequences having cysteines positioned such that there are 3 amino acid residues between the first and second cysteines, 9 amino acid residues between the second and third cysteines, 13 amino acid residues between the third and fourth cysteines, 9 amino acid residues between the fourth and fifth cysteines, 3 amino acid residues between the fifth and sixth cysteines, or combinations thereof.
[0110] In some embodiments, peptides (e.g., PD-L1-binding peptides) of the present disclosure may comprise a sequence having a cysteine residue at one or more of the following positions: 4, 15, 21, 25, 35, 42, 44, 48, e.g., with reference to SEQ ID NO: 58. For example, in certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 4. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 15. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 21. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 25. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 35. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 42. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 44. In certain embodiments, a peptide may comprise a sequence having a cysteine residue at corresponding position 48. In some embodiments, the peptide comprises a cysteine at corresponding position n, n+11±2, n+17±2, n+21±2, n+31±2, n+38±2, n+40±2, or n+44±2, or any combination thereof, where n corresponds to the amino acid position of the first cysteine residue (e.g., position 4 in SEQ ID NO: 58). In some embodiments, the peptide comprises a cysteine at corresponding position n, n+11, n+17, n+21, n+31, n+38, n+40, or n+44, or any combination thereof, where n corresponds to the amino acid position of the first cysteine residue (e.g., position 4 in SEQ ID NO: 58).For example, peptides of the present disclosure may include sequences having cysteines positioned such that the second cysteine residue is located 11 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the third cysteine residue is located 17 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the fourth cysteine residue is located 21 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the fifth cysteine residue is located 31 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the sixth cysteine residue is located 38 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, the seventh cysteine residue is located 40 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, and the eighth cysteine residue is located 44 amino acid residues from the first cysteine residue toward the C-terminus of the peptide, or any combination thereof. In some embodiments, peptides of the present disclosure may comprise a sequence having cysteines positioned such that there are 10 amino acid residues between the first and second cysteines, 5 amino acid residues between the second and third cysteines, 3 amino acid residues between the third and fourth cysteines, 9 amino acid residues between the fourth and fifth cysteines, 6 amino acid residues between the fifth and sixth cysteines, 1 amino acid residue between the sixth and seventh cysteines, 3 amino acid residues between the seventh and eighth cysteines, or a combination thereof.
[0111] In some embodiments, peptides of the present disclosure (e.g., PD-L1-binding peptides) comprise at least one cysteine residue. In some embodiments, peptides of the present disclosure comprise at least two cysteine residues. In some embodiments, peptides of the present disclosure comprise at least three cysteine residues. In some embodiments, peptides of the present disclosure comprise at least four cysteine residues. In some embodiments, peptides of the present disclosure comprise at least five cysteine residues. In some embodiments, peptides of the present disclosure comprise at least six cysteine residues. In some embodiments, peptides of the present disclosure comprise at least eight cysteine residues. In some embodiments, peptides of the present disclosure comprise at least ten cysteine residues. In some embodiments, peptides of the present disclosure comprise six cysteine residues. In some embodiments, peptides of the present disclosure comprise seven cysteine residues. In some embodiments, peptides of the present disclosure comprise eight cysteine residues. In some embodiments, peptides of the present disclosure comprise nine cysteine residues.
[0112] In some embodiments, the first cysteine residue in the sequence can form a disulfide bond with the fourth cysteine residue in the sequence, the second cysteine residue in the sequence can form a disulfide bond with the fifth cysteine residue in the sequence, and the third cysteine residue in the sequence can form a disulfide bond with the sixth cysteine residue in the sequence. Optionally, the peptide can include one disulfide bridge that passes through the ring formed by two other disulfide bridges, also known as a "two-and-through" structural system. In some embodiments, the peptides disclosed herein can have one or more cysteines mutated to serine. In some embodiments, the first cysteine residue in the sequence (e.g., position 4 of SEQ ID NO:1) can form a disulfide bond with the sixth cysteine residue in the sequence (e.g., position 46 of SEQ ID NO:1), the second cysteine residue in the sequence (e.g., position 8 of SEQ ID NO:1) can form a disulfide bond with the fifth cysteine residue in the sequence (e.g., position 42 of SEQ ID NO:1), and the third cysteine residue in the sequence (e.g., position 18 of SEQ ID NO:1) can form a disulfide bond with the fourth cysteine residue in the sequence (e.g., position 32 of SEQ ID NO:1). In some embodiments, this disulfide bond structure can be present in any one of the peptides set forth in SEQ ID NOs:1-4, 8-57, 59-63, 67-116, 118, 435, 436, or 554-567.
[0113] In some embodiments, the first cysteine residue in the sequence (e.g., position 4 of SEQ ID NO:58) can form a disulfide bond with the eighth cysteine residue in the sequence (e.g., position 48 of SEQ ID NO:58), the second cysteine residue in the sequence (e.g., position 15 of SEQ ID NO:58) can form a disulfide bond with the fifth cysteine residue in the sequence (e.g., position 35 of SEQ ID NO:58), the third cysteine residue in the sequence (e.g., position 21 of SEQ ID NO:58) can form a disulfide bond with the sixth cysteine residue in the sequence (e.g., position 42 of SEQ ID NO:58), and the fourth cysteine residue in the sequence (e.g., position 42 of SEQ ID NO:58) can form a disulfide bond with the seventh cysteine residue in the sequence (e.g., position 25 of SEQ ID NO:58).
[0114] In some embodiments, a peptide (e.g., a PD-L1-binding peptide) of the present disclosure comprises an amino acid sequence having a cysteine residue at one or more positions, e.g., with reference to SEQ ID NO: 1. The one or more cysteine residues are located at any of corresponding amino acid positions 4, 8, 18, 32, 42, 46, or any combination thereof. In some embodiments, the one or more cysteine residues are located at any of corresponding amino acid positions 4, 15, 21, 25, 35, 42, 44, 48, or any combination thereof. In some aspects of the disclosure, the one or more cysteine (C) residues are paired in various ways (e.g., C 10 -C 20 ) participate in disulfide bonds having the corresponding pairing pattern C. In some embodiments, the peptides described herein comprise at least one, at least two, at least three, or at least four disulfide bonds. In some embodiments, the peptides described herein comprise at least one, at least two, at least three, or at least four disulfide bonds having the corresponding pairing pattern C. 4 -C 46 , C 8 -C 42 , and C 18 -C 32 In some embodiments, the peptides described herein comprise three disulfide bonds having the corresponding pairing pattern C 4 -C 48 , C15 -C 35 , C 21 -C 42 , and C 25 -C 44 In some embodiments, the peptides described herein comprise four disulfide bonds having the corresponding pairing pattern C 15 -C 35 , C 21 -C 42 , and C 25 -C 44 It contains three disulfide bonds having the formula:
[0115] In some examples, one or more or all methionine residues in the peptide are substituted with leucine or isoleucine. In some examples, one or more or all tryptophan residues in the peptide are substituted with phenylalanine or tyrosine. In some examples, one or more or all asparagine residues in the peptide are substituted with glutamine. In some embodiments, the N-terminus of the peptide is blocked, such as with an acetyl group. Alternatively, or in combination, in some examples, the C-terminus of the peptide is blocked, such as with an amide group. In some embodiments, the peptide is modified by methylation of free amines. For example, complete methylation can be achieved through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0116] PD-L1 binding peptide Disclosed herein are peptide sequences, such as those listed in Table 1, that are capable of binding to PD-L1, or any combination or fragment thereof (e.g., the ectodomain). Peptides capable of binding to PD-L1 may be referred to herein as PD-L1-binding peptides. In some embodiments, the peptides disclosed herein are capable of penetrating, crossing, or entering target cells, or may be modified to penetrate, cross, or enter target cells (e.g., PD-L1-positive cells). In some embodiments, the peptides disclosed herein are capable of penetrating or crossing the blood-brain barrier (BBB), or may be modified to penetrate or cross the BBB. In some cases, the PD-L1-binding peptides may be part of a PD-L1-binding peptide complex that includes the PD-L1-binding peptide conjugated, linked, or fused to an active agent (e.g., a therapeutic agent or immune cell targeting agent), such as a small molecule or peptide with affinity for an additional target protein (e.g., an immune cell surface protein). In some cases, the peptide conjugates of the disclosure exert a biological effect mediated by the PD-L1-binding peptide, the additional active agent, or a combination thereof.
[0117] In some embodiments, the PD-L1-binding peptides of the present disclosure, including peptides comprising the amino acid sequences set forth in SEQ ID NOs:1-118, 435, 436, and 554-567, and any derivatives or variants thereof, block or reduce the binding of an endogenous PD-L1-binding substance (e.g., PD-1) to PD-L1. The PD-L1-binding peptides of the present disclosure (e.g., any one of SEQ ID NOs:1-118, 435, 436, or 554-567) may compete with PD-1 for binding to PD-L1. The PD-L1-binding peptides may displace PD-1 from PD-L1. In some embodiments, the PD-L1-binding peptide may be present in an amount of about 1 pM to about 10 μM, about 10 pM to about 10 μM, about 100 pM to about 10 μM, about 300 pM to about 10 μM, about 500 pM to about 10 μM, about 1 pM to about 1 μM, about 10 pM to about 1 μM, about 100 pM to about 1 μM, about 300 pM to about 1 μM, about 500 pM to about 1 μM, about 1 pM to about 100 nM, about 10 pM to about 100 nM, or about 100 pM to about 100 nM, about 300 pM to about 100 nM, about 500 pM to about 100 nM, about 1 pM to about 10 nM, about 10 pM to about 10 nM, about 100 pM to about 10 nM, about 300 pM to about 10 nM, about 500 pM to about 10 nM, about 1 pM to about 1 nM, about 10 pM to about 1 nM, about 100 pM to about 1 nM, about 1 pM to about 500 pM, about 10 pM to about 500 pM, or about 100 pM to about 500 pM 50) to inhibit binding of PD-1 to PD-L1 or displace PD-1 from PD-L1 in a subject (e.g., a human subject). In some embodiments, the PD-L1-binding peptide may be present at a concentration of about 1 pM to about 1 μM, about 10 pM to about 1 μM, about 100 pM to about 1 μM, about 300 pM to about 1 μM, about 500 pM to about 1 μM, about 1 pM to about 100 nM, about 10 pM to about 100 nM, about 100 pM to about 100 nM, about 300 pM to about 100 nM, about 500 pM to about 100 nM, Half the maximum inhibitory concentration (IC) of about 1 pM to about 10 nM, about 10 pM to about 10 nM, about 100 pM to about 10 nM, about 300 pM to about 10 nM, about 500 pM to about 10 nM, about 1 pM to about 1 nM, about 10 pM to about 1 nM, about 100 pM to about 1 nM, about 1 pM to about 500 pM, about 10 pM to about 500 pM, or about 100 pM to about 500 pM 50 ) can inhibit the binding of PD-1 to PD-L1 or displace PD-1 from PD-L1 on cells (e.g., human cells) under physiological conditions.
[0118] In some embodiments, peptides of the present disclosure include derivatives and variants having at least 40% homology, at least 50% homology, at least 60% homology, at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or 100% homology to the amino acid sequences set forth in SEQ ID NOs:1-118, SEQ ID NO:435, SEQ ID NO:436, or SEQ ID NOs:554-567. For example, a PD-L1-binding peptide may comprise a sequence that has at least 40% identity, at least 50% identity, at least 60% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, or at least 99% identity, or 100% identity to the amino acid sequence set forth in SEQ ID NO:1-SEQ ID NO:118, SEQ ID NO:435, SEQ ID NO:436, or SEQ ID NO:554-SEQ ID NO:567.
[0119] In some embodiments, the PD-L1-binding peptide has the same, similar, or higher affinity (e.g., a lower equilibrium dissociation constant K) compared to an endogenous molecule (e.g., PD-1 or any other endogenous PD-L1 ligand) or to another exogenous molecule (e.g., a PD-L1-binding antibody or antibody fragment). DIn some embodiments, the peptide or peptide complex binds to PD-L1 with a K for PD-L1 binding of 50 μM or less, 5 μM or less, 500 nM or less, 100 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.9 nM or less, 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less. D In some embodiments, PD-L1-binding peptides that exhibit improved PD-L1 binding may exhibit improved recruitment to PD-L1 positive cells, improved inhibition of PD-L1 or PD-1 binding, improved active agent delivery, improved immune cell recruitment, improved cell killing, improved tumor regression, or a combination thereof. In some embodiments, the K A , K. D , k on , k off The values, or combinations thereof, can be adjusted and optimized (e.g., via amino acid substitution) to provide a preferred ratio of PD-L1-binding peptides. PD-L1 binding affinity, binding rate to PD-L1, release rate from PD-L1, or a combination thereof. In some embodiments, the PD-L1-binding peptide binds to a site with low homology between human PD-L1 and mouse PD-L1, reducing the cross-reactivity of the PD-L1-binding peptide with human PD-L1 and mouse PD-L1. Because the binding kinetics of CDPs differ from those of antibodies, bispecific molecules comprising a PD-L1-binding CDP and an antibody may behave differently than antibody-based molecules. The PD-L1-binding CDPs described herein may have a faster on-rate to PD-L1 than antibody-based molecules.
[0120] In some embodiments, the peptides or variants thereof disclosed herein bind to PD-L1 at residues found in the binding interface (e.g., binding domain or binding pocket) between PD-L1 and other exogenous or endogenous ligands (e.g., PD-1, PD-1 derivatives, or PD-1-like peptides or proteins). In some embodiments, the PD-L1-binding peptides or variants thereof disclosed herein comprise at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to the sequence that binds to the residues of PD-L1 that make up the binding pocket. In some embodiments, the PD-L1-binding peptides or variants thereof disclosed herein comprise at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to an endogenous or exogenous polypeptide known to bind to PD-L1, e.g., endogenous PD-1 or any one of the peptides listed in Table 1. In other embodiments, the peptides described herein bind to a protein of interest that comprises at least 70% homology, at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology, or at least 100% homology to PD-L1, a fragment, homolog, or variant thereof.
[0121] In other embodiments, the nucleic acid, vector, plasmid, or donor DNA comprises a sequence encoding a peptide, peptide construct, peptide conjugate, or variant or functional fragment thereof described in this disclosure. In further embodiments, a specific portion or fragment of a PD-L1 binding motif (e.g., a conserved binding motif) may be grafted onto a peptide or peptide conjugate comprising any one of the sequences set forth in SEQ ID NOs: 1-118, 435, 436, or 554-567.
[0122] In some embodiments, peptides may be selected for further testing or use based on their ability to bind to certain amino acid residues or amino acid residue motifs. Certain amino acid residues or amino acid residue motifs in PD-L1 can be identified in the amino acid residues or amino acid residue sequences involved in the binding of PD-L1 to PD-1. Certain amino acid residues or amino acid residue motifs can be identified from the crystal structure of the PD-L1:PD-1 complex. In some embodiments, the peptide (e.g., CDP) exhibits resistance to heat, proteases (e.g., pepsin, trypsin, or others), and reduction.
[0123] Peptides and peptide conjugates (e.g., peptide conjugates or fusion peptides) comprising one or more of the amino acid sequences set forth in SEQ ID NOs:1-118, 435, 436, or 554-567 can bind to a protein of interest. In some embodiments, the protein of interest is PD-L1. In some embodiments, peptides and peptide conjugates (e.g., peptide conjugates or fusion peptides) that bind to PD-L1 comprise at least one of the amino acid sequences set forth in SEQ ID NOs:1-118, 435, 436, or 554-567. Table 1 lists exemplary peptide sequences in accordance with the methods and compositions of the disclosure. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8]
[0124] In some embodiments, the PD-L1-binding peptides disclosed herein comprise 1 X 2 X 3 CX 4 X 5 X 6 CX 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 CX 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 X 26 X 27 X 28 CX 29 X 30 X 31 X 32 X 33 X 34 X 35 X 36 X37 CX 38 X 39 X 40 CX 41 X 42 X 43 (SEQ ID NO: 358), wherein X 1 can be selected independently from E, M, V, or W; X 2 can be independently selected from G, E, L, or F; X 3 can be selected independently from D, E, or S; X 4 can be independently selected from K, R, or V; X 5 can be independently selected from E, Q, S, M, L, or V; X 6 can be independently selected from D, E, H, K, R, N, Q, S, or Y; X 7 can be selected independently from D, M, or V; X 8 can be independently selected from A, K, R, Q, S, or T; X 9 can be independently selected from A, D, E, H, Q, S, T, M, I, L, V, or W; X 10 can be independently selected from A, E, R, Q, S, T, W, or P; X 11 can be independently selected from A, E, K, R, N, Q, T, M, I, L, V, or W; X 12 can be independently selected from G, A, E, K, N, T, or Y; X 13 can be independently selected from G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 14 X can be independently selected from D, K, R, N, L, or V. 15 can be independently selected from G, A, D, T, L, W, or P; X 16 can be independently selected from G, A, E, H, K, N, S, F, or P; X 17 can be independently selected from G, A, D, E, N, or P; X 18 can be independently selected from G, D, H, K, R, N, Q, S, T, V, or Y; X19 can be independently selected from G, D, E, H, K, N, Q, S, T, M, I, F, W, Y, or P; X 20 can be independently selected from G, A, D, E, H, K, R, N, Q, S, Y, or P; X 21 can be independently selected from G, A, D, H, N, Q, S, V, F, or P; X 22 can be independently selected from A, D, H, N, Q, S, T, M, I, V, Y, or P; X 23 can be independently selected from G, A, D, K, R, T, W, or Y; X 24 can be independently selected from G, A, E, N, Q, T, I, V, or P; X 25 can be independently selected from G, D, N, Q, T, L, V, F, or P; X 26 can be independently selected from G, A, E, K, R, N, Q, S, T, I, Y, or P; X 27 can be independently selected from A, D, N, or I; X 28 can be independently selected from G, D, E, H, N, F, or W; X 29 can be independently selected from G, A, E, N, S, Y, or P; X 30 can be selected independently from G, M, or L; X 31 can be independently selected from G, A, D, K, N, Q, or W; X 32 can be independently selected from D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 33 can be independently selected from G, E, Q, or F; X 34 can be independently selected from D or K; X 35 can be selected independently from G, V, or P; X 36 can be independently selected from G, H, R, V, F, W, or P; X 37 can be independently selected from A, D, or K; X 38 can be independently selected from E, H, Q, L, or F; X 39can be independently selected from D, E, R, S, T, M, L, or F; X 40 can be independently selected from G, A, D, E, H, K, R, M, L, or P; X 41 can be independently selected from G, A, K, S, I, or L; X 42 can be independently selected from G, A, D, E, R, Q, T, or F; X 43 can be independently selected from A, H, N, Q, S, F, or P.
[0125] In some embodiments, the binding peptide disclosed herein is EEDCKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 CX 1 EX 1 X 4 X 1 X 1 X 1 X 1 X 1 X 1 X 1 AX 1 CX 1 GX 1 X 5 FX 6 VFX 6 CLX 1 X 1 CX 1 X 1 X 1 (SEQ ID NO: 359), wherein X 1 can be independently selected from any non-cysteine amino acid; X 2 can be independently selected from M, I, L, or V; X 3 can be independently selected from Y, A, H, K, R, N, Q, S, or T; X 4 can be independently selected from D, E, N, Q, or P; X 5 can be independently selected from K or P; X 6can be independently selected from D or K.
[0126] A PD-L1-binding peptide may contain a PD-L1-binding motif that forms part or all of the binding interface with PD-L1. One or more residues of the PD-L1-binding motif may interact with one or more residues of PD-L1 at the binding interface between the PD-L1-binding peptide and PD-L1. In some embodiments, multiple PD-L1-binding motifs may be present on the PD-L1-binding peptide. A PD-L1-binding motif may be CX 1 X 2 X 3 CX 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 C (SEQ ID NO: 360), wherein X 1 can be selected from K, R, or V; X 2 You can choose from E, Q, S, M, L, or V; X 3 can be selected from D, E, H, K, R, N, Q, S, or Y; X 4 You can choose from D, M, or V; X 5 can be selected from A, K, R, Q, S, or T; X 6 can be selected from A, D, E, H, Q, S, T, M, I, L, V, or W; X 7 can be selected from A, E, R, Q, S, T, W, or P; X 8 can be selected from A, E, K, R, N, Q, T, M, I, L, V, or W; X 9 can be selected from G, A, E, K, N, T, or Y; X 10 can be selected from G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 11 can be selected from D, K, R, N, L, or V; X 12can be selected from G, A, D, T, L, W, or P. In some embodiments, the PD-L1 binding motif is CKVX 1 CVX 1 X 1 X 1 X 1 X 2 X 3 KX 1 C (SEQ ID NO: 362), wherein X 1 can be independently selected from any non-cysteine amino acid; X 2 can be independently selected from M, I, L, or V; X 3 may be independently selected from Y, A, H, K, R, N, Q, S, or T. In some embodiments, the PD-L1 binding motif may comprise the sequence CKVHCVKEWMAGKAC (SEQ ID NO: 364). In some embodiments, the PD-L1 binding motif may comprise at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% identity to SEQ ID NO: 364.
[0127] The PD-L1 binding motif is X 1 X 2 X 3 X 4 X 5 X 6 CX 7 X 8 X 9 C SEQ ID NO: 361), 1 can be independently selected from D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 2 can be independently selected from G, E, Q, or F; X 3 can be independently selected from D or K; X 4 can be selected independently from G, V, or P; X 5 can be independently selected from G, H, R, V, F, W, or P; X 6can be independently selected from A, D, or K; X7 can be independently selected from E, H, Q, L, or F; X 8 can be independently selected from D, E, R, S, T, M, L, or F; X 9 can be independently selected from G, A, D, E, H, K, R, M, L, or P. In some embodiments, the PD-L1 binding motif is X 1 FX 2 VFX 2 CLX 3 X 3 C (SEQ ID NO: 363), wherein X 1 can be independently selected from K or P; X 2 can be independently selected from D or K; X 3 can be independently selected from any non-cysteine amino acid. In some embodiments, the PD-L1 binding motif may comprise the sequence KFDVFKCLDHC (SEQ ID NO: 365). In some embodiments, the PD-L1 binding motif may comprise at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% identity to SEQ ID NO: 365.
[0128] PD-L1-binding peptides of the present disclosure (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) may comprise one or more secondary structure elements. In some embodiments, PD-L1-binding peptides may comprise an α-helix, a β-sheet, a loop, or a combination thereof. PD-L1-binding peptides (e.g., any one of SEQ ID NOs: 1-56, or 60-115) may comprise an α-helix comprising amino acid residues n to n+20, where n corresponds to the amino acid position of the first cysteine residue. For example, the PD-L1-binding peptide of SEQ ID NO: 3 may comprise an α-helix comprising amino acid residues C4 to S24. PD-L1-binding peptides (e.g., any one of SEQ ID NOs: 1-56, or 60-115) may comprise an α-helix comprising amino acid residues n+29 to n+44, where n corresponds to the amino acid position of the first cysteine residue. For example, the PD-L1-binding peptide of SEQ ID NO: 3 may comprise an α-helix comprising amino acid residues S33 to A48. A PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1 to 56, or SEQ ID NOs: 60 to 115) may comprise an α-helix comprising amino acid residues n+34 to n+44, where n corresponds to the amino acid position of the first cysteine residue. For example, the PD-L1-binding peptide of SEQ ID NO: 3 may comprise an α-helix comprising amino acid residues F38 to A48. In some embodiments, the PD-L1-binding peptides of the present disclosure may bind to PD-L1 by forming hydrophobic interactions with I54, Y56, R113, M115, or Y123 of PD-L1. For example, residues V9, W12, M13, V39, or F40 of SEQ ID NO: 1 may form hydrophobic interactions with PD-L1. In some embodiments, the PD-L1-binding peptides of the present disclosure can form salt bridges with Q66, A121, and Y123 of PD-L1. For example, residues K5, K16, L43, and D44 of SEQ ID NO: 1 can form salt bridges with PD-L1.In some embodiments, the PD-L1-binding peptides of the present disclosure may bind to PD-L1 in a manner similar to their natural binding partner PD-1, which uses K78, I126, L128, A132, I134, and E136 to interact at the same sites on PD-L1 as K5, L43, V9, W12, F40, and D44, respectively, in SEQ ID NO: 1. In some embodiments, any one of SEQ ID NOs: 358 through 365 comprises the portion of the PD-L1-binding peptide that interacts with PD-L1 (e.g., to form a hydrophobic interaction or a salt bridge). For example, any one of SEQ ID NOs: 358 through 365 may include K5, V9, W12, M13, K16, V39, F40, L43, D44, or a combination thereof, with respect to SEQ ID NO: 1.
[0129] In some embodiments, the PD-L1-binding peptides of the present disclosure can bind to PD-L1 with an affinity that is pH-independent. For example, a PD-L1-binding peptide can bind to PD-L1 at extracellular pH (about pH 7.4) with substantially the same affinity as its binding affinity at endocytic pH (such as about pH 5.5 or about pH 6.5). In some embodiments, a PD-L1-binding peptide can bind to PD-L1 at extracellular pH (about pH 7.4) with a lower affinity than its binding affinity at endocytic pH (such as about pH 5.5 or about pH 6.5). In some embodiments, a PD-L1-binding peptide can bind to PD-L1 at extracellular pH (about pH 7.4) with a higher affinity than its binding affinity at endocytic pH (such as about pH 5.5 or about pH 6.5). In some embodiments, the binding affinity of a PD-L1-binding peptide to PD-L1 at extracellular pH (about pH 7.4) may differ from the binding affinity of a PD-L1-binding peptide to PD-L1 at endocytic pH (about pH 5.5) by about 1% or less, about 2% or less, about 3% or less, about 4% or less, about 5% or less, about 6% or less, about 7% or less, about 8% or less, about 9% or less, about 10% or less, about 12% or less, about 15% or less, about 17% or less, about 20% or less, about 25%, about 30% or less, about 35% or less, about 40% or less, about 45% or less, or about 50% or less. In some embodiments, the affinity of the PD-L1-binding peptide for PD-L1 at pH 7.4 and pH 5.5 may differ by no more than 5-fold, no more than 10-fold, no more than 10-fold, no more than 15-fold, no more than 20-fold, no more than 25-fold, no more than 30-fold, no more than 40-fold, or no more than 50-fold. In some embodiments, the receptor-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) may be modified to remove one or more histidine amino acids in the PD-L1-binding interface, thereby decreasing the pH dependence of the binding affinity of the PD-L1-binding peptide for PD-L1.In some embodiments, the PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) may lack the histidine amino acids in the PD-L1-binding interface.
[0130] In some embodiments, the PD-L1-binding peptide has an equilibrium dissociation constant (K) of 50 μM or less, 5 μM or less, 500 nM or less, 100 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.25 nM or less, 0.2 nM or less, or 0.1 nM or less, at, for example, extracellular pH (about pH 7.4). D In some embodiments, PD-L1-binding peptides with pH-independent binding can bind to PD-L1 with a dissociation constant (K) of 50 μM or less, 5 μM or less, 500 nM or less, 100 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, or 0.2 nM or less at endosomal pH (about pH 5.5). D ) In some embodiments, the PD-L1-binding peptide can bind to PD-L1 with an affinity that is pH-dependent. For example, the PD-L1-binding molecule can bind to PD-L1 with higher affinity at extracellular pH (about pH 7.4) and with lower affinity at endosomal pH (about pH 5.5), thereby releasing the peptide or peptide complex from PD-L1 upon entry and acidification of the endosomal compartment.
[0131] The PD-L1-binding peptides of the present disclosure may be cross-reactive with PD-L1 from more than one species, or the PD-L1-binding peptides may be selective for PD-L1 from one or more species. For example, a PD-L1-binding peptide may be cross-reactive with both human PD-L1 and cynomolgus PD-L1. The PD-L1-binding peptides may have equilibrium dissociation constants (K D), there may be cross-reactivity with the two species. In some embodiments, a PD-L1-binding peptide may not be cross-reactive with PD-L1 of one or more species. For example, a PD-L1-binding peptide may have an equilibrium dissociation constant (K D ) but with an equilibrium dissociation constant (K ) that is at least 10-fold, 50-fold, or 100-fold greater. D ) and can bind to mouse PD-L1.
[0132] Sequence identity and homology The percent (%) of sequence identity or homology is determined by conventional methods. (See, e.g., Altschul et al. (1986), Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff (1992), Proc. Natl. Acad. Sci. USA 89:10915.) Briefly, two amino acid sequences can be aligned to optimize the alignment score using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff and Henikoff (ibid.). Sequence identity or homology is then calculated as follows: ([total number of identical matches] / [length of the longer sequence + number of gaps introduced into the longer sequence to align the two sequences])(100).
[0133] Various methods and software programs, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm, can be used to determine homology between two or more peptides. Pairwise sequence alignment can be used to identify regions of similarity that may indicate functional, structural, and / or evolutionary relationships between two biological sequences (e.g., amino acid or nucleic acid sequences). Additionally, multiple sequence alignment (MSA) is the alignment of three or more biological sequences. From the results of MSA applications, homology can be estimated and evolutionary relationships between sequences can be assessed. As used herein, "sequence homology," "sequence identity," "percent sequence identity," and "percent sequence homology" are used interchangeably and refer to the relatedness or variation of a sequence relative to a reference polynucleotide or amino acid sequence, as appropriate.
[0134] Furthermore, several established algorithms are available for aligning two amino acid sequences. For example, the Pearson and Lipman "FASTA" similarity search algorithm may be a suitable protein alignment method for determining the level of sequence identity or homology shared between the amino acid sequence of a peptide disclosed herein and the amino acid sequence of a peptide variant. The FASTA algorithm is described, for example, by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988) and Pearson, Meth. Enzymol. 183:63 (1990). Briefly, FASTA characterizes sequence similarity by first identifying regions shared by a query sequence (e.g., SEQ ID NO: 1) and a test sequence with either the highest density of matches (when the ktup variable is 1) or match pairs (when ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The 10 regions with the highest density of matches are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only the residues that contribute the highest score. If there are multiple regions with scores greater than a "cutoff" value (calculated using a predetermined formula based on the sequence length and ktup value), the trimmed initial regions are examined to determine whether these regions can be combined to form a gapped approximate alignment. Finally, the highest-scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, Siam J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions. For example, exemplary parameters for FASTA analysis are ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62.These parameters can be introduced into the FASTA program by modifying the scoring matrix file ("SMATRIX") as described in Appendix 2 of Pearson, Meth. Enzymol. 183:63 (1990).
[0135] FASTA can also be used to determine sequence identity or homology of nucleic acid sequences or molecules using the ratios disclosed above. When comparing nucleic acid sequences, the ktup value can range from 1 to 6, preferably 3 to 6, and most preferably 3, with other parameters set as described herein.
[0136] Some examples of common amino acids that are "conservative amino acid substitutions" are exemplified by substitutions between amino acids within the following groups: (1) glycine, alanine, valine, leucine, and isoleucine; (2) phenylalanine, tyrosine, and tryptophan; (3) serine and threonine; (4) aspartic acid and glutamic acid; (5) glutamine and asparagine; and (6) lysine, arginine, and histidine. The BLOSUM62 table is an amino acid substitution matrix representing highly conserved regions of over 500 related protein groups derived from approximately 2,000 local multiple alignments of protein sequence segments (Henikoff and Henikoff, Proc. Nat'l Acad. Sci. USA 89:10915 (1992)). Therefore, BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that can be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely on chemical properties (as described above), the term "conservative amino acid substitution" preferably refers to a substitution represented by a BLOSUM62 value greater than -1. For example, an amino acid substitution is conservative if it is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2, or 3), and more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).
[0137] Amino acid residues within regions or domains that are important for maintaining structural integrity can be determined. Within these regions, specific residues that are tolerant to change and maintain the overall tertiary structure of the molecule can be determined. Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity or homology, and computer analysis using available software (e.g., Insight II.RTM Viewer and Homology Modeling Tools; MSI, San Diego, Calif.), secondary structure trends, binary patterns, complementary packing, and buried polar interactions (Barton, GJ, Current Opin. Struct. Biol. 5:372-6 (1995); and Cordes, MH et al., Current Opin. Struct. Biol. 6:3-10 (1996)). In general, when designing modifications to a molecule or identifying specific fragments, structural determination can typically be achieved by evaluating the activity of the modified molecule.
[0138] Peptide-active agent conjugates In some embodiments, PD-L1-binding CDPs such as those described in Table 1, including modified non-naturally occurring CDPs and naturally occurring CDPs, can be conjugated, linked, or fused to an additional active agent to selectively deliver the active agent to PD-L1-positive cells. The cells can be cancer cells, immune cells, pancreatic beta cells, or any combination thereof. The cells can be any cell that expresses PD-L1. The engineered peptide can be a non-naturally occurring, artificial, synthetic, designed, or recombinantly expressed peptide. In some embodiments, a PD-L1-binding peptide conjugate comprising a PD-L1-binding peptide (e.g., a PD-L1-binding bispecific immune cell engager or a PD-L1-binding chimeric antigen receptor) enables PD-L1-mediated delivery of an additional active agent (e.g., a therapeutic agent, a detectable agent, or an immune cell) to a target cell. The target cell (e.g., a PD-L1-positive target cell) can be associated with a disease or condition. In some embodiments, delivery of an active agent to a target cell can treat (e.g., prevent, alleviate, eliminate, diagnose, or alleviate the symptoms of) a disease or condition. In some cases, the target cell is a cancer cell. Cancers can include melanoma, non-small cell lung cancer, small cell lung cancer, kidney cancer, esophageal cancer, oral cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer, colorectal cancer, lymphoma, bladder cancer, liver cancer, gastric cancer, breast cancer, pancreatic cancer, prostate cancer, Merkel cell carcinoma, mesothelioma, brain tumor, metastatic brain tumor, primary brain tumor, glioblastoma, or PD-L1-overexpressing cancer. In some cases, the PD-L1-binding peptide or peptide conjugate can cross the blood-brain barrier to deliver the PD-L1-binding peptide or other active agent to a target cell in the central nervous system.
[0139] The PD-L1-binding peptides of the present disclosure can be linked, fused, conjugated, or otherwise complexed with an additional active agent to form a PD-L1-binding peptide complex. In some embodiments, the PD-L1-binding peptide and additional active agent may be complexed via a linker (e.g., a peptide linker or a small molecule linker). The activity (e.g., binding, inhibitory, or activating activity) of both the PD-L1-binding peptide and the additional active agent may be retained upon complex formation. In some embodiments, an appropriate linker is selected such that activity is retained. An active agent may be any agent capable of performing a function. Such functions may include binding, inhibition, activation, inactivation, recruitment, signal generation, synthesis, destruction, or a combination thereof. In some embodiments, the active agent may be a therapeutic agent (e.g., a therapeutic small molecule or therapeutic peptide) or a detectable agent (e.g., a fluorophore or radioisotope).
[0140] The active agent can form a complex with the PD-L1-binding peptide such that it does not disrupt binding to PD-L1. In some embodiments, the peptide-active agent complex can bind to PD-L1 with an equilibrium dissociation constant (KD) of 100 nM or less, 50 nM or less, 30 nM or less, 20 nM or less, 1 nM or less, 500 pM or less, 300 pM or less, 250 pM or less, or 200 pM or less.
[0141] Peptide Therapeutic Conjugates The PD-L1-binding peptides of the present disclosure (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) can be conjugated with a therapeutic agent to form a peptide-therapeutic conjugate. The therapeutic agent in the peptide conjugate can exert a therapeutic function upon delivery to a cell (e.g., a PD-L1-positive cell). The therapeutic function can include activating or inhibiting a target (e.g., a targeted enzyme), recruiting additional components to the cell, or killing the cell (e.g., a PD-L1-positive cancer cell). Examples of therapeutic agents that can be conjugated to PD-L1-binding peptides include anti-cancer agents, chemotherapeutic agents, radiotherapeutic agents, anti-inflammatory agents, pro-inflammatory cytokines, oligonucleotides, or combinations thereof. In some embodiments, the active agent (e.g., an Fc domain or a globular protein) can function as a steric blocker. For example, an Fc domain linked to a PD-L1-binding peptide may enhance the disruption of PD-1 binding to PD-L1 by the PD-L1-binding peptide by sterically blocking access to PD-L1. In some embodiments, the PD-L1-binding peptide can be complexed with an oncolytic viral vector to deliver the viral vector to PD-L1-positive cells.
[0142] Chemotherapeutic or anti-cancer agents may function by killing or inhibiting the growth of target cancer cells (e.g., PD-L1-positive cancer cells). Examples of chemotherapeutic or anti-cancer agents that can be complexed with the PD-L1-binding peptides of the present disclosure include anti-tumor agents, cytotoxic agents, tyrosine kinase inhibitors, mTOR inhibitors, retinoids, microtubule polymerization inhibitors, pyrrolobenzodiazepine dimers, or anti-cancer antibodies. Pro-inflammatory cytokines may function by stimulating an immune response against targets (e.g., PD-L1-positive cancer cells). Examples of pro-inflammatory cytokines that can be complexed with the PD-L1-binding peptides of the present disclosure include TNFα, IL-2, IL-6, IL-12, IL-15, IL-21, or IFNγ. Anti-inflammatory agents may function by inhibiting inflammatory responses within or around the target (e.g., by inhibiting cyclooxygenase enzymes or stimulating glucocorticoid receptors). Examples of anti-inflammatory agents that may be complexed to the PD-L1-binding peptides of the disclosure include an anti-inflammatory cytokine, a steroid, a glucocorticoid, a corticosteroid, a cytokine inhibitor, an ROR gamma inhibitor, a JAK inhibitor, a tyrosine kinase inhibitor, or a nonsteroidal anti-inflammatory drug (NSAID).
[0143] In some embodiments, the active agent is an immunotherapeutic agent, a cancer immunotherapeutic agent, a CTLA-4 targeted agent, a PD-1 targeted agent, a PDL-1 targeted agent, an IL15 agent, a fused IL-15 / IL-15Ra conjugate agent, an IFN gamma agent, an anti-CD3 agent, an ion channel modulating agent, an auristatin, MMAE, a maytansinoid, DM1, DM4, doxorubicin, a calicheamicin, a platinum compound, cisplatin, a taxane, paclitaxel, SN-38, a BACE inhibitor, a Bcl-xL inhibitor, WEHI-539, venetoclax, ABT-199, navitoclax, and AT-101, obatoclax, pyrrolobenzodiazepines or pyrrolobenzodiazepine dimers, dolastatins, cancer immunotherapies, agents targeting immune cells (e.g., targeting GITR, 4-1BB, CD27, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, CD28), or agents targeting tumor cells (e.g., GITRL, 4-1BBL, CD17, CD156 / CD112 / CD113, MHC11, CD40, OX40L, PD-L1 / L2, CD80 / 86).
[0144] In some embodiments, the PD-L1-binding peptide can target an active agent (e.g., a target-binding nucleotide, small molecule, peptide, or protein active agent) intracellularly. In further embodiments, the PD-L1-binding peptide can target the active agent into the nucleus. In some embodiments, the active agent has inherent tumor-homing properties, or the active agent can be engineered to have tumor-homing properties. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents can be linked to the peptide or nucleotide. Multiple active agents (e.g., ) can be attached by methods such as conjugation to multiple lysine residues and / or the N-terminus, or by linking multiple active agents to a scaffold such as a polymer or dendrimer and then attaching the drug-scaffold to the peptide (e.g., as described in Yurkovetskiy, AV, Cancer Res 75(16):3365-72 (2015)).Examples of active agents include peptides, oligopeptides, polypeptides, peptidomimetics, polynucleotides, polyribonucleotides, DNA, cDNA, ssDNA, RNA, dsRNA, microRNA, oligonucleotides, antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotides (ASOs), microRNAs (miRNAs), oligonucleotides complementary to natural antisense transcript (NAT) sequences, siRNAs, snRNAs, aptamers, gapmers, anti-mrRs, splice blocker ASOs, or U1 adaptors, antibodies, single chain variable fragments (scFvs), antibody fragments, aptamers, cytokines, interferons, hormones, enzymes, growth factors, checkpoint inhibitors, PD-1 inhibitors, PD-L1 inhibitors, CD47 inhibitors, CTLA4 inhibitors, CD antigens, chemokines, ion channel inhibitors, ion channel inducers, activators, G protein coupled receptor inhibitors, G protein coupled receptor activators, chemical agents, radiosensitizers, radioprotectants, radionuclides, therapeutic small molecules, steroids, corticosteroids, anti-inflammatory agents, immunomodulators, cancer immunotherapeutics, complement-fixing peptides or proteins, tumor necrosis factor inhibitors, tumor necrosis factor activators, tumor necrosis factor receptor family agonists, tumor necrosis receptor antagonists, Tim-3 inhibitors, protease inhibitors, amino sugars, chemotherapeutic agents, cytotoxic molecules, toxins, tyrosine kinase inhibitors, anti-infective agents, antibiotics, antivirals, antifungals, aminoglycosides, nonsteroidal anti-inflammatory drugs (NSAIDs), statins, nanoparticles, liposomes, polymers, biopolymers, polysaccharides, proteoglycans, glycosaminoglycans, polyethylene glycol, lipids, dendrimers, fatty acids, or Fc regions, or active fragments or modifications thereof.
[0145] Due to their low BBB penetration ability, only a small portion of currently available drug molecules are applicable to CNS diseases. Approximately 98% of small molecule drugs do not cross the BBB or cross it only to a very limited extent. In addition, nearly 100% of macromolecular drug molecules (e.g., antibodies) do not exhibit effective BBB penetration. (See, e.g., Mikitsh et al. Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier, Perspective Medicin Chem. 2014;6:11-24.) PD-L1-binding antibodies may not be able to cross the BBB at therapeutically sufficient levels. The PD-L1-binding peptides of the present disclosure may be able to cross the BBB due to their CDP properties, PD-L1-binding properties, or other properties. The PD-L1-binding peptides of the present disclosure can also be complexed with other agents, such as transferrin receptor (TfR)-binding agents, to enable the complex to cross the BBB. PD-L1-expressing cells, such as cancer cells in the brain (e.g., from primary or metastatic cancers), can be advantageously targeted by administering a PD-L1-binding molecule that can cross the BBB. Thus, the PD-L1-binding peptides of the present disclosure can be administered for therapeutic benefit in the CNS, such as to block PD-L1 in the brain or to deliver active agents (e.g., T cell binding agents or oligonucleotides) to the brain. The PD-L1-binding peptides of the present disclosure can also be complexed with a TfR-binding peptide (e.g., SEQ ID NO: 350) to deliver the PD-L1-binding peptides of the present disclosure across the BBB to the CNS. Brain tumors that can be treated or prevented using conjugates or fusion molecules comprising one or more PD-L1-binding peptides of the present disclosure can include metastatic cancers, including, but not limited to, glioblastoma, astrocytoma, glioma, medulloblastoma, ependymoma, choroid plexus carcinoma, midline glioma, metastatic melanoma, breast cancer, and lung cancer, as well as diffuse intrinsic pontine glioma.
[0146] Active agents that may be used in combination with the PD-L1-binding peptides described herein include cytotoxic molecules. For example, cytotoxic molecules that can be used include auristatins, MMAE, MMAF, dolostatin, auristatin F, monomethylauristatin D, DM1, DM4, maytansinoids, maytansine, calicheamicin, N-acetyl-γ-calicheamicin, pyrrolobenzodiazepines, PBD dimers, doxorubicin, vinca alkaloids (4-deacetylvinblastine), duocarmycins, cyclic octapeptide analogs of mushroom amatoxin, epothilones, and BACE (beta-secretase 1) inhibitors such as anthracylines, CC-1065, taxanes, paclitaxel, cabazitaxel, docetaxel, SN-38, irinotecan, vincristine, vinblastine, platinum compounds, cisplatin, methotrexate, verubecestat, chlorambucil, and mitomycin C. Additional examples of active agents are described in McCombs, JR, AAPS J, 17(2):339-51 (2015), Ducry, L., Antibody Drug Conjugates (2013), and Singh, SK, Pharm Res. 32(11):3541-3571 (2015). Additional examples of therapeutic payloads that may have significantly improved therapeutic efficacy when used in combination with the compositions and methods of the present disclosure include carmustine, cisplatin, cyclophosphamide, etoposide, irinotecan, lomustine, procarbazine, temozolomide, vincristine, and bevacizumab. Additional examples of therapeutic payloads are compounds with therapeutic benefit in neurodegenerative or autoimmune diseases, such as BACE inhibitors.
[0147] Peptide detectable agents and peptide radiotherapeutic agent conjugates A PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) or peptide conjugate of the present disclosure can be conjugated to a detectable agent or a radiotherapeutic agent to form a peptide-detectable agent conjugate or a peptide-radiotherapeutic agent conjugate. A peptide or peptide conjugate of the present disclosure (e.g., a PD-L1-binding peptide conjugate) can be conjugated, linked, or fused to a detectable agent or a radiotherapeutic agent. In some embodiments, a detectable agent or therapeutic agent may be combined with an additional active agent (e.g., a therapeutic agent, oligonucleotide, or therapeutic oligonucleotide) to form a conjugate to a PD-L1-binding peptide. For example, a detectable agent may be conjugated to a PD-L1-binding peptide-oligonucleotide conjugate. In some embodiments, a detectable agent or radiotherapeutic agent may be linked directly or indirectly to a PD-L1-binding peptide. In some embodiments, a detectable agent or radiotherapeutic agent may be linked directly or indirectly to the active agent of a PD-L1-binding peptide conjugate (e.g., the oligonucleotide of a PD-L1-binding peptide-oligonucleotide conjugate). Peptide conjugates comprising a detectable agent can be referred to as detectable drug-peptide conjugates or detectable drug-peptide conjugates. Peptides (e.g., PD-L1-binding peptides) can be conjugated, linked, or fused to agents used in imaging, research, therapeutics, theranostics, pharmaceuticals, chemotherapy, chelation therapy, targeted drug delivery, and radiation therapy. In some embodiments, the peptide is conjugated, linked, or fused to a detectable agent such as a fluorophore, near-infrared dye, contrast agent, nanoparticle, metal-containing nanoparticle, metal chelate, X-ray contrast agent, PET agent, metal, radioisotope, dye, radionuclide chelator, or another suitable substance that can be used for imaging.
[0148] In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents may be linked to a peptide or nucleotide. Non-limiting examples of radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters. In some embodiments, the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium. In some embodiments, the radioisotope is actinium-225 or lead-212. In some embodiments, the near-infrared dye is not easily quenched by biological tissues and fluids. In some embodiments, the fluorophore is a fluorescent agent that emits electromagnetic radiation at wavelengths between 650 nm and 4000 nm, and such radiation is used to detect such agents. Non-limiting examples of fluorescent dyes that can be used as conjugate molecules in the present disclosure include DyLight-680, DyLight-750, Vivoag-750, DyLight-800, IRDye-800, Vivotag-680, Cy5.5, or indocyanine green (ICG). In some embodiments, near-infrared dyes often include cyanine dyes (e.g., Cy7, Cy5.5, and Cy5).Further non-limiting examples of fluorescent dyes that can be used as conjugate molecules in the present disclosure include acradin orange or yellow, Alexa Fluor (e.g., Alexa Fluor 790, 750, 700, 680, 660, and 647) and any derivatives thereof, 7-actinomycin D, 8-anilinonaphthalene-1-sulfonic acid, ATTO dye and any derivatives thereof, auramine-rhodamine stain and any derivatives thereof, bensanthrone, bimane, 9-10-bis(phenylethynyl)anthracene, 5,12-bis(phenylethynyl)naphthacene, bisbenzimide, Brainbow, calcein, carbodifluorescein and any derivatives thereof, 1-chloro-9,10-bis(phenylethynyl)anthracene and any derivatives thereof, DAPI, DiOC6, DyLight Fluor and any derivatives thereof, epicocconone, ethidium bromide, FlAsH-EDT2, Fluo dyes and any derivatives thereof, FluoProbe and any derivatives thereof, fluorescein and any derivatives thereof, Fura and any derivatives thereof, GelGreen and any derivatives thereof, GelRed and any derivatives thereof, fluorescent proteins and any derivatives thereof, m isoform proteins and any derivatives thereof, such as mCherry, hetamethine dyes and any derivatives thereof, Hoechst stain, iminocoumarin, Indian Yellow, Indo-1 and any derivatives thereof Examples of fluorescent dyes include fluorescein, laurdan, lucifer yellow and any derivatives thereof, luciferin and any derivatives thereof, luciferase and any derivatives thereof, mercocyanin and any derivatives thereof, Nile dye and any derivatives thereof, perylene, phloxine, phycodyes and any derivatives thereof, propium iodide, pyranine, rhodamine and any derivatives thereof, ribogreen, RoGFP, rubrene, stilbene and any derivatives thereof, sulforhodamine and any derivatives thereof, SYBR and any derivatives thereof, synapto-pH fluorescein, tetraphenylbutadiene, tetrasodium tris, Texas Red, Titan Yellow, TSQ, umbelliferone, violanthrone, yellow fluorescent protein, and YOYO-1.Other suitable fluorescent dyes include fluorescein and fluorescein dyes (e.g., fluorescent isothiocyanine or FITC, naphthofluorescein, 4',5'-dichloro-2',7'-dimethoxyfluorescein, 6-carboxyfluorescein or FAM, etc.), carbocyanines, merocyanines, styryl dyes, oxonol dyes, phycoerythrin, erythrosine, eosin, rhodamine dyes (e.g., carboxytetramethyl-rhodamine or TAMRA, carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Lissamine rhodamine B, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine (TMR), etc.), coumarin and coumarin dyes (e.g., methoxycoumarin, dialkylaminocoumarin, hydroxycoumarin, aminomethylcoumarin (AMCA), etc.), Oregon Green dyes (e.g., Oregon Green 488, Oregon Green 500, Oregon Green 500), and the like. Green514, etc.), Texas Red, Texas Red-X, SPECTRUM RED, SPECTRUM GREEN, cyanine dyes (e.g., CY-3, Cy-5, CY-3.5, CY-5.5, etc.), ALEXA FLUOR dyes (e.g., ALEXA FLUOR350, ALEXA FLUOR488, ALEXA FLUOR532, ALEXA FLUOR546, ALEXA FLUOR568, ALEXA FLUOR594, ALEXA FLUOR633, ALEXA FLUOR660, ALEXA FLUOR680, etc.), BODIPY dyes (e.g., BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY Suitable detectable agents include, but are not limited to, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, etc.), IRDye (e.g., IRD40, IRD700, IRD800, etc.), etc. Additional suitable detectable agents are described in PCT / US14 / 56177.
[0149] In some embodiments, peptides of the present disclosure (e.g., PD-L1-binding peptides) may further comprise or be conjugated to a radioisotope, radiochelator, radiosensitizer, or photosensitizer. In some embodiments, the radioisotope, radiochelator, radiosensitizer, or photosensitizer may be incorporated into or directly or indirectly linked to the PD-L1-binding peptide. In some embodiments, the radioisotope, radiochelator, radiosensitizer, or photosensitizer. In some embodiments, the radioisotope, radiochelator, radiosensitizer, or photosensitizer may be incorporated into or conjugated to a PD-L1-binding peptide conjugate that comprises an additional active agent (e.g., a therapeutic agent, oligonucleotide, or therapeutic oligonucleotide). For example, the radioisotope, radiochelator, radiosensitizer, or photosensitizer may be incorporated into or directly or indirectly linked to the oligonucleotide of a PD-L1-binding peptide-oligonucleotide conjugate. Radioisotopes, radioactive chelators, radiosensitizers, and photosensitizers can function as detectable agents, therapeutic agents, or both. Non-limiting examples of radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters. In some embodiments, the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium. In some embodiments, the radioisotope is actinium-225 or lead-212. Additionally, the following radionuclides can be used for diagnosis and / or therapy: carbon (e.g., 11 C or 14 C), nitrogen (e.g., 13 N), fluorine (e.g., 18 F), gallium (e.g., 67 Ga or 68Ga), copper (e.g., 64 Cu or 67Cu), zirconium (e.g., 89Zr), lutetium (e.g., 177 In some embodiments, the radioisotope is indium-111, technetium-99m, yttrium-90, iodine-131, iodine-123, or astatine-211.
[0150] The active agent of the PD-L1-binding peptide or PD-L1-binding peptide complex can be conjugated, linked, or fused to a radiosensitizer or photosensitizer. Examples of radiosensitizers include, but are not limited to, ABT-263, ABT-199, WEHI-539, paclitaxel, carboplatin, cisplatin, oxaliplatin, gemcitabine, etanidazole, misonidazole, tirapazamine, and nucleobase derivatives (e.g., halogenated purines or pyrimidines such as 5-fluorodeoxyuridine). Examples of photosensitizers include fluorescent molecules or beads that generate heat upon exposure to light, nanoparticles, porphyrins and porphyrin derivatives (e.g., chlorins, bacteriochlorins, isobacteriochlorins, phthalocyanines, and naphthalocyanines), metalloporphyrins, metallophthalocyanines, angelicins, chalcogenapyrylium dyes, chlorophylls, coumarins, flavins and related compounds such as alloxazines and riboflavins, fullerenes, pheophorbides, pyropheophorbides, cyanines (e.g., merocyanine 540), ... Examples of suitable peptides include, but are not limited to, phytin, sapphyrin, texaphyrin, purpurin, porphycene, phenothiazinium, methylene blue derivatives, naphthalimide, Nile blue derivatives, quinones, perylenequinones (e.g., hypericin, hypocrellin, and cercosporin), psoralens, quinones, retinoids, rhodamines, thiophenes, verdine, xanthene dyes (e.g., eosin, erythrosine, rose bengal), dimeric and oligomeric porphyrins, and prodrugs such as 5-aminolevulinic acid. Advantageously, this approach allows for highly specific targeting of diseased cells (e.g., cancer cells) using both a therapeutic agent (e.g., a drug) and electromagnetic energy (e.g., radiation or light) simultaneously. In some embodiments, the peptide is conjugated, linked, fused, or covalently or non-covalently linked to the drug, e.g., directly or via a linker. Exemplary linkers suitable for use in the embodiments herein are discussed in further detail below.
[0151] The PD-L1-binding peptide or the active agent of the PD-L1-binding peptide conjugate can be conjugated, linked, or fused to a radionuclide via a chelator. In some embodiments, the radionuclide can be linked to the peptide of the peptide-oligonucleotide conjugate or the nucleotide of the peptide-oligonucleotide conjugate via a chelator. In some aspects of the present disclosure, the radionuclide is attached to the peptide-oligonucleotide conjugates described herein using a chelator. Exemplary chelator moieties include 2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,23-heptaoxa-2-azapentacosan-25-yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)trimethylsilyl Acetic acid;2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl 2,2'-(7-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic acid; Acetic acid;2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17,20,23,26,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;2,2',2''-(3-(4-(3-(25,28-dioxo-28-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17,20,23,26,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid 2,2',2''-(3-(4-(3-(37,40-dioxo-40-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxa- 36-Azatetracontyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;2,2',2''-(3-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)-3-oxo-6,9,12,15,18,21,24-heptaoxa-2-azaheptacosan-27-amido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;2,2',2''-(2-(4-(1-(4-(6-methyl-1,2,4,5 -tetrazin-3-yl)phenoxy)-3,6,9,12,15,18,21,24,27,30,33-undecaoxahexatriacontan-36-amido)benzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid;2,2',2''-(3-(4-(3-(5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;2,2'-(7-(4-(3-(5-amino-6-((4-6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic acid;2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic acid 2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
[0152] Bispecific immune cell engager (BiICE) In some embodiments, an active agent of the present disclosure may be an additional binding moiety (e.g., an immune cell-binding moiety). A PD-L1-binding peptide of the present disclosure (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) can be complexed with one or more additional binding moieties to form a bispecific or multispecific molecule. A bispecific or multispecific molecule may bind to two or more target molecules (e.g., PD-L1 and one or more additional target molecules). An example of a bispecific molecule is a bispecific immune cell engager (BiICE) comprising a PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) and an immune cell targeting agent (e.g., an immune cell-targeting antibody or antibody fragment, or an immune cell-targeting CDP, peptide, or peptide fragment). The immune cell targeting agent may bind to a molecule on the surface of an immune cell. For example, the immune cell targeting agent may bind to CD3, 4-1BB, CD28, CD137, CD89, CD16, CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1. The bispecific immune cell engager may function by recruiting immune cells to PD-L1-positive cells (e.g., PD-L1-positive cancer cells, immune cells associated with an autoimmune response, or pancreatic beta cells). In some embodiments, immune cell binding agents can bind to T cells, B cells, macrophages, natural killer cells, fibroblasts, regulatory T cells, regulatory immune cells, neural stem cells, or mesenchymal stem cells and can recruit T cells, B cells, macrophages, natural killer cells, fibroblasts, regulatory T cells, regulatory immune cells, neural stem cells, or mesenchymal stem cells to PD-L1-positive cells. For example, immune cell targeting agents that bind to CD3, 4-1BB, CD28, or CD137 can recruit T cells to PD-L1-positive cells. In another example, immune cell targeting agents that bind to CD89 can recruit macrophages to PD-L1-positive cells.In another example, an immune cell targeting agent that binds to CD16 can recruit natural killer cells to PD-L1-positive cells. In another example, an immune cell targeting agent that binds to CD25 can recruit regulatory T cells to PD-L1-positive cells. In another example, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1 can recruit mesenchymal stem cells or other immune cells to PD-L1-positive cells. An example of an immune cell targeting agent that binds to CD3 can include the sequence of SEQ ID NO: 122 or SEQ ID NO: 442-SEQ ID NO: 471. An example of an immune cell targeting agent that binds to CD28 can include the sequence of SEQ ID NO: 472-SEQ ID NO: 481. An example of an immune cell targeting agent that binds to CD25 can include the sequence of SEQ ID NO: 482-SEQ ID NO: 491. Examples of immune cell targeting agents are provided in Table 2. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6]
[0153] An immune cell targeting agent (e.g., a binding moiety that binds CD3, 4-1BB, CD28, CD137, CD89, CD16, CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1) can be conjugated to a PD-L1-binding peptide via a linker (e.g., a peptide linker). In some embodiments, the immune cell targeting agent and the PD-L1-binding peptide can form a single polypeptide chain. In some embodiments, the immune cell targeting agent and the PD-L1-binding peptide can be conjugated by forming a heterodimer via heterodimerization domains. The immune cell targeting agent can be linked or fused to a first heterodimerization domain, and the PD-L1-binding peptide can be linked or fused to a second heterodimerization domain. The first heterodimerization domain may bind to the second heterodimerization domain to form a heterodimeric complex comprising the immune cell-binding peptide and the PD-L1-binding peptide. For example, the PD-L1-binding peptide may be linked to or fused to an Fc "knob" peptide (e.g., SEQ ID NO: 124), and the immune cell targeting agent may be linked to or fused to an Fc "hole" peptide (e.g., SEQ ID NO: 125). In another example, the PD-L1-binding peptide may be linked to or fused to an Fc "hole" peptide (e.g., SEQ ID NO: 125), and the immune cell targeting agent may be linked to or fused to an Fc "knob" peptide (e.g., SEQ ID NO: 124). An example of a PD-L1-binding half of a heterodimeric T cell engager may comprise the sequence of SEQ ID NO: 119 or SEQ ID NO: 120. An example of an immune cell-targeting half of a heterodimeric T cell engager that binds CD3 may comprise the sequence of SEQ ID NO: 123. In some embodiments, a PD-L1-binding peptide (e.g., any one of SEQ ID NOs:1-118, 435, 436, or 554-567) may form a heterodimer with an immune cell-binding moiety via a heterodimerization domain shown in Table 3.For example, the PD-L1-binding peptide may be fused to chain 1 of an Fc pair (e.g., SEQ ID NO: 126), and the immune cell-binding moiety may be fused to chain 2 of the Fc pair (e.g., SEQ ID NO: 127). In another example, the PD-L1-binding peptide may be fused to chain 2 of the Fc pair (e.g., SEQ ID NO: 129), and the immune cell-binding moiety may be fused to chain 1 of the Fc pair (e.g., SEQ ID NO: 128). It is understood that paired heterodimerization domains (e.g., chains 1 and 2 of a given pair) designated by "pair" in Table 3 may form heterodimers in which one "chain" of the pair is fused to the immune cell-binding moiety and the other "chain" is fused to the PD-L1-binding peptide, or vice versa. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7]
[0154] In some cases, the PD-L1-binding peptide and immune cell targeting agent may both be presented as dimers, such as by placing or positioning the PD-L1-binding peptide at the N- or C-terminus of a homodimeric Fc fusion, or by placing or positioning the immune cell targeting agent at the other end (C- or N-terminus) of the homodimeric Fc fusion. An exemplary homodimeric Fc of SEQ ID NO: 1 and anti-CD3 scFv (EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL; SEQ ID NO: 122) is shown in SEQ ID NO: 121. Additional examples of homodimeric Fc fusions are provided in SEQ ID NOs: 438-441. Exemplary components that can homodimerize or heterodimerize to form bispecific immune cell engagers are shown in Table 4. For example, a PD-L1-binding Fc hole component (e.g., SEQ ID NO: 119 or SEQ ID NO: 120) may heterodimerize with an anti-CD3 Fc knob component (e.g., SEQ ID NO: 123) to form a PD-L1 / CD3-binding BiICE. [Table 4-1] [Table 4-2] [Table 4-3]
[0155] In some embodiments, the immune cell targeting agent can be a single-chain variable fragment (scFv), cysteine-dense peptide, avimer, Kunitz domain, affibody, adnectin, nanophytin, finomer, β-hairpin, stapled peptide, bicyclic peptide, antibody, antibody fragment, protein, peptide, peptide fragment, binding domain, small molecule, or nanobody that binds to an immune cell target (e.g., CD3, 4-1BB, CD28, CD137, CD89, CD16, CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1).
[0156] Upon delivery, the immune cells (e.g., T cells, B cells, macrophages, or natural killer cells) can inactivate, inhibit, kill, or protect the PD-L1-positive cells. The function of the bispecific immune cell engager may depend on the type of immune cell recruited. In some embodiments, the immune cells (e.g., regulatory T cells) can inhibit PD-L1-positive cells (e.g., PD-L1-positive T cells). For example, a bispecific immune cell engager comprising a CD25-binding agent can recruit regulatory T cells to PD-L1-positive T cells associated with an autoimmune response and inhibit the T cells.
[0157] Targeted immune cells (e.g., T cells, B cells, macrophages, or natural killer cells) interact with PD-L1-expressing cells via the immune cell-binding moiety of BiICE, creating an energetically favorable interface that allows the immune cell engager to form an immune synapse that is close to the cell, e.g., the targeted cancer cell, or a narrow enough immune synapse. The immune synapse allows signal exchange between the targeted cell bound by the PD-L1-binding peptide and the targeted immune cell bound by the immune cell-binding moiety, resulting in an immune response against the cancer cell. For example, a bispecific PD-L1-binding peptide-CD3 BiICE molecule (e.g., containing a PD-L1-binding CDP complexed with a CD3-binding moiety) can bind to both CD3 on the immune cell and PD-L1 on the target cell, creating an energetically favorable interface. The space between the immune cell and the target cell is called the immune synapse, and in normal T cells, it is primarily driven by the complex between the T cell receptor (TCR) on the T cell and the peptide-MHC complex on the target cell. In some embodiments, the immune synapse can function as a kinapse or a migratory synapse. The width of this synapse is the distance between the plasma membrane of the immune cell and the target cell. In some embodiments, such as a TCR-driven synapse, the synapse width can be about 15 nm. In some embodiments, the synapse can have a width of about 3 nm to about 25 nm, about 5 nm to about 20 nm, or about 10 nm to about 15 nm. In some embodiments, the synapse can have a width of about 3 nm, about 5 nm, about 8 nm, about 10 nm, about 13 nm, about 15 nm, about 18 nm, about 20 nm, about 23 nm, or about 25 nm. In some embodiments, synapses may have a width of less than 3 nm, less than 5 nm, less than 8 nm, less than 10 nm, less than 13 nm, less than 15 nm, less than 18 nm, less than 20 nm, less than 23 nm, less than 25 nm, less than 30 nm, less than 35 nm, less than 40 nm, less than 45 nm, less than 50 nm, less than 55 nm, less than 60 nm, less than 65 nm, less than 70 nm, less than 75 nm, less than 80 nm, less than 85 nm, less than 90 nm, less than 95 nm, or less than 100 nm.BiICE molecules can induce immune synapses whose dimensions depend on the size of the BiICE and the binding locations on their respective targets (e.g., immune cells and cancer cells). For example, larger molecules with greater spacing between binding entities generate larger synapses. The size of the immune synapse can determine the effectiveness of T cell responses, such as the rate of degranulation, the dynamics of activation and exhaustion, and the mobility of T cells within the tumor microenvironment. BiICE molecules containing small binding moieties, such as CDPs, can form smaller immune synapses than can be achieved with bispecific molecules containing larger binding moieties, such as antibodies. In some embodiments, smaller synapses formed between T cells and cancer cells can result in a more potent T cell killing response by allowing the T cells to approach the cancer cells more closely. The interaction between a PD-L1-binding CDP and PD-L1 (e.g., between SEQ ID NO: 1 and PD-L1) can position the terminus of the CDP near the surface of PD-L1. In contrast, scFvs can bind to PD-L1 in an orientation where the terminus of the scFv can be as much as 5 nm away from the surface of PD-L1, resulting in an immune synapse diameter that is 5 nm larger than that formed with PD-L1-bound CDPs. Because a typical immune cell synapse is approximately 15 nm, a 5 nm increase in synapse diameter can have substantial biochemical or physiological consequences. Narrow synapses, such as those formed by BiICE containing PD-L1-bound CDPs, can elicit potent T cell killing responses. In some embodiments, the immune synapse of a PD-L1-bound peptide complex (e.g., BiICE containing PD-L1-bound CDPs) is approximately 3 nm, 5 nm, 8 nm, 10 nm, 13 nm, 15 nm, 18 nm, 20 nm, 23 nm, or 25 nm. In some embodiments, the immune synapse of the PD-L1-binding peptide complex is 3 nm or less, 4 nm or less, 5 nm or less, 6 nm or less, 7 nm or less, 7 nm or less, 8 nm or less, 9 nm or less, 10 nm or less, 13 nm or less, 15 nm or less, 18 nm or less, 20 nm or less, 23 nm or less, 25 nm or less, 30 nm or less, 35 nm or less, 40 nm or less, 45 nm or less, 50 nm or less, 60 nm or less, 65 nm or less, 70 nm or less, 75 nm or less, 80 nm or less, 85 nm or less, 90 nm or less, 95 nm or less, or 100 nm or less.
[0158] Chimeric Antigen Receptor The PD-L1-binding peptides of the present disclosure (e.g., any one of SEQ ID NOs:1-118, 435, 436, or 554-567) can be complexed with one or more components of a chimeric antigen receptor to form a PD-L1-binding chimeric antigen receptor. In some embodiments, the PD-L1-binding peptide may be linked or fused to the transmembrane domain, cytoplasmic domain, heavy chain variable domain, light chain variable domain, or a combination thereof, of a chimeric antigen receptor (CAR). In some embodiments, the PD-L1-binding peptide may replace the single-chain variable fragment (scFv) of the chimeric antigen receptor to form a PD-L1-binding chimeric antigen receptor (PD-L1-binding CAR). For example, a PD-L1-binding CAR may comprise a PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567), a linker (e.g., SEQ ID NOs: 154-241, or 433), a transmembrane domain, and an intracellular costimulatory domain. In some embodiments, a nucleotide sequence encoding a PD-L1-binding chimeric antigen receptor may be expressed in an immune cell (e.g., a T cell). The PD-L1-binding chimeric antigen receptor may be expressed on the surface of the immune cell. In some embodiments, the PD-L1-binding chimeric antigen receptor may function by recruiting T cells to PD-L1-positive cells (e.g., PD-L1-positive cancer cells) and killing or inactivating the PD-L1-positive cells.
[0159] Peptide-oligonucleotide conjugates In some embodiments, the active agent may comprise an oligonucleotide. A PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) may be complexed with an oligonucleotide to form a peptide-oligonucleotide conjugate, also referred to as a peptide-nucleotide agent conjugate, peptide oligonucleotide conjugate, or peptide-targeted binding agent conjugate, and may comprise a peptide complexed with a nucleotide (e.g., an oligonucleotide). The peptide of the peptide-oligonucleotide conjugate may comprise a PD-L1-binding peptide as described herein. In some embodiments, the peptide may be a PD-L1-binding peptide (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567). The PD-L1-binding peptide of the peptide-oligonucleotide conjugate may mediate binding of the peptide-oligonucleotide conjugate to PD-L1, which may facilitate endocytosis or transcytosis of the peptide-oligonucleotide conjugate across cell barriers or entry into cancer cells or tissues. For example, peptide-oligonucleotide conjugates containing PD-L1-binding peptides can cross cell membranes, allowing interactions between the nucleotides of the peptide-oligonucleotide conjugate and various cytoplasmic or nuclear components (e.g., genomic DNA, ORF, mRNA, pre-DNA, mRNA, or DNA). In some embodiments, peptide-oligonucleotide conjugates containing PD-L1-binding peptides can cross cell membranes by being endocytosed into cells. The PD-L1-binding peptide of the peptide-oligonucleotide conjugate can be a pH-dependent PD-L1-binding peptide engineered to have a higher binding affinity for PD-L1 at extracellular pH (e.g., pH 7.4) and a lower binding affinity at endosomal pH (e.g., pH 5.5 or pH 6.5).
[0160] The nucleotide of the peptide-oligonucleotide complex may be a target binding agent comprising single-stranded DNA, single-stranded RNA, double-stranded DNA, double-stranded RNA, or a combination thereof. As used herein, the term "nucleotide" may refer to an oligonucleotide molecule or a polynucleotide molecule, or a single nucleotide base. For example, the nucleotide of the peptide-oligonucleotide complex may comprise a DNA oligonucleotide or an RNA oligonucleotide. In some embodiments, the nucleotide may be a small interfering RNA (siRNA), a microRNA (miRNA or miR), an antimiR, an antisense RNA, an antisense oligonucleotide (ASO), a complementary RNA, a complementary DNA, an interfering RNA, a small nuclear RNA (snRNA), a spliceosomal RNA, an inhibitory RNA, a nuclear RNA, an oligonucleotide complementary to a natural antisense transcript (NAT), an aptamer, a gapmer, a splice blocker ASO, or a U1 adaptor. For example, the nucleotide of the peptide-oligonucleotide conjugate can comprise a sequence complementary to a portion of any one of SEQ ID NOs: 366-396, or any of the sequences provided in SEQ ID NOs: 397-430, or 549, listed in Table 17, or an open reading frame. In some embodiments, the nucleotide can be an siRNA that inhibits translation of a target mRNA by promoting its degradation. In some embodiments, the nucleotide can be an miRNA that inhibits translation of a target mRNA by promoting its cleavage or destabilization. In some embodiments, the nucleotide can be an aptamer that binds to a target protein and thereby inhibits a protein-protein interaction with the target protein, inhibits the enzymatic activity of the target protein, or activates the target protein.
[0161] Exemplary structures of various peptide-oligonucleotide conjugates (e.g., CDP-oligonucleotide conjugates containing alternative and non-conventional bases) are shown in Figure 23. Exemplary oligonucleotides include aptamers, gapmers, anti-miRs, siRNAs, splice blocker ASOs, and U1 adaptors. The peptide portion of a peptide-oligonucleotide conjugate (e.g., the CDP of a CDP-oligonucleotide conjugate) can be used to direct a nucleotide sequence (e.g., the oligonucleotide of a CDP-oligonucleotide conjugate) to a specific tissue, target, or cell.
[0162] In some embodiments, the peptide-oligonucleotide conjugates bind to PD-L1 with an affinity of 10 nM, 5 nM, 1 nM, 800 pM, 600 pM, 500 pM, 400 pM, 300 pM, 250 pM, or 200 pM or less. In some embodiments, the affinity is the same or similar at pH 7.0 as at pH 7.4, the same or similar at pH 6.5 as at pH 7.4, the same or similar at pH 6.0 as at pH 7.4, or the same or similar at pH 5.5 as at pH 7.4. In some embodiments, the affinity is within ±1 nM, ±3 nM, ±5 nM, ±10 nM, ±30 pM, ±50 pM, ±100 pM, ±300 pM, ±500 pM, or ±1000 pM when comparing pH 7.0 and pH 7.4, pH 6.5 and pH 7.4, pH 6.0 and pH 7.4, or pH 5.5 and pH 7.4. In some embodiments, the affinity is within a 1-fold, 2-fold, 3-fold, 5-fold, or 10-fold relative difference when comparing pH 7.0 and pH 7.4, pH 6.5 and pH 7.4, pH 6.0 and pH 7.4, or pH 5.5 and pH 7.4. In some aspects, the affinity of the peptide-oligonucleotide complex binding to the PD1 molecule is higher at higher pH than at lower pH. In some aspects, the higher pH is pH 7.4, pH 7.2, pH 7.0, or pH 6.8. In some embodiments, the lower pH is pH 6.5, pH 6.0, pH 5.5, pH 5.0, or pH 4.5. In some embodiments, the affinity of the peptide oligonucleotide conjugate is higher at pH 7.4 than at pH 6.0. In some embodiments, the affinity of the peptide oligonucleotide conjugate is higher at pH 7.4 than at pH 5.5. In some embodiments, the target-binding peptide has a dissociation constant (K) of 100 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.2 nM or less, 1 nM or less, or 0.1 nM or less at pH 7.4. D In some embodiments, the target-binding peptide can bind to the target molecule with a dissociation constant (K) at pH 5.5 of 1 nM or greater, 2 nM or greater, 5 nM or greater, 10 nM or greater, 50 nM or greater, 100 nM or greater, 200 nM or greater, or 500 nM or greater. D) can bind to the target molecule at pH 7.4. In some embodiments, the affinity of the peptide oligonucleotide conjugate for PD-L1 at pH 7.4 is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold, at least 5000-fold, or at least 10,000-fold greater than the affinity of the peptide oligonucleotide conjugate for PD-L1 at pH 5.5.
[0163] The peptide oligonucleotide conjugates of the present disclosure can include nucleotides and nucleotide variants within the peptide oligonucleotide conjugate, where the nucleotide portion is targeted to a specific target molecule for modulation. Modulation of the target molecule can include degradation, inhibition of translation, decreased expression, increased expression, enhanced binding interactions (e.g., protein-protein interactions), or inhibition of binding interactions (e.g., protein-protein interactions). Disclosed herein are nucleotide sequences that can be used for the nucleotide portion of a peptide oligonucleotide conjugate, such as those targeting or complementary to nucleotides (e.g., DNA or RNA molecules) listed in SEQ ID NOs: 397-430 or SEQ ID NO: 549, or Table 10 or Table 17, or nucleotides (e.g., DNA or RNA molecules) encoding proteins listed in SEQ ID NOs: 397-430 or SEQ ID NO: 549, Table 10, or Table 17, or nucleotides otherwise described herein. Examples of nucleotide sequences that can be used for the nucleotide portion of a peptide oligonucleotide conjugate include SEQ ID NOs: 366-396 and SEQ ID NOs: 492-545. As disclosed herein, nucleic acid sequences, variants, and nucleic acid features used in the nucleic acid portion of a peptide-oligonucleotide conjugate may be referred to as nucleic acids of the disclosure, nucleotides of the disclosure, or similar terms.It will be understood that such nucleic acids or nucleotides are described in the context of the disclosed peptide oligonucleotide complexes, such as single-stranded (ssDNA, ssRNA), double-stranded (dsDNA, dsRNA), or combinations of single and double strands (e.g., having mismatched sequences, hairpins, or other structures), antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotides (ASOs), microRNAs (miRNAs), oligonucleotides complementary to natural antisense transcript (NAT) sequences, peptide oligonucleotides, siRNAs, snRNAs, aptamers, gapmers, anti-miRs, splice blocker ASOs, or nucleotide sequences comprising a U1 adaptor, as appropriate for the described modifications, functions, and uses within the oligonucleotide complex.
[0164] In some embodiments, the nucleotide sequence (e.g., a targeted binding agent capable of binding to a target molecule) is single-stranded (ssDNA, ssRNA) or double-stranded (dsDNA, dsRNA), or a combination of single and double strands (e.g., with mismatch sequences, hairpins, or other structures), antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotide (ASO), microRNA (miRNA), oligonucleotide complementary to a natural antisense transcript (NAT) sequence, siRNA, snRNA, aptamer, gapmer, antimiR, splice blocker ASO, or U1 adaptor. Peptides according to the present disclosure can be conjugated, linked, or fused to such nucleotide sequences to create peptide-oligonucleotide conjugates. Furthermore, other active agents (e.g., small molecules, proteins, or peptide active agents) described herein can be conjugated, linked, complexed, or fused to such nucleotide sequences, peptides, or peptide-oligonucleotide conjugates to form peptide-oligonucleotide conjugate conjugates.
[0165] Nucleotides (e.g., nucleotides of a peptide-oligonucleotide conjugate) can be fully or partially reverse complementary to all or a portion of a target molecule (e.g., a target DNA or RNA sequence). In some embodiments, the target molecule expresses or encodes a protein (e.g., an mRNA encoding a protein associated with a disease). In some embodiments, the nucleotides can be fully or partially reverse complementary to a portion of an open reading frame encoding a gene or protein of interest. In some embodiments, the nucleotides can be reverse complementary to any portion of an RNA or open reading frame encoding a transcript or protein of interest. Examples of sequences that can serve as target molecules for the target-binding nucleotides described herein are provided in SEQ ID NOs: 397-430 and 549 along any portion of their length. In some embodiments, the target molecule can comprise a fragment of any of the sequences provided in Table 17 along any portion of its length. In some embodiments, the target molecule can comprise a fragment of any of the sequences provided in SEQ ID NOs: 397-430 or 549. In some embodiments, the target molecule can comprise a sequence in which one or more T residues are substituted with U, or one or more U residues are substituted with T.
[0166] Disclosed herein are numerous techniques that can be used to generate therapeutically active nucleotide sequences for use in peptide-oligonucleotide conjugates containing PD-L1-binding peptides (e.g., SEQ ID NOs: 1-118, 435, 436, or 554-567). Some have molecular examples in clinical or advanced clinical development and can be used as the nucleotide portion of the peptide-oligonucleotide conjugates described herein. The nucleotides of the peptide-oligonucleotide conjugates can bind to target molecules (e.g., target DNA, RNA, or proteins) and modulate the activity of the target molecules. In this way, the nucleotides can function as target binding agents (also referred to as targeting agents). Examples of nucleotides that can function as target binding agents include nucleotide antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotides, microRNA, oligonucleotides complementary to natural antisense transcripts, small interfering RNA, small nuclear RNA, aptamers, gapmers, anti-miRs, splice blocker antisense oligonucleotides, and U1 adaptors.
[0167] Nucleotides (e.g., oligonucleotides targeting specific sequences for their regulation) can enter cells by complexing with PD-L1-binding peptides to form PD-L1-binding peptide-oligonucleotide conjugates. The PD-L1-binding peptide-oligonucleotide conjugates can be endocytosed by PD-L1 or can enter cells through other mechanisms. Oligonucleotides with or without a PD-L1-binding peptide complex (e.g., after linker cleavage) can exit endosomes or lysosomes slowly over time, either independently or via endosomal escape or other mechanisms. Peptide-oligonucleotide conjugates can exit endosomes or lysosomes. Fragments or cleavage products of peptide-oligonucleotide conjugates can exit endosomes or lysosomes. The oligonucleotide, peptide-oligonucleotide conjugate, or any fragment thereof can enter the cytosol or the nucleus.
[0168] The possible mechanisms of action of oligonucleotides are shown in Figure 22. In one embodiment, upon entering the nucleus, the oligonucleotide can (1) directly bind to mRNA structures and prevent maturation (e.g., capping or splicing) of the target sequence, (2) modulate alternative splicing of the target sequence, or (3) recruit RNase H1 to induce cleavage of the target sequence. In another embodiment, the oligonucleotide in the cytoplasm can directly bind to the target mRNA and sterically block ribosomal subunits from attaching to and / or running along the mRNA transcript during translation, resulting in a lack of translation of the target sequence. In another embodiment, the oligonucleotide can also be designed to (4) directly bind to microRNA (miRNA) or natural antisense transcript (NAT) sequences, each of which inhibits miRNAs and NATs from inhibiting their specific RNA targets, ultimately resulting in decreased degradation or increased translation of one or more sequences targeted by the miRNA or NAT. In another embodiment, siRNA (which targets specific sequences and can regulate the expression of the target sequence) can alternatively be used to bind to and regulate target sequences in the cytoplasm (5). A multiprotein complex incorporating a single strand of small interfering RNA (siRNA) or microRNA (miRNA) can participate in the RNA-induced silencing complex (RISC), which uses the siRNA or miRNA as a template to recognize the complementary mRNA of the target sequence. Upon finding a complementary strand, its RNase domain cleaves the target sequence. In another embodiment, aptamers (e.g., nucleotides that regulate specific proteins or other targets) can alternatively be used to bind to and regulate targets (6). Aptamers (e.g., extracellular or intracellular) can function by directly binding to and regulating the activity of protein targets, e.g., by forming aptamer-protein interactions rather than through base-pairing or hybridization interactions.
[0169] For example, conventional ASOs, or antisense oligonucleotides, are typically 18–30 nucleotides (nt) in length. Several ASO therapeutic strategies exist, two of which (different mechanisms of targeted RNA interference) are discussed further below. The first type of ASO is sometimes called a "gapmer." This is because it contains a central region containing DNA-based sugar nucleotides, often (but not always) flanked by non-DNA sugar nucleotides that are highly resistant to nucleases. The DNA region is at least 4 nt, typically greater than 6 nt, in length, and forms a DNA / RNA hybrid that binds to RNase H endonuclease and cleaves the target RNA. Clinically approved gapmers include fomivirsen and mipomersen. In some embodiments, the DNA region of a gapmer can comprise about 4 to about 30, about 4 to about 25, about 4 to about 20, about 4 to about 15, about 4 to about 10, about 6 to about 30, about 6 to about 25, about 6 to about 20, about 6 to about 15, or about 6 to about 10 nucleotide residues. In some embodiments, the non-DNA region of a gapmer can comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide residues 3' of the DNA region. In some embodiments, the non-DNA region of a gapmer can comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide residues 5' of the DNA region. Examples of gapmers are shown in Table 5. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4]
[0170] The second type of conventional ASO simply binds to target transcripts but does not induce RNase degradation, thus not using DNA-based sugars. Instead, binding is designed to interfere with processing into mature mRNA. One such activity relies on binding to mRNA at or near splice sites, driving specific splice isoforms within the target RNA, disrupting mRNA splicing, and modulating the target RNA by causing exon skipping. These are commonly referred to as "splice-blocking" or "splice blocker" ASOs, among other known names. One example is eteplirsen, which is designed to alter the splicing of the DMD (dystrophin) gene in patients with Duchenne muscular dystrophy, correcting the mutation that would otherwise create a truncated, nonfunctional dystrophin by splicing out the mutant exon and introducing a different, truncated (but functional) protein.
[0171] Another example is siRNA molecules, which specifically interact with the canonical RNAi pathway (RISC complex) to cleave or sterically block hybridized transcripts, depending on whether the match is perfect (cleavage) or incomplete but stable (blocking). They are typically double-stranded RNAs with overlapping regions of 19–22 nt, each with two extra nt at the 3' end of the strand. Their chemical structure is primarily composed of RNA-based sugars, with the 3' overhang also containing DNA-based sugars. Clinical examples include patisiran (targeting TTR) and givosiran (targeting ALAS1). In some embodiments, the overlapping regions of the siRNAs are about 10 to about 40, about 10 to about 35, about 10 to about 30, about 10 to about 25, about 10 to about 22, about 10 to about 21, about 10 to about 20, about 15 to about 40, about 15 to about 35, about 15 to about 30, about 15 to about 25, about 15 to about 22, about 15 to about 21, about 15 to about 20, about 17 to about 40, about 17 to about 35, about 17 to about 30, about The overhang region may comprise 17 to about 25, 17 to about 22, 17 to about 21, 17 to about 20, 18 to about 40, 18 to about 35, 18 to about 30, 18 to about 25, 18 to about 22, 18 to about 21, 18 to about 20, 19 to about 40, 19 to about 35, 19 to about 30, 19 to about 25, 19 to about 22, 19 to about 21, or 19 to about 20 nucleotide residues. In some embodiments, the overhang region may comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide residues. Examples of siRNAs are shown in Table 6. [Table 6-1] [Table 6-2] [Table 6-3]
[0172] Another example is anti-miRs. Anti-miRs can function as steric blockers designed against miRNAs, blocking the RISC complex from loading specific disease-related miRNAs without being cleaved by the RNase subunit of the RISC complex. One clinical example is miravirsen, a 15-base oligonucleotide containing a mixture of DNA and LNA sugars that targets miR-122 in patients with hepatitis C. Anti-miR nucleotides can be long enough to specifically and stably anneal to their target miRs, but the length of the sequence can vary. For example, anti-miRs can be up to approximately 21 nt in length, corresponding to the maximum size that can be loaded into RISC. In some embodiments, the anti-miR nucleotides can comprise about 10 to about 25, about 10 to about 23, about 10 to about 21, about 10 to about 20, about 10 to about 19, about 10 to about 18, about 13 to about 25, about 13 to about 23, about 13 to about 21, about 13 to about 20, about 13 to about 19, about 13 to about 18, about 15 to about 25, about 15 to about 23, about 15 to about 21, about 15 to about 20, about 15 to about 19, about 15 to about 18, about 16 to about 25, about 16 to about 23, about 16 to about 21, about 16 to about 20, about 16 to about 19, or about 16 to about 18 nucleotide residues.
[0173] Another example is the U1 adaptor, which has two parts. One anneals to the U1-snRNA in the U1-snRNP complex, and the other binds to the target RNA, bringing the U1-snRNP to the poly(A) site and inhibiting polyadenylation. Absence of the poly(A) tail results in mRNA degradation. The U1-binding region is at least 10 nt but can be as long as 19 nt. The target-binding region can be approximately 15 nt to approximately 25 nt. Early studies of the chemistries frequently used LNA and 2'-O-methyl sugars. In some embodiments, the U1 binding region can comprise about 10 to about 25, about 10 to about 23, about 10 to about 21, about 10 to about 20, about 10 to about 19, about 10 to about 18, about 13 to about 25, about 13 to about 23, about 13 to about 21, about 13 to about 20, about 13 to about 19, about 13 to about 18, about 15 to about 25, about 15 to about 23, about 15 to about 21, about 15 to about 20, about 15 to about 19, about 15 to about 18, about 16 to about 25, about 16 to about 23, about 16 to about 21, about 16 to about 20, about 16 to about 19, or about 16 to about 18 nucleotide residues. In some embodiments, the target binding regions are about 10 to about 40, about 10 to about 35, about 10 to about 30, about 10 to about 25, about 10 to about 22, about 10 to about 21, about 10 to about 20, about 15 to about 40, about 15 to about 35, about 15 to about 30, about 15 to about 25, about 15 to about 22, about 15 to about 21, about 15 to about 20, about 17 to about 40, about 17 to about 35, about 17 to about 30, about 17 about 17 to about 22, about 17 to about 21, about 17 to about 20, about 18 to about 40, about 18 to about 35, about 18 to about 30, about 18 to about 25, about 18 to about 22, about 18 to about 21, about 18 to about 20, about 19 to about 40, about 19 to about 35, about 19 to about 30, about 19 to about 25, about 19 to about 22, about 19 to about 21, or about 19 to about 20 nucleotide residues.
[0174] Another example of a nucleotide of the present disclosure is an aptamer. Aptamers disrupt target activity using a mechanism distinct from the other nucleotides described herein, which form base-pairing interactions with target nucleotides. Aptamers are nucleic acids that form secondary structures (e.g., a single strand of nucleic acid that base-pairs with itself upon folding, forming loops at various positions). Aptamers can be screened for interactions with target proteins. Aptamers can have a variety of nucleotide chemical structures and can include mixtures of conventional RNA and / or DNA sugars and modified sugars (e.g., 2'-O-methyl (2'-O-Me) RNA sugars or 2'-fluoro (2'-F) RNA sugars). For example, one clinically approved aptamer, pegaptanib (a VEGF-binding aptamer), has a mixture of 2'-O-methyl (2'-O-Me) and 2'-fluoro (2'-F) RNA sugars, as well as conventional RNA and DNA sugars. Aptamer sequences can be long enough to form a stable secondary structure (e.g., through intramolecular base pairing), but the length can vary. In some embodiments, aptamer sequences can comprise about 20 nt to about 40 nt. For example, in experiments identifying pegaptanib, oligos of 20 to 40 nt in length were used. Because longer oligonucleotides may complicate nucleotide synthesis or be involved in the interferon response pathway, shorter oligonucleotides (e.g., sequences shorter than about 40 nt) may be advantageous. In some embodiments, the aptamer may contain about 15 to about 60, about 15 to about 50, about 15 to about 40, about 15 to about 35, about 15 to about 30, about 20 to about 60, about 20 to about 50, about 20 to about 40, about 20 to about 35, about 20 to about 30, about 25 to about 60, about 25 to about 50, about 25 to about 40, about 25 to about 35, or about 25 to about 30 nucleotide residues.
[0175] Nucleotides can be designed for use in the peptide-nucleotide conjugates of the present disclosure. In some embodiments, nucleotides that modify processing, translation, or other RNA function (e.g., gapmers, splice blockers, siRNAs, anti-miRs, or U1 adaptors) have one or more of the following characteristics: (a) 8-50 nt in length, but preferably 12-30 nt in length. It is understood that any nucleotide (nt) length within the aforementioned range can be used; (b) interspecies homology (e.g., by targeting highly conserved motifs) is often a desirable feature but is not required for activity or clinical development; (c) avoidance of common SNPs in humans is often a desirable feature but is not required for activity or clinical development unless the SNP is involved in disease pathology (e.g., allele-specific oligos); (d) gene specificity (minimal homology with other sequences, e.g., one sequence is unique to all other sequences) (e) avoid predicted secondary structures in both the oligo and target regions (software tools are available for in silico screening for such secondary structure formation); (f) G / C-rich sequences (e.g., CCAC, TCCC, GCCA) can help increase the affinity of nucleotides for the target, so a higher G / C content may be preferable, while A / T-rich sequences (e.g., TAA) or 4+G (GGGG) sequences may exhibit low values or cause the formation of structures (G-quadruplexes). The oligonucleotide sequence may be 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary or identical to the target sequence. In some circumstances, 100% complementary oligonucleotides may result in degradation of the target RNA. In some circumstances, oligonucleotides that are less than 100% complementary may not cause degradation of the target RNA, but may interfere with translation and production of the encoded protein.
[0176] In some embodiments, gapmers have one or more of the following characteristics: (a) a length of 12 to 30 nt. It is understood that any nucleotide (nt) length within the aforementioned range can be used. (b) The target site can be anywhere in the pre-mRNA, including UTRs, exons, or introns. (c) A central DNA region of at least four contiguous DNA nucleotides, often 10 or more, is used. Due to the requirement for RNase H recognition, artificial substitutions at the 2' position (e.g., 2'-O-methyl [2'-O-ME] or 2'-O-methoxyethyl [2'-O-MOE]) are not permitted. (d) The flanking regions can be DNA- or RNA-based sugars. 2' substitutions such as 2'-O-ME or 2'-O-MOE are permitted. Linked nucleic acid (LNA) and morpholino (phosphorodiamidate morpholino oligo) chemistries can also be used in the flanking regions. (e) The backbone can be natural phosphodiester (PO) or non-natural phosphorothioate (PS) linkages. A clinical example is fomivirsen, a 21-nt gapmer in which all oligos have a PS backbone DNA. Another example is mipomersen, a 20-nt gapmer in which the entire backbone is PS-linked and the central region uses DNA sugars adjacent to 2'-O-MOE-modified RNA. In these two examples, all C bases are 5-methyl-C, although this is not a strict requirement for RNase H1 binding. Similarly, thiophosphorodiamidate chemistry can also be used.
[0177] In some embodiments, the steric blocker has one or more of the following properties: (a) The molecule does not require binding to RNase H or other enzymes, allowing for greater diversity in backbone and sugar chemistry; (g) the nucleotide target site is complementary to one or more splice sites in the target RNA. A clinical example is eteplirsen, a 30-nt splice-blocking ASO that uses morpholino (phosphorodiamidate morpholino oligo) chemistry throughout the oligonucleotide. Another clinical example is nusinersen, an 18-nt ASO whose backbone is entirely PS-linked and uses 2'-O-MOE RNA chemistry. All C bases are 5-methyl-C, although this is not a strict requirement for RNase H1 binding. Similarly, thiophosphorodiamidate chemistry can also be used.
[0178] In some embodiments, the siRNA has one or more of the following characteristics: (a) it can be 15-25 nt long per strand (each with a 13-23 nt overlap), or up to 25 nt (23 nt overlap), although 21 nt (19 nt overlap) is common. It is understood that any length of nucleotide (nt) overlap can be used within the aforementioned range. (b) it complements a 21 nt long sequence within the target mRNA, typically, but not exclusively, beginning with "AA." (c) the target site is ideally found in mature spliced mRNA, since RISC complexes for RNA cleavage are primarily present in the cytosol; (d) it is preferable, but not exclusive, to avoid sequences within 100 nt of the mRNA start site, since transcripts from the start site are likely to be occupied by RNA polymerase. (e) Successful siRNA constructs typically have more G / C at the 5' end of the sense strand and more A / T at the 3' end of the sense strand, with a G / C content of approximately 30-60%.
[0179] In some embodiments, anti-miRs (anti-miRNAs) have one or more of the following characteristics: (a) They perfectly match the target sequence (especially the 5' end of the miRNA's guide strand). (b) They are variable in length and can be longer than the length of the mature guide strand. Screening for effective anti-miR constructs begins with the shortest sequence that achieves specificity (no off-target homology) and then increases in length to empirically determine the ideal minimal length for potent miRNA inhibition. (c) 2' sugar modifications (2'-O-Me, 2'-O-MOE, 2'-F) and LNA sugars are commonly used. Sugars may also be mixtures. A clinical example of an anti-miR is miravirsen, which uses a mixture of DNA and LNA sugars. (d) PS linkages in the backbone are common. PS linkages may decrease affinity, while sugar modifications may increase affinity.
[0180] In some embodiments, aptamers have one or more of the following properties: (a) Because aptamers do not interact with a biological complex (e.g., RISC) to function, their length can vary widely. Although composed of nucleic acids, they are functionally more protein-like (e.g., binding to target proteins). While their minimum length can be empirically determined to maintain sufficient stability for intrastrand hybridization to fold into secondary structures, the upper size limit is limited only by pharmacology, as longer sequences carry a higher risk of involvement in inflammatory pathways. Aptamer screening typically begins with libraries of 20-40 nt in length (not including flanking regions necessary for library amplification during screening). (b) Because they form interactions through secondary structure rather than base-pairing interactions, there are few restrictions on base patterns, as secondary structure is not only desirable but essential for function. Design can be empirical for each target. (c) Selection is typically performed by systematic evolution of ligands by exponential enrichment (SELEX), in which random or semi-random sequences between primer-binding flanking regions are exposed to the target of interest on a solid substrate. The pooled oligonucleotide mixture is washed from the substrate, leaving only the sequences that interact with the target; the bound sequences are eluted and amplified by PCR. (d) Commonly used sugar modifications include 2'-fluoro (2'-F), 2'-O-MOE, and 2'-O-Me; other chemistries are also possible, including, but not limited to, LNA and non-locked nucleic acid (UNA). (e) The backbone is typically PO or PS, although other linkages, such as methylphosphonate, are also possible. While pegaptanib, an example of a clinical aptamer, uses an entirely PO backbone, other aptamers in development use other linkages. (f) Aptamer ends are typically capped with unnatural nucleotide chemistries (e.g., 3' inverted thymidine) or biotinylated nucleotides to reduce susceptibility to nucleases. (g) Because activity is not based on base pairing, aptamers allow for more creative chemical modifications of the bases themselves.These may include bases designed to induce covalent binding to target proteins, rendering them permanently ineffective. (h) Because unmodified bases are required for nucleic acid amplification during SELEX, such modifications are tested after selection of active, high-affinity aptamers. (i) If the target protein is extracellular, cell penetration ability is not as important a consideration.
[0181] In some embodiments, other general design considerations aimed at enhancing the pharmacokinetic (PK) properties of nucleotide, peptide, or peptide-oligonucleotide conjugates include one or more of the following properties: (a) Conjugation to a moiety that reduces clearance or increases cellular uptake, including cholesterol or other lipids, diacylglycerol, GalNAc, palmitoyl, PEG, RGD motifs, cell-penetrating peptides or moieties (e.g., the PD-L1-binding peptides or cell-penetrating peptides described herein). Addition of cholesterol to peptide-oligonucleotide conjugates can improve biodistribution to target tissues, increase cellular uptake by endocytosis, and alter serum pharmacokinetics.
[0182] The therapeutic activity and molecular methodology of peptide-oligonucleotide conjugates can depend on which target molecule (e.g., DNA or RNA) the nucleic acid complements, or in the case of an aptamer, which target molecule (e.g., a protein or other macromolecule) it binds to. Target selection can be classified into one or more mutually exclusive categories, such as tissue targeting or disease selection. Known targets have known mRNA and genomic sequences that can be used to design various complementary nucleic acids for use in the peptide-nucleotide conjugates described herein, depending on the desired activity (e.g., gene regulation, protein degradation, reduction of cancer cell activators). Examples of targets are provided in SEQ ID NOs: 397-430 or SEQ ID NO: 549, Table 10, and Table 17. For example, tissue targeting can involve selecting a target that acts within a tissue preferentially accessed or accumulated by the PD-L1-binding peptide portion of the peptide-oligonucleotide conjugate. For example, serum proteins produced in the liver, such as those produced by TTR to treat transthyretin-associated amyloid disease, or by various apolipoproteins to treat hypercholesterolemia or cardiovascular disease, can be targeted. Additionally, they can be used to target proteins produced in the lungs or lung tissues that express PD-L1, targeting inflammatory cytokines or cytokine receptors to treat lung disorders (e.g., COPD), or downregulating receptors (e.g., ACE2) that determine the tropism of airborne infection of viruses (e.g., SARS-CoV-2).
[0183] Alternatively, targets can be selected based on known PD-L1 expression in the tissue or target cell type to act in areas where PD-L1-binding peptides accumulate (e.g., PD-L1-expressing cancer cells) or where oligonucleotides not complexed with PD-L1-binding peptides are excluded, including tumors. Tumor targeting can be used with the peptide-oligonucleotide conjugates of the present disclosure, as tumors often have high levels of PD-L1 and are often sufficiently vascularized to allow rapid perfusion of serum-resident PD-L1-binding peptides and their oligonucleotide cargo. Targets of peptide-oligonucleotide conjugates can include oncogenes, for example, by designing the nucleic acid portion of the conjugate to target an overexpressed gene or a gene for which the tumor lacks a redundant ortholog (i.e., X is targeted because normal cells function by using X or Y, but the tumor does not express Y). Furthermore, disease-selective targeting can be used to treat conditions in which transcripts are selectively found and preferentially accumulate in diseased tissues, improving safety and reducing off-target effects. PD-L1 may also be expressed in tissues such as the colon or other gastrointestinal tissues, skeletal muscle, adipose tissue, lymphoid tissue, soft tissue, placenta, seminal vesicles, tonsils, resting or activated T cells, B cells, dendritic cells, and macrophages. Accordingly, the PD-L1-binding peptides of the disclosure can be used to deliver oligonucleotides or other active agents to those tissues.
[0184] The target binding agent (e.g., the nucleotide of the peptide-oligonucleotide conjugate) can bind to a target set forth in SEQ ID NO:397-430 or SEQ ID NO:549, Table 10, or Table 17, or to a nucleotide (e.g., a DNA or RNA molecule) encoding a protein listed in SEQ ID NO:397-430 or SEQ ID NO:549, Table 10, or Table 17, or described herein. Examples of nucleotide sequences that can be used for the nucleotide portion of the peptide-oligonucleotide conjugate include SEQ ID NO:366-396 and SEQ ID NO:492-545. It is understood that any oligonucleotide that is complementary to a portion of the target DNA or RNA molecule can be used. Such targeted binding agents may include nucleotide sequences that are single-stranded (ssDNA, ssRNA) or double-stranded (dsDNA, dsRNA), or a combination of single- and double-stranded (e.g., with mismatched sequences, hairpins, or other structures), antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotides (ASOs), microRNAs (miRNAs), oligonucleotides complementary to natural antisense transcript (NAT) sequences, siRNAs, snRNAs, aptamers, gapmers, antimiRs, splice blocker ASOs, or U1 adaptors. Such oligos may span any portion of the target RNA and be approximately 5-30 nt, 10-25 nt, 15-25 nt, 19-23 nt, or at least 10 nt, at least 15 nt, at least 20 nt, at least 25 nt, or at least 30 nt, at least 50 nt, or at least 100 nucleotides in length. Examples of sequences to which such oligonucleotides may bind (e.g., are complementary to) include SEQ ID NOs: 397 to 430 and SEQ ID NOs: 546 to 549, or any genomic or ORF sequences referenced in Table 17.Those skilled in the art can readily design or determine the length of a targeted binding agent and whether it is complementary to a reference target RNA sequence, and thus can use the chemical structures of RNA and DNA to determine where such a targeted binding agent will bind to such a reference target RNA sequence of a designed length over any portion of the target RNA. Thus, targeted binding agents of any nt length are described for any RNA target described herein, including any of the targets or target-encoding molecules listed in Table 10, and SEQ ID NOs:397-430 and 546-549, or any genomic or ORF sequence referenced in Table 17.
[0185] In some embodiments, the nucleotide binds to the target molecule with a melting temperature of 37° C. to 99° C. In some embodiments, the nucleotide binds to the target molecule with a melting temperature of 40° C. to 85° C., 40° C. to 65° C., 40° C. to 55° C., 50° C. to 85° C., 60° C. to 85° C., or 55° C. to 65° C.
[0186] In some embodiments, the nucleotide binds to the target molecule with an affinity of 500 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, 1 nM or less, 500 pM or less, 400 pM or less, 300 pM or less, 200 pM or less, or 100 pM or less. In some embodiments, the nucleotide binds to the target molecule with an affinity of 500 nM or less, 100 pM or more, 100 nM or less, 200 pM or more, 50 nM or less, 300 pM or more, 10 nM or less, 400 pM or more, or 1 nM or less, 500 pM or more.
[0187] In some embodiments, the nucleotide comprises at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 366-396. In some embodiments, the nucleotide comprises the sequence of any one of SEQ ID NOs: 366-396, the sequence of any one of SEQ ID NOs: 366-396 in which U is substituted with T, or the sequence of any one of SEQ ID NOs: 366-396 in which T is substituted with U. In some embodiments, the nucleotide comprises no more than 1, 2, 3, 4, or 5 base changes compared to the sequence of any one of SEQ ID NOs: 366-396.
[0188] In some embodiments, the nucleotide is at least 60%, at least 70%, at least 80%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% reverse complementary to the target sequence. In some embodiments, the nucleotide is 100% reverse complementary to the target molecule. In some embodiments, the nucleotide contains no more than 1, 2, 3, 4, or 5 base pair mismatches when binding to the target molecule. In some embodiments, the nucleotide contains at least 1, 2, 3, 4, or 5 base pair mismatches when binding to the target molecule.
[0189] In some embodiments, the nucleotide may modulate the activity of a target molecule. In some embodiments, modulating the activity of a target molecule includes decreasing the expression of the target molecule, increasing the expression of the target molecule, decreasing the translation of the target molecule, degrading the target molecule, decreasing the level of the target molecule, altering the processing of the target molecule, altering the splicing of the target molecule, inhibiting the processing of the target molecule, decreasing the level of a protein encoded by the target molecule, or blocking interaction with the target molecule. In some embodiments, the expression of the target molecule is decreased by at least 10%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, 99.5%, or 99.9%. In some embodiments, the translation of the target molecule is decreased by at least 10%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, 99.5%, or 99.9%. In some embodiments, expression of the target molecule is reduced by a factor of at least 2, 4, 8, 10, 15, 16, 20, 32, 50, 64, 100, 128, 200, 256, 500, 512, or 1000. In some embodiments, translation of the target molecule is reduced by a factor of at least 2, 4, 8, 10, 15, 16, 20, 32, 50, 64, 100, 128, 200, 256, 500, 512, or 1000. In some embodiments, at least 10%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, 99.5%, or 99.9% of the target molecule is degraded. In some embodiments, the level of the protein encoded by the target molecule is reduced by at least 10%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, 99.5%, or 99.9%. In some embodiments, modifying the splicing of the target molecule increases the level of the protein encoded by the target molecule by at least 10%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, 99.5%, or 99.9%.
[0190] The peptide-oligonucleotide conjugates of the present disclosure may comprise a nucleotide complexed with a protein (e.g., a PD-L1-binding peptide). The nucleotide may comprise single-stranded DNA, single-stranded RNA, double-stranded DNA, double-stranded RNA, or a combination thereof. In some embodiments, the nucleotides of the peptide-oligonucleotide conjugates are non-naturally occurring, also referred to as "engineered nucleotides." In some embodiments, the nucleotides may comprise naturally occurring sequences. The nucleotides may be exogenously expressed, enzymatically synthesized in vitro, or chemically synthesized. For example, the nucleotides may be expressed in bacterial, yeast, or mammalian cell lines and purified for use in the peptide-oligonucleotide conjugates of the present disclosure. In another example, the nucleotides may be enzymatically synthesized in vitro using RNA polymerase or DNA polymerase. In another example, the nucleotides may be chemically synthesized on a solid support using protected nucleotides.
[0191] One example of a chemical synthesis method that can be used to prepare nucleotides for use in the peptide-oligonucleotide complexes of the present disclosure is phosphoramidite synthesis. Briefly, by repeating the steps of deblocking (detritylation), coupling, capping, and oxidation, single nucleotide residues can be added sequentially from 3' to 5' to the growing nucleotide chain. Phosphoramidite synthesis can be carried out on a solid support such as controlled pore glass (CPG) or macroporous polystyrene (MPPS). Similarly, thiophosphorodiamidates can be used.
[0192] The nucleotides of the peptide-oligonucleotide conjugate can bind to a target molecule (e.g., a target DNA, a target RNA, or a target protein). In some embodiments, binding of the oligonucleotide to a target molecule can alter the activity of the target molecule. For example, binding of an oligonucleotide (e.g., an siRNA, an miRNA, a gapmer, or a U1 adapter) to a target mRNA or pre-mRNA can increase or decrease translation of the target mRNA or pre-mRNA. In another example, binding of a nucleotide to a target DNA can increase or decrease expression of a gene encoded by the target DNA. In another example, binding of a nucleotide to an RNA (such as a transcript, pre-RNA, unspliced RNA, nuclear RNA, a sequence complementary to a NAT, or an mRNA) expressed from a target DNA, such as a gene or ORF, can increase or decrease expression of a gene encoded by the target DNA. In another example, binding of an oligonucleotide (e.g., an aptamer) to a target protein can increase or decrease the activity (e.g., enzymatic activity or binding activity) of the target protein. In some embodiments, the target molecule may be associated with a disease or condition, and increasing or decreasing the activity of the target molecule can treat the disease or condition.
[0193] The sequence of the oligonucleotide in the peptide-oligonucleotide conjugate can be selected for its ability to bind to or modulate the activity of a target molecule. In some embodiments, the oligonucleotide can be reverse complementary to a target DNA or RNA molecule. For example, an siRNA oligonucleotide can be reverse complementary to a target RNA molecule. In some embodiments, the oligonucleotide can be partially reverse complementary (e.g., containing one or more mismatched base pairs) to a target DNA or RNA molecule. For example, an siRNA oligonucleotide can contain base mismatches to a target RNA molecule. In some embodiments, the sequence of the oligonucleotide can be selected for its annealing temperature relative to the target DNA or RNA molecule. A preferred annealing temperature can be achieved by selecting the nucleotide length, the degree of nucleotide complementarity to the target molecule, the chemical structure of the nucleotide, or any combination thereof. Nucleotide sequence parameters (e.g., complementarity, annealing temperature, melting temperature, base mismatch, and binding affinity) can be calculated using any available software, such as ITD OligoAnalyzer. In some embodiments, the oligonucleotide can adopt a secondary structure that binds to a target DNA, RNA, or protein molecule. For example, aptamers can adopt secondary structures to bind to target proteins. Aptamer sequences can be selected to adopt secondary structures that bind to target proteins. The secondary structure of nucleotides can be predicted using available software such as RNAfold. In some embodiments, nucleotide sequences can be experimentally determined by selecting the ability to bind to target molecules. For example, a nucleotide library can be contacted with a target molecule, and sequences that bind to the target molecule can be identified.
[0194] In some embodiments, the nucleotides comprise a G / C content of 20% to 80%. In some embodiments, the nucleotides comprise a G / C content of 30% to 65%. In some embodiments, the nucleotides comprise a G / C content of 20% to 25%, 30% to 35%, 40% to 45%, or 50% or more. In some embodiments, the nucleotides comprise a G / C content of 80% to 75%, 70% to 65%, or 50% or less. In some embodiments, the nucleotides comprise an A / T or A / U content of 20% to 80%. In some embodiments, the nucleotides comprise an A / T or A / U content of 30% to 65%. In some embodiments, the nucleotides comprise an A / U (or A / T, or a combination of A / U and A / T) content of 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more. In some embodiments, the nucleotides comprise an A / U (or A / T, or a combination of A / U and A / T) content of 80% or less, 75% or less, 70% or less, 65% or less, or 50% or less. In some embodiments, the nucleotides have a length of 1000 nt, 600 nt, 200 nt, 100 nt, 60 nt, 56 nt, 52 nt, 50 nt, 48 nt, 46 nt, 44 nt, 22 nt, 40 nt, 38 nt, 36 nt, 34 nt, 32 nt, 30 nt, or 24 nt or less. In some embodiments, the nucleotides are 24 to 100 nt, 24 to 60 nt, 24 to 50 nt, or 36 to 50 nt in length. In some embodiments, the nucleotides are about 42 nt in length. In some embodiments, the nucleotides are 500 nt, 300 nt, 100 nt, 50 nt, 30 nt, 28 nt, 26 nt, 25 nt, 24 nt, 23 nt, 22 nt, 21 nt, 20 nt, 19 nt, 18 nt, 17 nt, 16 nt, 15 nt, or 12 nt or less in length. In some embodiments, the nucleotides are 12 to 50 nt, 12 to 30 nt, 12 to 25 nt, 18 to 25 nt, 18 to 25 nt, 19 to 23 nt, or 20 to 22 nt in length. In some embodiments, the nucleotides are about 21 nt in length.
[0195] Peptide oligonucleotide conjugates of the present disclosure (e.g., peptide oligonucleotide conjugates comprising a PD-L1-binding peptide and a nucleotide) can be further conjugated, linked, or fused to an active agent in addition to the nucleotide active agent (e.g., a targeted binding agent capable of binding to a target molecule). Such additional active agents can be conjugated, fused, linked, or conjugated to one or more of the peptides, nucleotides, or linkers within the peptide oligonucleotide conjugate. In some embodiments, the active agent can be linked directly or indirectly to the peptide of the peptide oligonucleotide conjugate or the nucleotide of the peptide oligonucleotide conjugate. A peptide nucleic acid conjugate further comprising an additional active agent may be referred to as a peptide-active agent conjugate or peptide construct.
[0196] The peptide-oligonucleotide conjugates of the present disclosure can also be used to deliver another active agent. Peptides according to the present disclosure can be conjugated, linked, or fused to drugs used in the treatment of tumors, cancer, or other diseases. For example, in certain embodiments, the peptides described herein are fused or conjugated to another molecule, such as an active agent, that provides additional functional capabilities. A peptide or nucleotide can be fused to an active agent via expression of a vector containing the peptide sequence and the active agent sequence. In various embodiments, the peptide sequence and the active agent sequence can be expressed from the same open reading frame (ORF). In various embodiments, the peptide sequence and the active agent sequence can comprise contiguous sequences. The peptide and the active agent can each retain similar functional capabilities in a peptide construct compared to their functional capabilities when expressed individually. In certain embodiments, examples of active agents may include other peptides.
[0197] As another example, in certain embodiments, the peptides or nucleotides described herein are linked to another molecule, such as an active agent, that provides a functional capability. The active agent can be any active agent described herein (e.g., a therapeutic agent, a detectable agent, or a binding moiety). In some embodiments, the peptide is covalently or non-covalently linked to the active agent, for example, directly or via a linker. Exemplary linkers suitable for use in embodiments herein are discussed in more detail below.
[0198] Peptide Modification Peptides can be modified in one or more different ways (e.g., chemically, mutationally, or peptide-based). In some embodiments, peptides can be mutated to add function, remove function, or alter in vivo behavior. One or more loops between disulfide linkages in a peptide (e.g., a PD-L1-binding peptide or peptide conjugate) can be modified or replaced to include active moieties derived from other peptides (e.g., as described in Moore and Cochran, Methods in Enzymology, 503, pp. 223-251, 2012). In some embodiments, peptides (e.g., PD-L1-binding peptides or peptide conjugates) of the present disclosure can be further functionalized and multimerized by adding additional functional domains. For example, an albumin-binding domain can be added to the albumin-binding domain of Finegoldia magna. Peptostreptococcal albumin-binding protein (SEQ ID NO: 245, MKLNKKLLMAALAGAIVVGGGVNTFAADEPGAIKVDKAPEAPSQELKLTKEEAEKALKKEKPIAKERLRRLGITSEFILNQIDKATSREGLESLVQTIKQSYLKDHPIKEEKTEETPKYNNLFDKHELGGLGKDKGPGRFDENGWENNEHGYETRENAEKAAVKALGDKEINKSYTI SQGVDGRYYYVLSREEAETPKKPEEKKPEDKRPKMTIDQWLLKNAKEDAIAELKKAGITSDFYFNAINKAKTVEEVNALKNEILKAHAGKEVNPSTPEVTPSVPQNHYHENDYANIGAGEGTKEDGKKENSKEGIKRKTAREEKPGKEEKPAKEDKKENKKKENTDSPNKKKKEKAALPEAGRRKAEILTLAAASLSSVAGAFISLKKRK). For example, the albumin binding domain of SEQ ID NO: 243 (LKNAKEDAIAELKKAGITSDFYFNAINKAKTVEEVNALKNEILKA) can be added to a peptide of the disclosure.In some embodiments, peptides of the present disclosure can be functionalized with an altered albumin-binding domain for improved albumin affinity, improved stability, reduced immunogenicity, improved manufacturability, or a combination thereof. For example, a peptide can be functionalized with an altered albumin-binding domain of SEQ ID NO: 244 (LKEAKEKAIEELKKAGITSDYYFDLINKAKTVEGVNALKDEILKA), which has increased thermal stability and improved serum half-life compared to the albumin-binding domain of SEQ ID NO: 243. The albumin-binding domain contains a simple three-helix structure that is unlikely to disrupt the independent folding of other peptide domains (e.g., CDP domains). In some embodiments, a functional domain (e.g., albumin-binding domain) can increase the serum half-life of a peptide or peptide complex of the present disclosure. A functional domain (e.g., albumin-binding domain) can be included in any orientation relative to the PD-L1-binding peptide. For example, a functional domain can be linked to the PD-L1-binding peptide. The additional functional domains can be linked to one or more peptides (e.g., PD-L1-binding peptides or peptide conjugates) via a linker (e.g., SEQ ID NO: 154 to SEQ ID NO: 241 or SEQ ID NO: 433).
[0199] Amino acids of a peptide or peptide conjugate (e.g., a PD-L1-binding peptide or peptide conjugate) can also be mutated to extend half-life, alter, add, or eliminate in vivo binding behavior, add new targeting functions, alter surface charge and hydrophobicity, or enable conjugation sites. N-methylation is one example of methylation that can be performed on the peptides of the present disclosure. In some embodiments, the peptides are modified by methylation on free amines. For example, complete methylation can be achieved through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0200] Peptides can be modified to add function, such as by grafting loops or sequences from other proteins or peptides onto the peptides of the present disclosure. Similarly, domains, loops, or sequences from the present disclosure can be grafted onto other peptides or proteins, such as antibodies, with additional function.
[0201] In some embodiments, the PD-L1-binding peptide or peptide conjugate can comprise a tissue-targeting domain and accumulate in a target tissue upon administration to a subject. For example, the PD-L1-binding peptide can be conjugated, linked, or fused to a molecule (e.g., a small molecule, peptide, or protein) that has targeting or homing function for a cell of interest or a target protein located on the surface or within that cell. In some embodiments, the PD-L1-binding peptide can be conjugated, linked, or fused to a molecule that extends the plasma half-life and / or biological half-life of the peptide, or alters the pharmacodynamics (e.g., improved binding to the target protein) and / or pharmacokinetic properties (e.g., rate and mode of clearance), or any combination thereof.
[0202] Chemical modifications can result in, for example, an increase in the half-life of the peptide or an alteration of its biodistribution or pharmacokinetic profile. Chemical modifications can include polymers, polyethers, polyethylene glycol, biopolymers, polyamino acids, fatty acids, dendrimers, Fc regions, simple saturated carbon chains such as palmitic acid or myristic acid, or albumin. Polyamino acids can include, for example, polyamino acid sequences in which a single amino acid is repeated (e.g., polyglycine), and mixed polyamino acid sequences that may or may not follow a pattern (e.g., gly-ala-gly-ala (SEQ ID NO: 550)), or any combination of the foregoing.
[0203] The peptides of the present disclosure can be modified such that the modification increases the stability and / or half-life of the peptide. The half-life of the peptides of the present disclosure can be extended using attachment of hydrophobic moieties, such as to the N-terminus, C-terminus, or internal amino acids. The peptides can also be modified to increase or decrease their intestinal or cellular permeability. In some cases, peptides of the present disclosure exhibit high accumulation in intestinal glandular cells, demonstrating applicability in the treatment and / or prevention of intestinal diseases or conditions, such as Crohn's disease or, more generally, inflammatory bowel disease. The peptides of the present disclosure can include post-translational modifications (e.g., methylation and / or amidation and / or glycosylation) that can affect, for example, serum half-life. In some embodiments, simple carbon chains (e.g., by myristoylation and / or palmitylation) can be conjugated and linked to fusion proteins or peptides. The simple carbon chains can allow the fusion proteins or peptides to be easily separated from unconjugated materials. For example, methods that can be used to separate fusion proteins or peptides from non-conjugated materials include, but are not limited to, solvent extraction and reverse-phase chromatography. The lipophilic moiety can extend half-life by reversible binding to serum albumin. The conjugate moiety can be, for example, a lipophilic moiety that extends the half-life of the peptide by reversible binding to serum albumin. In some embodiments, the lipophilic moiety can be cholesterol or a cholesterol derivative, including cholestene, cholestane, cholestadiene, and oxysterols. In some embodiments, the peptide can be conjugated or linked to myristic acid (tetradecanoic acid) or a derivative thereof. In other embodiments, the peptides of the present disclosure can be linked (e.g., conjugated, linked, or fused) to a half-life modifying agent.Examples of half-life modifying agents may include, but are not limited to, polymers, polyethylene glycol (PEG), hydroxyethyl starch, polyvinyl alcohol, water-soluble polymers, zwitterionic water-soluble polymers, water-soluble poly(amino acids), water-soluble polymers of proline, alanine, and serine, water-soluble polymers comprising glycine, glutamic acid, and serine, Fc regions, fatty acids, palmitic acid, albumin, or molecules that bind to albumin. In some embodiments, the half-life modifying agent may be a serum albumin-binding peptide, such as SA21 (SEQ ID NO: 242, RLIEDIC LPRWGCLWEDD). In some embodiments, the SA21 peptide may be conjugated or fused to a CDP of the present disclosure (e.g., any of SEQ ID NOs: 1-118, 435, 436, or 554-567). Additionally, conjugation of the peptide to a near-infrared dye, such as Cy5.5, or an albumin-binding agent, such as an Albu tag, can extend the serum half-life of any of the peptides described herein. In some embodiments, immunogenicity is reduced and the serum half-life of the peptide is extended by using minimal non-human protein sequences.
[0204] In some embodiments, the first two N-terminal amino acids (GS) of SEQ ID NO:60-118, SEQ ID NO:435, SEQ ID NO:436, or SEQ ID NO:554-567 serve as a spacer or linker to facilitate conjugation or fusion to another molecule and to facilitate cleavage from such conjugated, linked, or fused molecule. In some embodiments, the fusion proteins or peptides of the present disclosure may be conjugated, linked, or fused to other moieties that may, for example, modify or change the properties of the peptide.
[0205] In some embodiments, the peptides or peptide complexes of the present disclosure may also be conjugated, linked, or fused to other affinity handles. Other affinity handles may include gene fusion affinity handles. Gene fusion affinity handles include 6xHis (HHHHHH (SEQ ID NO: 248); allows for immobilized metal affinity column purification), FLAG (DYKDDDDK (SEQ ID NO: 432); anti-FLAG immunoprecipitation), and "shorty" FLAG (DYKDE (SEQ ID NO: 431)). In some embodiments, the peptides or peptide complexes of the present disclosure may also be conjugated, linked, or fused to expression tags or sequences that improve protein expression and / or purification.
[0206] Furthermore, more than one peptide sequence (e.g., peptides derived from toxins or venom proteins) may be present, conjugated, linked, or fused to a particular peptide. Peptides can be incorporated into biomolecules by a variety of techniques. Peptides can be incorporated by chemical transformations, such as the formation of covalent bonds, such as amide bonds. Peptides can be incorporated, for example, by solid-phase or solution-phase peptide synthesis. Peptides can be incorporated by preparing a nucleic acid sequence encoding the biomolecule, where the nucleic acid sequence includes a subsequence encoding the peptide. The subsequence may be added to the sequence encoding the biomolecule or may replace a subsequence of the sequence encoding the biomolecule.
[0207] The PD-L1-binding peptides of the present disclosure (e.g., any one of SEQ ID NOs: 1-118, 435, 436, or 554-567) may be modified with a cell-penetrating peptide to form a cell-penetrating PD-L1-binding peptide. The cell-penetrating peptide may facilitate delivery of the PD-L1-binding peptide or peptide conjugate into a cell or across a cell layer (e.g., across the blood-brain barrier or across an endosome to the cytosol). In some embodiments, the cell-penetrating PD-L1-binding peptide can be further conjugated to an additional active agent to facilitate delivery of the additional active agent into a cell or across a cell layer. This may enable delivery of the active agent (e.g., a therapeutic agent) to an intracellular target. Examples of cell-penetrating peptides that may be used in combination with the PD-L1-binding peptides of the present disclosure are provided in Table 7. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5]
[0208] In some embodiments, the tissue-targeting domain can comprise a transferrin receptor-binding (TfR-binding) peptide, such as SEQ ID NO: 350 (REGCASRCMKYNDELEKCEARMMSMSNTEEDCEQELEDLLYCLDHCHSQ), which can facilitate transcytosis across the blood-brain barrier and deliver the PD-L1-binding peptide to the central nervous system, including brain tumors. In some embodiments, the TfR-binding peptide can be derived from a scaffold of SEQ ID NO: 351 (REGCASHCTKYKAELEKCEARVSSRSNTEETCVQELFDFLHCVDHCVSQ) or SEQ ID NO: 352 (GSREGCASHCTKYKAELEKCEARVSSRSNTEETCVQELFDFLHCVDHCVSQ). For example, access to the CNS via transcytosis across the BBB can be achieved by binding the PD-L1-binding peptide complexed with the TfR-binding peptide to the transferrin receptor (TfR), followed by recycling the complex to the cell surface. A portion of the PD-L1-binding peptide / TfR-binding peptide complex can access the low-pH early endosome. The PD-L1-binding peptide or additional active agent complex may be exposed to endosomes during TfR endocytosis and may remain there without degradation due to the stability of the PD-L1-binding peptide. If the PD-L1-binding peptide / TfR-binding peptide complex contains additional cell-penetrating capability, the peptide can facilitate the escape of the PD-L1-binding peptide or additional active agent from the endosomal compartment into the cytosol. Even without the addition of cell-penetrating capability, the PD-L1-binding peptide or additional active agent can slowly leak out of the endosome and access the cytosol.
[0209] Nucleotide Modifications In some embodiments, the nucleic acid portion of a peptide-oligonucleotide conjugate (e.g., the oligonucleotide of a PD-L1-binding peptide-oligonucleotide conjugate) contains one or more modified bases within the nucleic acid molecule. Such modifications can occur whether the nucleic acid portion is single-stranded (ssDNA, ssRNA) or double-stranded (dsDNA, dsRNA), or a combination of single and double strands (e.g., having mismatched sequences, hairpins, or other structures), antisense RNA, complementary RNA, inhibitory RNA, interfering RNA, nuclear RNA, antisense oligonucleotide (ASO), microRNA (miRNA), oligonucleotide complementary to a natural antisense transcript (NAT) sequence, siRNA, snRNA, aptamer, gapmer, antimiR, splice blocker ASO, or U1 adaptor. One or more bases in a given nucleotide sequence can be modified to increase in vivo stability, increase resistance to enzymes such as nucleases, increase protein binding, including serum proteins, extend in vivo half-life, alter tissue biodistribution, or alter the way the immune system responds. The phosphonate, ribose, or base may be modified.In some embodiments, the modification is a phosphorothioate modification, a phosphodiester modification, a thiophosphoramidate modification, a methyl phosphonate modification, a phosphorodithioate modification, a methoxypropyl phosphonate modification, a 5'-(E)-vinyl phosphonate modification, a 5' methyl phosphonate modification, an (S)-5'-C-methyl with phosphate modification, a 5'-phosphorothioate modification, a peptide nucleic acid (PNA), a 2'-O methyl modification, a 2'-O-methoxyethyl (2'-O-Me) modification, a 2'-fluoro (2'-F) modification, a 2'-deoxy-2'-fluoro modification, a 2' arabino-fluoro modification, a 2'-O-benzyl modification, a 2'-O-methyl-4-pyridine modification, a locked nucleic acid (LNA), an amino-LNA, a thio-LNA, an ENA, an amino ENA, a carbo-ENA (S)-cEt-bridged nucleic acids, (S)-MOE, bridged nucleic acids, tricyclo-DNA, morpholino nucleic acids (PMO), unlocked nucleic acids (UNA), glycol nucleic acids (GNA), bridged nucleic acids (BNA), ethyl (S)-cEt nucleic acids, pseudouridine, 2'-thiouridine, N6'-methyl adenosine, 5'-methylcytidine, 5'-fluoro-2'-deoxyuridine, N'-ethylpiperidine 7'-EAA triazole-modified adenine, N-ethylpiperidine 6'-triazole-modified adenine, 6'-phenylpyrrolocytosine, 2',4'-difluorotoluyl ribonucleoside, 5'-nitroindole, 5'-methyl, 5'-phosphonate, inverted A base, 2'-H (deoxyribose), 2'-OH (ribose), or any combination thereof. The oligonucleotide may be composed entirely of a combination of 2'-O-Me and 2'-F modifications. Diastereomers or one or both stereoisomers may be used. Any stabilization chemistry or pattern, including STC, ESC, Advanced, ESC, AD1-3, and AD5, as disclosed in Hu Signal Transduction and Targeted Therapy 2020, 5:101, can be used. Pyrimidines can be 2'-fluoro-modified, which not only enhances nuclease stability but also enhances immune system activation.The RNA backbone can be phosphorothioate-substituted (non-bridging oxygens replaced with sulfur), which not only increases resistance to nuclease digestion but also alters biodistribution and tissue retention, enhances pharmacokinetics by increasing protein binding, and induces enhanced immune stimulation. Methylphosphonate modifications of RNA can also be used. 2'-O-methyl and 2'-F RNA bases can be used, which protect against base hydrolysis and nucleases and increase the melting temperature of the duplex. Bridged Nucleic Acids (BNAs, LNAs, cEts) in crosslinked, locked, and other similar forms, including optional chemical bridges such as an NO bond between the 2' oxygen and the 4' carbon of ribose, can be incorporated to increase resistance to exonucleases and endonucleases and enhance biological stability. These include BNAs with an NO bond between the 2' and 4' carbons, which can be stabilized by adding optional chemical modifications to the nitrogen within the bridge (including, but not limited to, NH, N-CH3, and N-benzene). RNA backbone or base modifications can be made anywhere within the RNA sequence, including at one, several, or all base positions. Optionally, phosphorothioate nucleic acids can be used at two to four terminal nucleic acids of one or both sequences. Optionally, 2'F-modified nucleic acids can be used at at least two to four internal positions, at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, or up to 100% of the internal positions, at all internal positions, or at all positions. Optionally, 2'F bases, LNA bases, BNA bases, ENA bases, 2'O-MOE bases, morpholino bases, 2'OMe bases, 5'-Me bases, (S)-cEt bases, or combinations thereof can be used at at least two to four internal positions, at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, or up to 100% of the internal positions, at all internal positions, or at all positions.
[0210] Modified bases can be used to extend the in vivo half-life of oligonucleotides. They allow oligonucleotides to remain intact in serum, endosomes, cytosol, or nucleus for days, weeks, or even months. This allows for continued activity within certain cells, including when the oligonucleotide is slowly released from endosomes over days, weeks, or months (such as those described in Brown et al., Nucleic Acids Research, 2020, p11827-11844).
[0211] In some embodiments, the nucleotide comprises at least one phosphorothioate linkage. In some embodiments, the peptide-oligonucleotide conjugate comprises 1 to 12 phosphorothioate linkages. In some embodiments, the nucleotide comprises at least one thiophosphoramidate linkage. In some embodiments, the nucleotide comprises 1 to 12 thiophosphoramidate linkages. In some embodiments, the nucleotide comprises at least one modified base. In some embodiments, the at least modified base comprises a 2'F base, an LNA base, a BNA base, an ENA base, a 2'O-MOE base, a 5'-Me base, an (S)-cEt base, a 2'OMe base, a morpholino base, or a combination thereof.
[0212] Linker A peptide (e.g., a PD-L1-binding peptide or peptide conjugate) according to the present disclosure can be attached, via a linker or directly in the absence of a linker, to another moiety (e.g., an active agent or detectable agent), such as a small molecule, a second peptide, a second CDP, a protein, a miniprotein, an antibody, an antibody fragment, Fc, an Fc knob, an Fc hole, an aptamer, a polypeptide, a polynucleotide, a fluorophore, a radioisotope, a radionuclide chelator, a polymer, a biopolymer, a fatty acid, an acyl adduct, a chemical linker, a linker moiety, or a sugar, or other active agent or detectable agent described herein. In the absence of a linker, for example, the active agent or detectable agent may be conjugated, linked, or fused to the N-terminus or C-terminus of the peptide to generate an active agent or detectable agent fusion peptide. In other embodiments, the linkage may be generated through peptide fusion by reductive alkylation. In some embodiments, a cleavable linker is used for in vivo delivery of the peptide, such as a linker that can be cleaved or degraded upon entry into a cell, endosome, or nucleus. In some embodiments, in vivo delivery of peptides requires small linkers that do not interfere with cell penetration or localization to the cell nucleus. Linkers can also be used to covalently attach the peptides described herein to another moiety or molecule that has a distinct function, such as a targeting, cytotoxic, therapeutic, homing, imaging, or diagnostic function.
[0213] Peptides can be directly linked to another molecule by covalent bond. For example, peptides can be linked to the end of the amino acid sequence of a larger polypeptide or peptide molecule, or to a side chain such as the side chain of lysine, serine, threonine, cysteine, tyrosine, aspartic acid, non-natural amino acid residue, or glutamic acid residue. Linkage can be via an amide bond, an ester bond, an ether bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carbon-carbon single, double, or triple bond, a disulfide bond, or a thioether bond. In some embodiments, analogous regions of the disclosed peptide(s) themselves (such as at the termini of the amino acid sequence; amino acid side chains such as lysine, serine, threonine, cysteine, tyrosine, aspartic acid, unnatural amino acid residues, or glutamic acid residue side chains; amide bonds; ester bonds; ether bonds; carbamate bonds; carbon-nitrogen bonds; triazoles; macrocycles; oxime bonds; hydrazone bonds; carbon-carbon single, double, or triple bonds; disulfide bonds; thioether bonds; or linkers as described herein) can be used to link the disclosed peptide(s) to other molecules.
[0214] Linkage via a linker may involve the incorporation of a linker moiety between the other molecule and the peptide. Both the peptide and the other molecule may be covalently attached to the linker. The linker may be cleavable, unstable, non-cleavable, self-immolative, hydrophilic, or hydrophobic. As used herein, the terms "non-cleavable" or "stable" (e.g., in connection with amide, cyclic, or carbamate linkers, or others described herein) are often used by those skilled in the art to distinguish relatively stable structures from more unstable or "cleavable" ones (e.g., as used in connection with cleavable linkers that can be structurally dissociated or cleaved by enzymes, proteases, self-immolation, pH, reduction, hydrolysis, certain physiological conditions, or otherwise described herein). It is understood that a "non-cleavable" or "stable" linker provides stability against cleavage or other dissociation compared to a "cleavable" linker, and the term is not intended to be construed as an absolute non-cleavable or non-dissociable structure under any conditions. Therefore, as used herein, a "non-cleavable" linker is also referred to as a "stable" linker. A linker can have at least two functional groups, one attached to the peptide and the other to another molecule, and a linking group between the two functional groups. Some example linkers are described in Jain, N., Pharm Res. 32(11):3526-40 (2015), Doronina, SO, Bioconj Chem. 19(10):1960-3 (2008), Pillow, TH, J Med Chem. 57(19):7890-9 (2014), Dorywalksa, M., Bioconj Chem. 26(4):650-9 (2015), Kellogg, BA, Bioconj Chem. 22(4):717-27 (2011), and Zhao, RY, J Med Chem. 54(10):3606-23 (2011).
[0215] Non-limiting examples of functional groups for linkages include functional groups capable of forming amide, ester, ether, carbonate, carbamate, or thioether bonds. Non-limiting examples of functional groups capable of forming such bonds include amino groups, carboxyl groups, hydroxyl groups, aldehyde groups, azide groups, alkyne and alkene groups, ketones, hydrazides, acid halides such as acid fluorides, chlorides, bromides, and iodides, acid anhydrides including symmetric, mixed, and cyclic acid anhydrides, carbonates, carbonyl functional groups bonded to leaving groups such as cyano, succinimidyl, and N-hydroxysuccinimidyl, hydroxyl groups, sulfhydryl groups, and molecules having alkyl, alkenyl, alkynyl, aryl, or benzyl leaving groups such as halides, mesylates, tosylates, triflates, epoxides, phosphates, sulfates, and besylates.
[0216] Non-limiting examples of linking moieties can include alkylene, alkenylene, alkynylene, polyethers such as polyethylene glycol (PEG), hydroxycarboxylic acids, polyesters, polyamides, polyamino acids, polypeptides, cleavable peptides, valine-citrulline, aminobenzyl carbamate, D-amino acids, and polyamines, any of which are unsubstituted or substituted with any number of substituents such as halogens, hydroxyl groups, sulfhydryl groups, amino groups, nitro groups, nitroso groups, cyano groups, azide groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, urethane groups, epoxides, and ester groups.
[0217] In some cases, the linker can include a triazole group, such as any one of the heterocyclic compounds having the molecular formula CHN, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms, and optionally has a hydrogen atom attached to the N at any position within the ring, e.g., [ka] For example, 1,2,3-triazoles (such as 1H1,2,3-triazole, 2H1,2,3-triazole, or 1-methyl-4,5,6,7,8,9)-hexahydro-1H-cycloocta[d][1,2,3]triazole) or 1,2,4-triazoles (such as 1H1,2,4-triazole or 4H1,2,4-triazole).
[0218] Further non-limiting examples of linkers include linear or acyclic linkers such as: [ka] [ka] and (wherein each n is independently 0 to about 1,000; 1 to about 1,000; 0 to about 500; 1 to about 500; 0 to about 250; 1 to about 250; 0 to about 200; 1 to about 200; 0 to about 150; 1 to about 150; 0 to about 100; 1 to about 100; 0 to about 50; 1 to about 50; 0 to about 40; 1 to about 40; 0 to about 30; 1 to about 30; 0 to about 25; 1 to about 25; 0 to about 20; 1 to about 20; 0 to about 15; 1 to about 15; 0 to about 10; 1 to about 10; 0 to about 5; or 1 to about 5). In some embodiments, each n is independently 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50. In some embodiments, m is from 1 to about 1,000; from 1 to about 500; from 1 to about 250; from 1 to about 200; from 1 to about 150; from 1 to about 100; from 1 to about 50; from 1 to about 40; from 1 to about 30; from 1 to about 25; from 1 to about 20; from 1 to about 15; from 1 to about 10; or from 1 to about 5. In some embodiments, m is 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, abou...
Claims
1. (a) X 1 X 2 X 3 X 4 X 5 X 6 C.X. 7 X 8 X 9 C (SEQ ID NO: 361) 1 is D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X 2 is G, E, Q, or F; X 3 is D or K; X 4 is G, V, or P; X 5 is G, H, R, V, F, W, or P; X 6 is A, D, or K; X 7 is E, H, Q, L, or F; X 8 is D, E, R, S, T, M, L, or F; X 9 is G, A, D, E, H, K, R, M, L, or P; or (b) X 1 Forex 2 Visual Effects 2 CLX 3 X 3 C (SEQ ID NO: 363) 1 is K or P; X 2 is independently D or K; X 3 and wherein each of said peptides is a PD-L1-binding peptide having a PD-L1-binding motif comprising the sequence of:
2. The PD-L1-binding peptide of claim 1, comprising at least six cysteine residues.
3. 3. The PD-L1-binding peptide of claim 2, wherein the at least six cysteine residues are located at amino acid positions n, n+4, n+14, n+28, n+38, and n+42, where n corresponds to the position of a first cysteine residue of the at least six cysteine residues.
4. 3. The PD-L1-binding peptide of claim 2, wherein amino acid position n corresponds to amino acid position 4, such that at least six cysteine residues are located at amino acid positions 4, 8, 18, 32, 42, and 46.
5. The first PD-L1 binding motif is X1, X2, X3, X4, X5, X6, CX7, X8, X9, C (SEQ ID NO:361), where X1 is D, E, H, K, N, Q, S, T, L, V, F, Y, or P; X2 is G, E, Q, or F; X3 is D or K; X4 is G, V, or P; X5 is G, H, R, V, F, W, or P; X6 is A, D, or K; X7 is E, H, Q, L, or F; X8 is D, E, R, S, T, M, L, or F; and X9 is C, X10, X20, X30, X40, X50, X60, X70, X80, X90, is G, A, D, E, H, K, R, M, L, or P.
6. 5. The PD-L1-binding peptide of claim 4, wherein the first PD-L1-binding motif comprises the sequence KFDVFKCLDHC (SEQ ID NO: 365).
7. CX 1 X 2 X 3 C.X. 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 C (SEQ ID NO: 360) 1 is K, R, or V; X 2 is E, Q, S, M, L, or V; X 3 is D, E, H, K, R, N, Q, S, or Y; X 4 is D, M, or V; X 5 is A, K, R, Q, S, or T; X 6 is A, D, E, H, Q, S, T, M, I, L, V, or W; X 7 is A, E, R, Q, S, T, W, or P; X 8 is A, E, K, R, N, Q, T, M, I, L, V, or W; X 9 is G, A, E, K, N, T, or Y; X 10 is G, A, D, E, H, K, R, N, Q, S, T, M, I, L, V, W, Y, or P; X 11 is D, K, R, N, L, or V; X 12 is G, A, D, T, L, W, or P).
8. 8. The PD-L1-binding peptide of claim 7, wherein the second PD-L1-binding motif comprises the sequence CKVHCVKEWMAGKAC (SEQ ID NO: 364).
9. 2. The PD-L1-binding peptide of claim 1, wherein the PD-L1-binding peptide comprises the sequence of SEQ ID NO:
358.
10. 2. The PD-L1-binding peptide of claim 1, wherein the PD-L1-binding peptide comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-4 or SEQ ID NO:
554.
11. The PD-L1-binding peptide of claim 1, wherein the PD-L1-binding peptide comprises any one of the sequences set forth in SEQ ID NO:1 to SEQ ID NO:4 or SEQ ID NO:
554.
12. A peptide conjugate comprising the PD-L1-binding peptide of claim 7 conjugated to an active agent.
13. The peptide conjugate of claim 12 , wherein the active agent comprises an immune cell targeting agent.
14. 14. The peptide conjugate of claim 13, wherein the immune cell targeting agent comprises a single chain variable fragment (scFv), a cysteine dense peptide, an avimer, a Kunitz domain, an affibody, an adnectin, a nanophytin, a finomer, a beta hairpin, a stapled peptide, a bicyclic peptide, an antibody, an antibody fragment, a protein, a peptide, a peptide fragment, a binding domain, a small molecule, or a nanobody capable of binding to an immune cell.
15. 14. The peptide conjugate of claim 13, wherein the immune cell targeting agent is fused to a first heterodimerization domain and the PD-L1 binding peptide is fused to a second heterodimerization domain, or the immune cell targeting agent and the PD-L1 binding peptide are fused to a homodimerization domain.
16. 16. The peptide complex of claim 15, wherein the first heterodimerization domain, the second heterodimerization domain, the homodimerization domain, or a combination thereof comprises an Fc domain.
17. The peptide conjugate of claim 13, wherein the active agent comprises a targeted binding agent.
18. The peptide conjugate of claim 13, wherein the immune cell targeting agent and the PD-L1-binding peptide are linked via a linker.
19. The peptide conjugate of claim 18 , wherein the linker comprises an Fc domain.
20. The peptide complex of claim 12, wherein the active agent comprises a therapeutic agent, the therapeutic agent comprising an anti-cancer agent, a chemotherapeutic agent, a radiation therapy agent, an anti-inflammatory agent, a pro-inflammatory cytokine, an oligonucleotide, a tumor immunotherapy agent, or a combination thereof.
21. 21. The peptide conjugate of claim 20, wherein the anti-inflammatory agent comprises an anti-inflammatory cytokine, a steroid, a glucocorticoid, a corticosteroid, a cytokine inhibitor, a ROR gamma inhibitor, a JAK inhibitor, a tyrosine kinase inhibitor, or a nonsteroidal anti-inflammatory drug.
22. 21. The peptide conjugate of claim 20, wherein the anti-cancer agent comprises an anti-tumor agent, a cytotoxic agent, a tyrosine kinase inhibitor, an mTOR inhibitor, a retinoid, a microtubule polymerization inhibitor, a pyrrolobenzodiazepine dimer, or an anti-cancer antibody.
23. 10. A composition for use in a method of inhibiting PD-L1 in a subject, the composition comprising the PD-L1-binding peptide of claim 1, a cell expressing the PD-L1-binding peptide, or a polynucleotide encoding the PD-L1-binding peptide, the method comprising: administering said composition to said subject; Binding the PD-L1-binding peptide to PD-L1 on PD-L1-positive cells; Inhibiting PD-L1; and The composition comprising:
24. The composition of claim 23, wherein the method further comprises reducing immunosuppression, reducing T cell exhaustion, restoring immune function, or a combination thereof.
25. The composition of claim 23, wherein the method further comprises treating a condition in the subject.
26. 26. The composition of claim 25, wherein the condition is cancer and the PD-L1 positive cells are cancer cells.
27. 13. A composition for use in a method of delivering an active agent to a PD-L1 positive cell in a subject, said composition comprising the peptide conjugate of claim 12 comprising the PD-L1 binding peptide complexed to the active agent, a cell expressing the peptide conjugate, or a polynucleotide encoding the peptide conjugate, said method comprising: administering said composition to said subject; Binding the PD-L1-binding peptide to a PD-L1-positive cell; delivering said active agent to said PD-L1 positive cells; The composition comprising:
28. 28. The composition of claim 27, wherein the active agent comprises an immune cell targeting agent, and the method further comprises binding the immune cell targeting agent to an immune cell and recruiting the immune cell to the PD-L1 positive cell.
29. 30. The composition of claim 28, wherein the immune cells comprise T cells, B cells, macrophages, natural killer cells, fibroblasts, regulatory T cells, regulatory immune cells, neural stem cells, or mesenchymal stem cells.
30. 30. The composition of claim 28 or 29, wherein the immune cell targeting agent binds to CD3, 4-1BB, CD28, CD137, CD89, CD16, CD25, CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, CD27, GITR, TIGIT, LAG3, TCR, CD40L, OX40, PD-1, CTLA-4, or STRO-1.
31. The composition of claim 28, wherein the method further comprises killing or inhibiting the PD-L1 positive cells during delivery of the immune cells to the PD-L1 positive cells.
32. The composition described in claim 28, characterized in that the method further comprises treating a condition in the subject.
33. The composition of claim 32, wherein the condition is cancer and the PD-L1 positive cells are cancer cells.
34. 34. The composition of claim 33, wherein the cancer comprises melanoma, skin cancer, non-small cell lung cancer, small cell lung cancer, lung cancer, renal cancer, esophageal cancer, oral cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer, colorectal cancer, colon cancer, rectal cancer, head and neck cancer, lymphoma, acute myeloid leukemia, erythroleukemia, bladder cancer, liver cancer, gastric cancer, breast cancer, triple negative breast cancer, pancreatic cancer, prostate cancer, Merkel cell carcinoma, mesothelioma, brain cancer, or PD-L1 expressing cancer.
35. 35. The composition of claim 34, wherein the brain tumor comprises a glioblastoma, an astrocytoma, a meningioma, a primary brain tumor, or a metastatic brain tumor.
36. 33. The composition of claim 32, wherein the condition is hyperglycemia, type 1 or type 2 diabetes, an autoimmune disorder, or an inflammatory disorder.
37. 37. The composition of claim 36, wherein the autoimmune or inflammatory disorder comprises rheumatoid arthritis, atherosclerosis, ischemia-reperfusion injury, colitis, psoriasis, lupus, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, type 1 diabetes, type 2 diabetes, or neuroinflammation.
38. A polynucleotide encoding the PD-L1 binding peptide described in claim 1.
39. A cell expressing the PD-L1 binding peptide described in claim 1.
40. The cell described in claim 39, wherein the cell is an immune cell.
